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ABSTRACT. 
 
Identification and characterisation of a novel gene, DWNN, isolated 
from promoter-trapped CHO cell lines. 
 
A. Skepu 
 
PhD thesis, Department of Biotechnology, Faculty of Science, University of the 
Western Cape. 
 
The process of cytotoxic T lymphocyte (CTL) killing involves the recognition and 
destruction of foreign antigens by cytotoxic T cells and is of crucial importance to the 
defence of the organism against viral infections. Defects in this process can lead to 
various autoimmune diseases and cancer. The aim of this study was to identify more 
genes involved in the cell death pathway and to link CTL killing, apoptosis and 
cancer. 
 
A number of CTL resistant cell lines have been generated in a previous study, using a 
retroviral promoter trap mutagenesis system, in order to identify novel components 
involved in the CTL killing pathway. Four of these cell lines were used in this study 
in order to identify genes mutated in them. The sites of the insertion of the retrovirus 
into the genome of these cell lines were analysed using inverse PCR. This method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
yields two products, one from the 3' end, which is of constant size in all the cell lines 
and a variable 5' end fragment, containing the insertion site into the unknown gene 
sequence, which is characterised by sequencing the PCR products. A novel gene, 
named DWNN, has been identified in two of the four promoter-trapped cell lines and 
the remaining two cell lines failed to identify any significant genes.  
 
This thesis describes the characterisation of the DWNN gene, in order to identify its 
function. The sequence analysis of this gene revealed that it constitutes a highly 
conserved domain found in all eukaryotes. The human DWNN gene encodes two 
overlapping proteins, which were termed DWNN-13 and DWNN-200, encoding the 
predicted 13 kD and 200 kD proteins respectively. In different phyla, including 
humans, it has been shown that the DWNN domain is attached to a number of other 
conserved domains, including CCHC Zinc finger, C3HC4 RING finger, SR RNA 
binding domain, Rb binding domain and p53 binding domains found previously in 
the RBBP6 gene (which is a partial cDNA from the DWNN-200 transcript).  
 
The cDNA constructs encoding the two proteins have been isolated and completely 
sequenced. A number of mutations within this gene in human cancers and 
transformed cell lines have been characterised. 
 
Immunofluorescence and GFP studies have been undertaken in order to determine the 
localisation of this protein. Fusion proteins of GFP linked to DWNN-13 and DWNN-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
200 were expressed in CHO cells, and were found to localize to the nucleus. 
Immunostaining with anti-DWNN antibodies have shown that the endogenous 
DWNN protein localizes in the nucleus CHO cells and several human cell lines. 
However, in DWNN-mutant cell lines, anti-DWNN antibodies did not stain the 
nucleus, but only stained the cytoplasm. 
 
Stable mutant cell lines complemented with both transcripts of DWNN have been 
generated. These cell lines, as well as DWNN-mutant cell lines, were characterised 
further in order to clarify the role played by DWNN in mammalian cells and its 
involvement in CTL killing and apoptosis. Both the DWNN-mutant cell lines and the 
mutant cell lines complemented by DWNN expression were shown to be totally 
resistant to CTL killing, compared to the parental cell line, Y10. It was also 
discovered that some of the DWNN-complemented mutant cell lines were less 
susceptible to staurosporine-induced apoptosis than the DWNN-mutant cell lines. 
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CHAPTER 1: INTRODUCTION. 
 
1.1 The immune system 
1.1.1 Overview of the immune system 
 
The immune system is responsible for protecting our bodies against any life-
threatening diseases. It has the ability to recognise anything that is ‘non-self’ and 
destroys it. It does this by eliciting an immune response. The immune response can be 
defined as the ability of the immune system to respond to the presence of infectious 
organisms in the tissues of the host (Elgert, 1996). It should be stated that the immune 
system for animals works in a similar way as that for humans. 
 
1.1.2 Types of immunity 
 
The human immune system defends the body against invading organisms through 
two types of immunity: the innate and the adaptive immunity. 
 
Innate immunity is the first generalised defence against all kinds of pathogens. It 
provides an immediate, non-specific and rapid protection against the invading 
pathogen (Abbas et al., 1997). It however, does not provide protection against the 
same pathogen when encountered for the second time. The innate immune system is 
made up of dendritic cells, macrophages, neutrophils and natural killer cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adaptive immunity provides a specific defence against pathogens. This type of 
immunity can recognise previously encountered pathogens and reacts faster and more 
efficiently (Abbas et al., 1997). The adaptive immune cells include B and T 
lymphocytes. There are two types of adaptive immune responses: humoral and cell 
mediated responses. 
 
The humoral response is based on the production of antibodies by the immune system 
for the recognition and destruction of the extracellular antigen. This provides 
protection against bacteria, fungi, parasites and toxins. This type of immune response 
is mediated by B lymphocytes. 
 
Cell mediated response is based on the recognition of an intracellular antigen by T 
lymphocytes. This immune response destroys cells that are infected with viruses or 
mutating cells. Figure 1.1 shows a diagrammatic representation of the two types of 
adaptive immunity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 1.1 Representation of the two types of adaptive immune response (taken from 
Clancy, 1998). 
 
1.1.3 Cells of the immune system 
 
The immune system is composed of interdependent cell types that collectively protect 
the body from bacteria, parasites, fungi, viruses and tumor cells (Clancy, 1998). 
These cells develop from stem cells starting at a gestational age of 5 weeks. They are 
distributed through various organs in the lymphatic system as the fetus develops. 
Many of these cell types have specialised functions. They can engulf bacteria; kill 
parasites, tumor cells and viral infected cells. The cells include T and B lymphocytes, 
Natural killer cells, granulocytes, dendritic cells and macrophages. A comprehensive 
description of T lymphocytes and natural killer cells is presented below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TYPE OF CELL DESCRIPTION CD 
MARKERS 
T lymphocytes Mature in the thymus gland and are divided into two 
subsets. The cytotoxic T lymphocytes destroy 
infected cells, while the helper T lymphocytes 
regulate the immune system by controlling the 
quality of all immune responses. More details about 
this type of lymphocyte are discussed in section 1.2. 
CD2, CD3, 
CD4, CD28, 
CD45R, CD8. 
TcR 
B lymphocytes Mature in the bone marrow. The major function of B 
lymphocytes is to produce antibodies in response to 
foreign proteins of bacteria, viruses and tumour cells. 
The antibodies bind to and mediated the destruction 
of the foreign proteins. 
CD19-22, 
CD35, CD40, 
CD45, CD32 
Natural killers 
(NK) cells 
Similar to cytotoxic T lymphocytes, but they mature 
in the bone marrow. They function as effector cells 
that directly kill certain tumours. More on NK cells is 
discussed in section 1.3. 
NK1, CD16 
Granulocytes Are a group of white blood cells composed of three 
cell types: neutrophils, eosinophils and basophils. 
These cells are important in the removal of bacteria 
and parasites from the body. They engulf these 
foreign bodies and degrade them using their powerful 
enzymes. 
CD13, CD15, 
CD16, CD30 
Macrophages- Are important in the regulation of immune responses. 
They are often referred to as antigen-presenting cells 
(APC) because they phagocytose foreign antigens 
and present these antigens to T and B lymphocytes. 
CD26 
Dendritic cells Originate in the bone marrow. They are usually 
found in the structural compartment of the lymphoid 
organs. However, they are also found in the 
bloodstream and other tissues of the body. It is 
believed that they capture the antigen and bring it to 
the lymphoid organs, where an immune response is 
initiated. Dendritic cells are believed to function as 
APC. 
CD21, CD23 
Table 1.1 Functions of the cells of the immune system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 T lymphocytes 
1.2.1 T lymphocyte receptor (TcR) 
 
T lymphocytes have antigen receptor molecules on their surface, which are composed 
of two different polypeptide chains: alpha (α) and beta (β) chains. A minor 
population of T lymphocytes have two other chains, a gamma (γ) and delta (δ) chain 
(Davis and Bjorkman, 1988). Little is understood about the activities of the γ-δ T 
lymphocytes. The TcR has a constant and a variable region. The variable region is 
created by gene rearrangement and selection of minigenes in a random order to create 
diversity of antigen recognition sites in the population of TcR (Clancy, 1998). 
The α and β chains are associated with a group of five proteins called CD3. The TcR 
complex includes the α, β and the associated CD3 proteins. The recognition of the 
antigen-MHC complex by the TcR-CD3 complex does not require any other 
molecules. TcR recognise antigens in a different manner than antibodies. Antibodies 
recognise antigens in their native form, while the T cell antigen recognition by the 
TcR requires the antigen to be digested into short peptides and presented on the 
surface of another cell (e.g. APC) in context with the MHC class I or class II 
molecules (section 1.2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 T lymphocyte development 
 
T lymphocyte development occurs in the thymus. Immature lymphocytes develop 
from stem cells in the bone marrow, from where they migrate into the thymus 
(Benoist and Mathis, 1998). In the thymus, they mature and are positively or 
negatively selected depending on the affinity of their TcRs for self major 
histocompatibility (MHC) antigens (Krammer, 2000). The MHC antigens are 
molecules that bind with peptide fragments from foreign and self protein and present 
them to the T cells. Every cell produces thousands of MHC molecules. T cells with 
high affinity for self MHC molecules and peptides are eliminated to ensure tolerance 
to normal tissues and to prevent autoimmunity. T cells develop their specific T cell 
markers, including TcR, CD3, CD4 or CD8 and CD2, during development and 
maturation (Fig 1.2). 
 
There are two types of MHC molecules: the MHC class I and MHC class II. T cells 
that interact with MHC class II molecules develop into cells expressing CD4 
molecules on their surface (Pieters, 1997), and those interacting with MHC class I 
molecules turn into T lymphocytes that express CD8 antigens (Benoist and Mathis, 
1999). Only mature T cells that produce a functional TcR leave the thymus and enter 
the secondary lymphoid organs. Mature CD4+ T cells function as helper T cells and 
secrete cytokines that regulate either cellular immune responses or antibody 
responses. Mature CD8+ T cells function as cytokine effector (killer) cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 1.2 An illustrative representation of T lymphocyte development (from Krammer, 
2000). 
 
1.2.3 Types of T lymphocytes 
 
There are two subpopulations of T cells that develop and surface markers can trace 
their development in the thymus. The least mature T cells have a TcR associated with 
CD3. In the thymus, the cells express both the CD4 and CD8 markers. These cells are 
referred to as double positive (CD4+CD8+). Eventually the cells lose either CD4 or 
CD8 to become one of the functional subsets. The CD4+CD8- cells are called helper 
T cells (Th cells) and the CD4-CD8+ cells are the cytotoxic T lymphocytes (CTL). Th 
cells and CTL both have a TcR, but they perform different functions in the immune 
system (Clancy, 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.3.1 Helper T cells (Th cells) 
 
The generation of an immune response, both humoral (by B lymphocytes) and cell-
mediated by (CTLs), depends on the activation of Th cells. The importance of Th 
cells has become apparent because of their involvement in AIDS (Clancy, 1998). 
There are two subsets of Th cells, Th1 and Th2. Th1 and Th2 look the same and have 
the same T cell markers and receptors. However, they differ in the cytokines that they 
secrete upon activation. In addition, the Th1 subset produces the cytokines IL-2 and 
IFN γ, which are important in cell mediated immunity. The Th2 subset helps B cells 
by secreting IL-4, -5 and 6. The cytokines produced by the two subsets are said to 
have a cross-regulatory role, meaning that Th1 cytokines down regulate the Th2 
responses, and vice versa. 
 
1.2.3.2 Cytotoxic T lymphocytes (CTLs) 
 
CTLs are derived from a lymphocyte stem cell matured in the thymus. These cells are 
characterised by the presence of a CD8 marker on their surface, and an antigen-
specific TcR, which recognises antigens in the context of MHC class I. 
 
The major role of CTL is to kill other cells, especially virus-infected and tumor cells. 
The cytotoxic T cells must be activated in order to be able to kill. The activation of 
CTL requires firstly, that the TcR on the CD8+ cell interact with an antigen-MHC 
class I on the surface of a target cell. Secondly, the CD8+ T cell must be stimulated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
by cytokines. Once activated, the CTLs are effective in killing target cells. The killing 
happens in three steps: (1) conjugate formation between the CTL and the target cell, 
(2) membrane attack on the target cell, and (3) dissociation of the two cells and the 
target cell death. 
 
1.2.4 The MHC class I antigen presentation pathway  
 
The MHC class I antigen presentation pathway plays a crucial role in the detection of 
virally infected cells. CD8+ T cells recognise peptides in association with MHC class 
I molecules. The principle pathway of antigen processing in association with MHC 
class I involves three major steps: cytosolic peptide generation, peptide transport into 
the endoplasmic reticulum (ER) and peptide assembly with class I molecules. Both 
the MHC class I and class II molecules present peptides rather than intact proteins to 
T cells.  
 
Following synthesis of antigenic proteins, peptides may be generated following the 
action of ubiquitin and proteosomes. The newly processed peptides are transported 
into the ER by the transporter associated with antigen processing (TAP), an ABC 
transporter, in order to access the class I molecules (Koopmann et al., 1997). The 
class I molecules do not leave the ER unless they have bound a peptide with 
sufficient affinity. Newly synthesised class I peptides first associate with calnexin. 
After binding with β2 microglobulin, human class I molecules bind to the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
calreticulin, while murine ones remain associated with calnexin. In the presence of 
tapasin, empty MHC class I molecules complex with calreticulin/calnexin and the 
reductase Erp57 can associate with TAP transporters (Sadasivan et al., 1996). Once a 
peptide has bound to them, class I molecules are exported to the cell surface for 
recognition by CTL. Calnexin is thought to assist in the folding of class I heavy 
chains and to promote their assembly with β2-microglobulin light chain. Tapasin 
plays an essential role in efficient peptide assembly with class I molecule, while the 
Erp57 is a cysteine protease and a chaperone for other proteins. There is still much 
remaining to be learned about the mechanism of peptide translocation by TAP (van 
Endert, 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 1.3 The MHC class I presentation pathway (taken from Lehner et al., 2000). 
 
1.2.5 CTL mediated killing 
 
CTLs are able to recognise and kill virus-infected and malignant cells (Berke, 1995). 
There are two mechanisms by which CTLs destroy their target cells and both are 
caspase-dependent mechanisms. These mechanisms trigger apoptotic signals either 
through a Fas receptor or by granule-mediated exocytosis (Fig 1.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 1.4 Diagrammatic representation of the two pathways by which CTLs kill their 
target cells: the CD95 (yellow) / CD95L (red) mediated killing and 
perforin/Granzyme B (GRb) mediated killing (taken from Krammer, 2000). 
 
1.2.5.1 Granule-mediated exocytosis pathway: 
 
The granule-mediated exocytosis involves the release of the lytic granules from CTLs 
after the adhesion of CTLs and target cells. The granules migrate towards the site of 
contact, where they release their contents. The granules consist of proteins necessary 
for inducing target cells, including a pore-forming protein, perforin, other granule-
containing proteins and a family of serine proteases known as granzymes. Perforin is 
thought to facilitate the entry of other granule components into the cytoplasm of the 
target cell (Krahenbuhl and Tschopp). 
 
Granzyme B is a member of a family of serine proteases that reside in the cytolytic 
granules of CTL, Natural killer (NK) and Lymphokine- activated killer (LAK) cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Masson and Tshopp, 1987). The first substrate to be identified for granzyme B was 
caspase 3, which is a member of a family of cysteine proteases involved in inducing 
apoptosis (Darmon et al., 1995). Multiple caspases have been identified as substrates 
for granzyme B in vitro (Darmon et al., 1995) and this suggests that granzyme B 
induces apoptosis by triggering the activation of multiple caspases within intact cells. 
Perforin alone has been shown to cause necrosis by osmolysis, while apoptosis is 
mediated by the actions of both perforin and granzymes. Granzyme B and perforin 
have been shown to cause DNA fragmentation in target cells (Darmon et al., 1995). It 
has been demonstrated that the activation of caspases 8, another substrate for 
granzyme B, can directly cleave proapoptotic molecule, Bid, resulting in caspase-
independent collapse of mitochondria and cell death (Barry et al., 2000). 
 
1.2.5.2 Fas-FasL pathway (Fig 1.5) 
 
The second pathway by which CTLs destroy target cells is through a Fas pathway. 
Fas and FasL play an important role in three types of physiological apoptosis: (i) 
peripheral deletion of activated mature T cells at the end of an immune response; (ii) 
killing of targets such as virus-infected cells or cancer cells by CTLs and by NK 
cells; and (iii) killing of inflammatory cells (Krammer, 2000). 
 
Like other TNF family members, FasL is a homotrimeric molecule. The crystal 
structure of lymphotoxin in complex with TNFR1 suggests that each FasL trimmer 
binds three Fas molecules (Smith et al., 1994). Because death domains have a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tendency to associate with one another, Fas ligation leads to clustering of the 
receptor’s death domains. An adapter protein called FADD (Fas-associated death 
domain; also called Mort 1) (Chinnaiyan et al., 1995) then binds through its own 
death domain to the clustered receptor death domains. FADD also contains a death 
effector domain (DED) that binds to an analogous domain repeated in tandem within 
the zymogen form of caspase-8 (Boldin et al., 1996). Upon recruitment by FADD, 
caspase-8 oligomerisation drives its activation through self-cleavage. Caspase-8 then 
activates downstream effector caspases such as caspase-9, 3, 6 and 7 and initiates 
mitochondrial damage. 
 
It has also been demonstrated that BID, a death agonist member of the Bcl-2 family, 
is a specific proximal substrate of caspase-8 in the Fas signalling pathway (Li et al., 
1998). Cleavage of BID by caspase-8 leads to the release of cytochrome c from the 
mitochondria, which will result in the inactivation of the electron transfer chain and 
triggers caspase-3 activation through Apaf 1 (Krippner et al., 1996), which will 
induce mitochondrial damage. Expression of BclxL inhibits all the apoptotic 
phenotypes induced by truncated BID, whereas caspase inhibitors inhibit the loss of 
mitochondrial membrane potential, cell shrinkage, and nuclear condensation, but not 
cytochrome c release. 
 
A family of viral proteins called vFLIPs and a related cellular protein called cFLIP 
(also called Casper, I-FLICE or CASH) (Thorne et al., 1997) contain a death effector 
domain that is similar to the corresponding segment in FADD and caspase-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overexpression of FLIP either inhibits or activates apoptosis (Thorne et al., 1997). 
Several other cytoplasmic proteins besides FADD can bind to CD95, including Daxx, 
which recognises the CD95 death domain (Yang, 1997). Daxx can activate a FADD-
independent death pathway that involves the stress-activated c-Jun NH2-terminal 
kinase (JNK). 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig 1.5 Diagrammatic representation of the Fas-FasL pathway (from Yang, 1997). 
 
 
1.3 Natural killer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Natural Killer (NK) cells were discovered in the 1970’s and are a subset of large 
granular lymphocytes that are cytotoxic. They are derived from the bone marrow and 
lack most markers for T and B cells. They are called “natural” killers because, unlike 
cytotoxic T cells, they do not need to recognize a specific antigen before killing 
(Stone et al., 1997). They can spontaneously kill tumor or virus-infected cells 
(Trinchieri, 1989) and attack cells that lack the expression of MHC class I antigens. 
They are said to be the first line of defence against malignant cells and cells infected 
with viruses, bacteria and protozoa. They account for about 15 % of the human white 
blood cells. 
Fig 1.6 Electron micrograph showing a Natural killer cell. 
 
NK cells share several similarities with CTLs. They both kill certain tumor cells and 
virus-infected cells. NK cells have similar mechanisms for killing with CTLs, 
including the secretion of pore-forming proteins, serine proteases and other proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, NK cells can be distinguished from T lymphocytes in that they do not 
express the TCR and bind antigen through a different set of receptors. Unlike CTLs, 
NK killing is non-specific, they do not recognize antigen/MHC on the target cell and 
they do not have T cell receptors. 
 
1.3.1 How NK cells kill? 
 
There are two ways in which NK cells kill certain mutant and virus-infected cells. 
The first mechanism involves the killing of cells to which antibody molecules have 
attached. This process is called antibody-dependent cellular cytotoxicity (ADCC) 
(Fig 1.7). NK cells bind and kill targets coated with IgG antibodies via their receptors 
for IgG (CD16). The NK cell is then able to contact the cell and release perforins, 
granzymes and chemokines. The granzymes pass through the pores and activate the 
enzymes that lead to apoptosis of the target cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig 1.7 Killing of the target cell by NK cell using ADCC mechanism. 
 
The second mechanism involves the killing of cells lacking the MHC class I 
molecules on their surface. NK cells use a dual receptor system in determining 
whether to kill human cells or not (Fig 1.8). NK cells express two families of 
membrane receptors: the killer-activating receptor and the killer-inhibitory receptor. 
 
 
 
 
 
 
 
 
Fig 1.8 The dual receptor system of NK cells for killing of target cell. 
1.3.2 Killer-activating receptors 
 
Killer-activating receptors belong to the immunoglobulin (Ig), integrin and C-type 
lectin families. These receptors activate NK cells in response to MHC class I 
molecules (Lanier and Bakker, 2000). They have charged amino acid residues in their 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
transmembrane domain, allowing them to interact with other signaling proteins 
containing immunoreceptor tyrosine-based activation motifs (ITAMs). When the NK 
stimulatory receptors bind to their ligands, ITAM recruit downstream molecules, 
resulting in the stimulation of NK cells and the killing of the target cell. 
 
1.3.3 Killer-inhibitory receptors 
 
This type of receptor recognizes class I MHC molecules and prevents the lysis of the 
cells that express class I molecules and allow destruction of the cells not expressing 
class I molecules (Long, 1999). There are two types of inhibitory receptors of NK 
cells: the Ig-like and lectin-like receptors. They have short amino acid sequences in 
their cytoplasmic domains called immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs), which contribute to the activation of certain tyrosine phosphatases. When 
these receptors bind to the MHC class I ligands, the ITIMs are phosphorylated and 
recruit phosphatases, preventing killing by NK cells (Janeway-Travers, 1996).  
 
 
1.4 Apoptosis 
1.4.1 Introduction 
 
The word apoptosis has been derived from a Greek word meaning ‘a falling away’, 
which is used in the context of leaf fall, as opposed to necrosis, meaning ‘to make 
dead’ (Kerr et al., 1972). Apoptosis is a physiological process, which plays a central 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
role in the development of multicellular eukaryotes and in maintaining homeostasis. 
Apoptosis is the mode of death by which cells reactive to T cells in the thymus are 
eliminated. NK cells also utilise the apoptotic mechanism to kill virally infected cells. 
 
The physiological role of apoptosis is crucial; malfunctions of this process can be 
detrimental. Too little apoptosis may result in cancers and autoimmune diseases. 
Whereas, too much apoptosis can be associated with the damage observed in stroke 
or the neurodegeneration of Alzheimer’s disease (Thompson, 1995). 
 
1.4.2 Apoptosis versus Necrosis 
1.4.2.1 Definitions 
 
There are two ways in which cells die: they are either killed by injurious agents 
(necrosis) or induced to commit suicide (apoptosis). Necrosis is an accidental death, 
which occurs when cells are exposed to a serious physical or chemical insult, while 
apoptosis is a programmed cell death by which unwanted cells are eliminated during 
development and other normal biological processes. 
1.4.2.2 Morphological changes between necrosis and apoptosis 
 
There are many morphological and biochemical differences between necrosis and 
apoptosis. Some of the changes are listed in Table 1.2 and illustrated in Figure 1.9. 
 
NECROSIS APOPTOSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loss of membrane integrity Membrane blebbing, no loss of integrity 
Swelling of cytoplasm and mitochondria Shrinkage of cytoplasm and condensation of 
the nucleus 
Total cell lysis Fragmentation of cell into smaller bodies 
No vesicle formation Formation of membrane bound vesicles 
(apoptotic bodies) 
Disintegration of organelles Mitochondria leakage 
Random digestion of DNA Non-random mono- and oligonucleosomal 
length fragmentation of DNA 
Significant inflammatory response No inflammatory response 
Table 1.2: Morphological and biochemical differences between apoptosis and 
necrosis. 
 
Exposure to extreme variance from physiological conditions (e.g. hypothermia and 
hypoxia) may lead cells to undergo necrosis, resulting in plasma membrane damage. 
Under physiological conditions, agents like complement and lytic viruses cause direct 
damage to the plasma membrane. Necrosis begins when there is impairment in the 
cell’s ability to maintain homeostasis, leading to an influx of water and extracellular 
ions. Intracellular organelles, including the mitochondria, and the entire cell swell and 
rupture (Kroemer et al., 1995). Ultimately, the plasma membrane breaks down and 
the cytoplasmic contents are released into the extracellular fluid (Fig 1.9a). In vivo, 
necrosis is associated with tissue damage resulting in an inflammatory response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 1.9a Illustration of the morphological features of necrosis (taken from Boehringer 
Mannheim manual, 1998). 
 
Apoptosis, however, occurs under physiological conditions and the cell is responsible 
for it’s own demise. It is mostly found during tissue homeostasis, embryogenesis, 
induction and maintenance of immune tolerance and development of the nervous 
system. Morphological and biochemical features of cells undergoing apoptosis 
include chromatin aggregation, nuclear and cytoplasmic condensation, and the 
division of cytoplasm and nucleus into membrane-bound vesicles known as apoptotic 
bodies Kerr et al., 1972). In vivo, the apoptotic bodies are recognised and 
phagocytosed by macrophages. Due to this efficient removal of apoptotic bodies in 
vivo, no inflammation is induced. However, in vitro, the apoptotic bodies swell up 
and lyse, and this phase is called ‘secondary necrosis’ (Fig 1.9b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 1.9b Illustration of the morphological features of apoptosis (taken from 
Boehringer Mannheim manual, 1998). 
 
1.4.3 Molecules controlling apoptosis 
 
The process of apoptosis must be carefully controlled. There are two groups of 
molecules which are responsible for this: caspases and the Bcl-2 family. 
 
1.4.3.1 The Caspase Family 
 
Most of the morphological and cellular changes of apoptosis are caused by a well-
conserved, highly specific set of cysteine proteases known as caspases. The term 
caspases is a short form for Cysteine Aspartate-specific Proteases, because of the 
substrate specificity of the caspases (Alnemri et al., 1996). Caspases specifically 
cleave their substrates after Asp residues (Wolf and Green, 1999). All caspases exist 
within the cell as inactive zymogens. These zymogens can be cleaved to form active 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
enzymes following the induction of apoptosis (Wilson et al., 1994). The initial 
cleavage of a procaspase into its active form is accomplished either by self-catalysis 
or cleavage by another caspase. Since a single caspase molecule can trigger the 
activation of many procaspases, a propagation of active caspases, termed a caspase 
cascade, can occur (Feleiro et al., 1997). 
 
Caspases share a number of common structural motifs (Wolf and Green, 1999, 
Cohen, 1997). There is an N-terminal pro-domain, which varies in length amongst the 
caspases, a large subunit containing cysteine active site, a C-terminal small subunit, 
an Aspartate between pro-domain and large subunit and an interdomain containing 1 
or 2 aspartate residues between the large and small subunit (Fig1.10). 
 
 
 
 
Fig 1.10 General structure of procaspase. 
 
Activation of the pro-caspase is accompanied by proteolysis of the interdomain and 
results in the removal of the prodomain. The active site is composed of residues from 
both small and large domains. 
 
 
1.4.3.1.1 Types of caspases 
N C Prodomain Large subunit Small subunit 
Asp 
Active site, 
Cys containing 
Interdomain containing 
1 or 2 Asp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Although members of the caspase family share a common structure (Fig 1.10), there 
are subfamily differences that reflect their slightly different roles in apoptosis (Lincz, 
1998). So far, fourteen different members of the caspase family have been identified 
in mammals. Caspases can be divided into three classes based on their roles in 
cellular processes (Talanian et al., 2000). 
 
Initiator caspases (2, 8, 9 and 10) 
 
This group of caspases contain functional pro-domains, which allow association with 
receptor complexes for receptor-stimulated apoptosis. Caspases 2 and 10 contain 
CARDs and caspases 8 and 9 contain DEDs. The initiator caspases act upstream of 
the execution caspases. 
 
Execution caspases (3, 6 and 7) 
 
This group of caspases contain short (23 amino acid) non-functional pro-domains. 
They are responsible for interacting with other caspases and non-caspase molecules 
to induce apoptosis. 
 
 
Cytokine processor caspases (1, 4, 5, 12, 13, and 14) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not much is known about the members of this group. Caspases 1, 4, 5 and 11 may 
play a role in inflammation (Cohen, 2000). Caspase 11 acts as a cofactor for caspase 
1 activation. 
 
1.4.3.1.2 Activation of Caspases 
 
Induction of apoptosis via cell death receptors results in the activation of initiator 
caspases, such as caspase 8 or 10. These caspases can then activate other caspases in 
a cascade. This cascade eventually leads to the activation of the effector caspases, 
such as caspase 3 and 6. These caspases are responsible for the cleavage of the key 
cellular proteins that leads to the typical morphological changes observed in cells 
undergoing apoptosis (section 1.4.2.2).  
 
There are other mechanisms through which caspases can be activated. For example, 
granzyme B can be delivered into cells by CTLs and is able to directly activate 
caspases 3, 7, 8 and 10 (section 1.2.3.2.2).  
 
The mitochondria are also the key regulators of the caspase cascade and apoptosis. 
The release of cytochrome c from the mitochondria can lead to the activation of 
caspase 9 and then caspase 3 (section 1.4.4.2). 
The following table lists the main caspases and some of their substrates and 
functions: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CASPASE ALTERNATE 
NAME 
SUBSTRATES FUNCTION 
Caspase-1 ICE Pre-Interleukin-1b 
Lamins 
Processing of interleukins. 
Can also induce apoptosis. 
Caspase-2 Ich-1 (human) 
Nedd2 (rat, mouse) 
Golgin-160 Apoptosis 
Caspase-3 CPP32, YAMA, 
apopain 
PARP 
Caspases-6, 7, 9 
DNA-PK 
MDM2 
Fodrin 
Lamins 
Topoisomerase I 
ICAD 
Apoptosis 
Caspase-4 Ich-2, ICE (rel)II Caspase-1 Inflammation/Apoptosis 
Caspase-5 ICE(rel)III ? Inflammation/Apoptosis 
Caspase-6 Mch2 PARP 
Lamins 
NuMA 
FAK 
Caspase-3 
Apoptosis 
Caspase-7 Mch3, ICE-LAP3, 
CMH-1 
PARP 
Gas2 
SREB1 
EMAP II 
FAK 
Calpastatin 
Apoptosis 
Caspase-8 FLICE, MACH, Mch5 Caspases-3, 4, 6, 7, 
9, 10, 13 
PARP 
Bid 
Apoptosis 
(death receptors) 
Caspase-9 Apaf-3, ICE-LAP6, 
Mch6 
Caspase-3, 7 
Pro-caspase-9 
PARP 
 
Apoptosis 
Caspase-10 FLICE-2, Mch4 Caspases-3, 4, 6, 7, 
8, 9 
Apoptosis 
(death receptors) 
Caspase-11 Ich-3, ICE-B ? Inflammation and apoptosis 
Caspase-12 ICE-C ? Apoptosis 
Caspase-13 ERICE ? Inflammation 
Table 1.3 Types of caspases and their function. 
1.4.3.2 The Bcl-2 Family 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The gene bcl-2 (B-cell lymphoma–2) was first identified on human chromosome 18 
(Friend et al., 1986). It encodes a membrane-associated protein, Bcl-2, present in ER, 
nuclear and outer mitochondrial membranes. Bcl-2 proteins are the mammalian 
homologues to the C. elegans protein ced-9 and pro-apoptotic protein, egl-1. At least 
15 Bcl-2 family members have been identified in mammalian cells and several others 
in viruses. The members of the Bcl-2 family are classified into three functional 
groups (Fig 1.11). Group I members, such as Bcl-2 and Bcl-XL, are characterised by 
four short, conserved Bcl-2 homology (BH) domains (BH1-4) (White et al., 1994). 
They also contain a C-terminal hydrophobic tail, which localises the proteins to the 
outer surface of mitochondria. Members of group I all possess an anti-apoptotic 
activity and protect cells from death. Group II consists of Bcl-2 family members with 
pro-apoptotic activity. Members include Bax and Bak, and they have a similar overall 
structure to group I proteins, except for the absence of the N-terminal BH4 domain 
(Adams and Cory, 1998). Group III consists of a large and diverse proteins, whose 
common feature is the presence of a 12-16 amino acid BH3 domain (Adams and 
Cory, 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 1.11 The Bcl-2 family members (taken from Hengartner, 2000). 
 
Some of the members of the Bcl-2 family known to date include: 
Bcl-2: B cell lymphoma 2. It codes for 2 proteins, α and β. Bcl-2 refers to Bcl-2α, 
which is anti-apoptotic. 
Bcl-X: It codes for two proteins: Bcl-XL, which is anti-apoptotic and Bcl-XS, is pro-
apoptotic. 
Bad: Bcl-XL/Bcl-2-associated death promoter homologue. It is pro-apoptotic. 
Bid: Bcl-2 Interacting Protein. It is pro-apoptotic. 
Bak: Bcl-2 homologous antagonist killer. 
A1: a novel haemopeotic specific early response gene. 
Mcl-1: myeloblastic leukaemia cell line gene. 
Bax: It is pro-apoptotic and is seen as the most fundamental member of the Bcl-2 
family as the other members act (directly or indirectly) to control the actions of Bax. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.4 The Apoptotic pathways 
 
There are two different mechanisms involved in apoptosis: the death receptor or 
extrinsic pathway and the mitochondrial or intrinsic pathway (Fig 1.13). 
 
1.4.4.1 Death receptor or extrinsic pathway 
 
Death receptors belong to the tumour necrosis factor receptor (TNFR) gene 
superfamily, with cysteine-rich extracellular domains (Smith et al., 1994). The death 
receptors also contain a homologous cytoplasmic domain known as the “death 
domain" (Tartaglia et al., 1993). Death domains enable death receptors to engage the 
cell’s apoptotic machinery. The best-characterised death receptors are CD95 (also 
called Fas or Apo1) and TNFR1 (also called p55 or CD120a) (Smith et al., 1994). 
Additional death receptors are avian CAR1; death receptor 3 (DR3; also called Apo3, 
WSL-1, TRAMP, or LARD) (Chinnaiyan et al., 1997); DR4 (Pan et al., 1997); and 
DR5 (also called Apo2, TRAIL-R2, TRICK2 or KILLER). The ligands that activate 
these receptors are structurally related molecules that belong to the TNF gene 
superfamily (Smith et al., 1994). Fas ligand (FasL) binds Fas; TNF and lymphotoxin 
bind to TNFR1; Apo3L (also called TWEAK) binds to DR3; and Apo2L (also called 
TRAIL) binds to DR4 (Pan et al., 1997) and DR5. The ligand for CAR1 is unknown.  
 
Receptors such as TNFR1 and Fas (section 1.2.3.2.2) interact with their respective 
ligands at the surface of the cell, which then induces the formation of a death-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
inducing signalling complex (DISC). This complex recruits several procaspase-8 
molecules through an adaptor molecule such as Fas-associating death domain 
(FADD) or MORT1 (Mediator of receptor-induced toxicity). This results in caspase-8 
activation, which initiates a cascade of caspase activation leading to the destruction of 
the cell. 
 
1.4.4.2 Mitochondrial or intrinsic pathway 
 
In a healthy cell, the outer mitochondrial membranes express Bcl-2 on their 
cytoplasmic surface. Bcl-2 is bound to a protein called Apaf-1 (apoptotic protease 
activating factor-1). Internal damage to the cell, such as DNA damage, causes Bcl-2 
to release Apaf-1 and the release of cytochrome c. Apaf-1, cytochrome c and ATP 
activate caspase-9. The activated caspase-9, in turn, activates caspase-3, which is 
responsible for the execution of the cell. 
 
Although the two pathways operated independently of each other under most 
conditions, each of them involves the activation of specific initiator caspases, such as 
caspase-8 and 9. Both pathways eventually converge at the level of caspase-3 
activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 1.12 Diagrammatic representation of the two mechanisms by which apoptosis 
occurs: the death receptor and the mitochondrial pathways (from Hengartner, 2000). 
 
1.5 Tumor suppressor genes 
 
Tumour suppressor genes are negative regulators of the cell cycle growth, DNA 
replication and division (Vogelstein et al., 2000). Tumour suppressor genes are 
needed to keep cell division under control. Many tumour suppressor proteins function 
by inducing apoptosis in response to DNA damage, hypoxia and other stresses 
(Macleod, 2000). It has been shown that a loss of function of the tumour suppressor 
gene results in reduced apoptosis and increased tumour growth. There are at least 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tumor suppressor genes that have been described (Table 1.4). The two best 
understood tumor suppressor genes are the retinoblastoma (Rb) and the p53 genes. 
 
Tumor suppressor 
gene 
Location on human 
chromosomal 
Human tumors 
RB1 13q14 Retinoblastoma, osteosarcoma 
Wt1 11p13 Nephroblastoma 
P53 17q11 Sarcomas, breast/brain tumors 
NF1 17q11 Neurofibromas, sarcomas, gliomas 
NF2 22q12 Schwannomas, meningiomas 
VHL 3p25 Hemangiomas, renal, 
pheochromocytoma 
APC 5q21 Colon cancer 
INK4a 9p21 Melanoma, pancreatic 
PTC 9q22.3 Basal cell carcinoma, medulloblastoma 
BRCA1 17q21 Breast/ ovarian tumors 
BRCA2 13q12 Breast/ ovarian tumors 
DPC4 18q21.1 Pancreatic, colon, hamartomas 
FHIT 3p14.2 Lung, stomach, kidney, cervical 
carcinoma 
PTEN 10q23 Glioblastoma, prostate, breast 
TSC2 16 Renal, brain tumors 
NKX3.1 8p21 Prostate 
LKB1 19p13 Hamartomas, colorectal, breast 
E-Cadherin 16q21.1 Breast, colon, skin, lung carcinoma 
MSH2 2p22 Colorectal cancer 
MLH1 3p21 Colorectal cancer 
PMS1 2q31 Colorectal cancer 
PMS2 7p22 Colorectal cancer 
MSH6 2p16 Colorectal cancer 
Table 1.4 Tumor suppressor genes and associated human cancers (from Macleod, 
2000). 
 
1.5.1 The p53 gene 
 
p53 was the second tumour suppressor gene to be identified in 1979 after the Rb 
gene, and it was found to be associated with the transforming protein of SV40 tumour 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
virus (Linzer and Levine, 1979). p53 was named in reference to its molecular weight 
of 53 kD. It has been discovered that in most human cancers, p53 was inactivated due 
to mutations in the gene (Rodrigues et al., 1990). About 50 % of human cancers can 
be associated with a p53 mutation including cancers of the bladder, breast, cervix, 
colon, lung, liver, prostate and skin. It has been shown that p53 related cancers are 
more aggressive and have a higher degree of fatalities (Rodrigues et al., 1990). 
 
1.5.1.1 The structure of p53 protein 
 
p53 is a nuclear protein whose gene is located on human chromosome 17p13 and 
consists of 393 amino acids. It has been shown that a single amino acid substitution 
can lead to a loss of function of the p53 protein (Hupp et al., 2000). p53 protein is 
divided into four domains (Fig 1.13): (1) the N terminal transactivation domain, 
which is a highly charged, acidic region of 75- 80 residues. This domain contains 
binding sites for transactivating factors, MDM2 and regulatory phosphorylation sites; 
(2) the core sequence-specific DNA binding domain, containing most of the p53 
mutations found in human cancers (Hollstein et al., 1991). It is a hydrophobic, 
proline-rich domain; (3) the tetramerisation domain which ensures the assembly of 
p53 into conformationally active tetramers (Jeffrey et al., 1995); and (4) a negative 
regulatory, basic C terminal domain containing a heat-shock cognate 70 stress protein 
(hsc70)-binding site (Hansen et al., 1996), a cyclin A docking site (Luciani et al., 
2000) and multiple sites for phosphorylation (Hupp and Lane, 1994), SUMOlation 
(Rodriguez et al., 1990) and acetylation (Gu and Roeder, 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Fig 1.13 Structure of p53 showing the functional and regulatory domains (taken from 
Hupp et al., 2000). 
 
1.5.1.2 Functions of the p53 gene 
 
The p53 tumor suppressor gene plays an important role in the prevention of tumor 
development. It suppresses progression through the cell cycle in response to DNA 
damage in order to allow DNA repair to occur. If the damage to the cell is severe, p53 
will initiate apoptosis. These responses prevent replication of or eliminate cells with 
damaged DNA. Defective p53 can allow abnormal cells to grow, resulting in cancer. 
p53 functions as a transcription factor and binds to DNA as a tetramer, thereby 
regulating the transcription of a large number of genes (el-Deiry et al., 1992). These 
genes include those that are involved in cell cycle arrest (e.g. the cyclin-dependent 
kinase inhibitor, p21Waf1/Cip1); DNA repair (e.g. p53R2) and those involved in 
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apoptosis (e.g. Bax, and Apaf-1 (Vousden, 2000). p53 also represses the transcription 
of other genes, such as those involved in stimulating cell growth.  
 
Other functions of p53 include the ability of p53 to relocalise death receptors like Fas 
from the Golgi to the cell surface (Bennett et al., 1998), and the direct involvement of 
p53 in the mitochondria (Marchenko et al., 2000). 
 
1.5.1.3 p53-activating pathways 
 
There are three independent pathways that play a role in activating the p53 network. 
One pathway is triggered by DNA damage, e.g. ionising radiation. This pathway 
depends on two protein kinases: ATM (ataxia telangiectasia mutated) and Chk2 
(checkpoint kinase 2) (Carr, 2000). ATM is activated by double stranded breaks in 
DNA, and in turn stimulates Chk2. 
 
The second pathway is stimulated by aberrant growth signals, resulting from the 
expression of the oncogenes Ras and Myc. In humans, the activation of p53 network 
depends on p14ARF tumor suppressor protein (Lowe and Lin, 2000).  
 
The third pathway is triggered by a wide of range of chemotherapeutic drugs, UV 
light and protein kinase inhibitors. It involves kinases called ataxia telangiectasia 
related (ATR) and casein kinase II (Meek, 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All three pathways inhibit the degradation of p53 protein and therefore stabilize p53 
at high concentrations. Increased p53 concentrations allow p53 to bind to particular 
DNA sequences and activate transcription of adjacent genes. It is these genes that 
ultimately lead to cell death or the inhibition of cell division. 
 
1.5.1.4 Regulation of p53 activity 
 
Signals that activate the p53 response lead to rapid increase in p53 protein 
concentration through stabilization of the protein and activation of the DNA binding 
function of p53 (Ashcroft and Vousden, 1999). p53 levels must be tightly regulated. 
Although p53 suppresses tumors, high levels of p53 may increase the aging process 
by excessive apoptosis. The major regulator of p53 is Mdm2 (murine double minute 
clone 2) (section 1.5.1.2). The p53 protein binds specifically to Mdm2 promoter and 
activates its transcription (Barak et al., 1993). The resultant Mdm2 protein binds 
directly to p53 and targets it for degradation through an ubiquitin-dependent pathway 
(section 1.6.1) (Kubbutat et al., 1997). This defines a negative feedback loop (Fig 
1.14), which keeps p53 in check. The importance of the p53-Mdm2 feedback loop 
was illustrated in Mdm2 knockout mice. These experiments showed that the 
inactivation of Mdm2 resulted in excess p53 activity, which lead to embryonic death 
(Jones et al., 1995 and Montes de Oca Luna et al., 1995). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig 1.14 The p53-Mdm2 negative feedback loop (taken from Oren, 1999). 
 
It has been reported that stabilisation and activation of p53 protein upon stress also 
involves covalent modifications of p53, including phosphorylation, acetylation and 
glycosylation. Phosphorylation within the p53-Mdm2 binding interface blocks the 
binding, and thereby preventing p53 from degradation (Shieh et al., 1997). Mdm2 
may also become phosphorylated, blocking p53 degradation. Other types of 
modification of both p53 and Mdm2 have also been reported. Acetylation and 
glycosylation of p53 have been reported to result in increased DNA binding (Gu and 
Roeder, 1997 and Shaw et al., 1996). 
 
Protein-protein interactions also play a role in regulating cellular p53 levels and 
activity. An example is provided by the ARF (alternative reading frame) protein. 
ARF is a small protein, which arises through the translation of an alternative reading 
frame derived from the INK4A tumor suppressor gene (Kamijo et al., 1998). ARF 
binds to Mdm2 and p53, thus preventing p53 degradation (Zhang et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.1.5 p53-binding proteins 
 
Wild-type p53 binds to specific genomic sites with a consensus binding site 5'- 
PuPuPuC (A/T)(T/A)GpyPyPy-3' (el-Deiry et al., 1992). A number of targets for p53 
have been identified (reviewed by Tokino and Nakamura, 2000). Table 1.5 lists the 
p53 target genes and their function. 
 
TARGET GENES FUNCTION 
Mdm2 Involvement in p53 control 
P21 WAF1/CIP1, GADD45, WIP1, Mdm2, 
EGFR, PCNA, CyclinD1, Cyclin G, TGFα 
Involvement in cell cycle control 
GADD45, PCNA, p21 WAF1/CIP1 Involvement in DNA repair 
BAX, Bcl-L, FAS1, FASL, DR5 Involvement in apoptosis 
TSP-1, BAI1 Involvement in angiogenesis 
TP53TG1, CSR, PIG3 Involvement in cellular stress response 
Table 1.5 p53-binding proteins and their function. 
 
1.5.1.6 MDM2 protein 
 
MDM2 (murine double minute-2) was first identified as an amplified gene in a 
spontaneously transformed mouse 3T3 cell line (reviewed in Gu et al., 2003). It is 
overexpressed in many human tumours and cancers (Oliner et al., 1992). It functions 
as an E3 ligase for p53 and itself through its RING finger domain at the C-terminus 
(Honda et al., 1997). MDM2 binds to p53 and targets p53 protein degradation via the 
ubiquitin-mediated pathway (Haupt et al., 1997). It interferes with p53’s ability to 
transactivate target genes. It binds to the N terminus of p53 at its transactivation 
domain (Fig 1.13) and inhibits its ability to function as a transcription factor. It 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
delocalises p53 from the nucleus to cytoplasm where it undergoes proteosomal 
degradation (Tao and Levine, 1999). p53 binds to the promoter region of MDM2 and 
activates its transcription. The MDM2 protein then binds to p53 and stimulates p53 
degradation. MDM2 can ubiquitinate p53 and itself (Lohrum and Vousden, 2000). 
 
Another member of MDM2 family, MDMX, has been shown to bind to p53 and 
MDM2 and both these interactions can stabilize p53 (Ashcroft and Vousden 1999). 
The MDMX protein is structurally homologous to MDM2. The interaction of MDMX 
with MDM2 is mediated through the RING-finger domains of the two proteins and 
results in the inhibition of MDM2-mediated degradation (Ashcroft and Vousden, 
1999). MDMX binding therefore stabilizes MDM2 as well as p53. 
 
MDM2 has also been shown to interact with the Rb tumor suppressor protein and 
regulates the transcription factor E2F1 to promote cell cycle S-phase entry (Xiao et 
al., 1995). It inhibits the growth suppression at G1 imposed by p53 and Rb. Rb has 
been shown to regulate the apoptotic function of p53 through binding to MDM2, thus 
preventing MDM2 from targeting p53 for degradation (Hsieh et al., 1999). Rb does 
this by forming a trimeric complex with p53 via binding to MDM2. However, Rb 
cannot prevent MDM2 from inhibiting p53-mediated transactivation (Hsieh et al., 
1999). This, therefore, directly links the function of the two tumour suppressor 
proteins and demonstrates a new role of Rb in regulating the apoptotic function of 
p53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another interesting protein that has been shown to interact with MDM2 is the ARF 
tumour suppressor protein. ARF activates p53 by binding directly to MDM2, thereby 
inhibiting the E3-ligase activity of MDM2 and interfering with nucleocytoplasmic 
cycling of MDM2 that is necessary for p53 degradation (Tao and Levine, 1999). 
 
1.5.2 Retinoblastoma (Rb) gene 
 
Retinoblastoma is a tumour of the retina. It occurs in two forms: the familial 
retinoblastoma in which multiple tumours occur in the retinas of both eyes in the first 
week of infancy; while in sporadic retinoblastoma a single tumour occurs in one eye 
early in childhood before the retina is fully developed. Both forms are caused by a 
mutation in the Retinoblastoma (Rb) gene, located on human chromosome 13.  
 
The Rb gene was the first tumor suppressor gene to be identified and was isolated 
from retinoblastoma tumors (Lee et al., 1987). It is a member of a family of proteins, 
which includes p107 and p130. The protein product of the retinoblastoma gene, Rb, is 
a nuclear phosphoprotein that arrests cells during the G1 phase of the cell cycle by 
repressing transcription of genes required for the G1-to-S-phase transition (Weinberg, 
1995). The retinoblastoma protein is a master regulator of the cell cycle, cell 
differentiation and apoptosis (Williams and Grafi, 2000). Rb is frequently mutated in 
tumours such as retinoblastoma, osteosarcoma and small-cell lung carcinoma 
(reviewed in Hsieh et al., 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.2.1 Structure of Rb protein 
 
The human Rb protein contains 928 amino acids, with a relatively long half-life (>8 
hours) (Morris and Dyson, 2001). The Rb protein is made up of three type of pocket 
domains: A, B and C and they are situated at residues 379-928 (Hsieh et al., 1999) 
(Fig 1.15). The A and B domains are separated by a spacer region and are important 
in the binding of viral oncoproteins. The C domain binds to the tyrosine kinase c-Abl 
(Welch and Wang, 1993) and can also interact with Mdm2 (Xiao et al., 1998). 
 
 
 
 
 
Fig 1.15 The structure of the retinoblastoma (Rb) pocket domain protein (from 
Morris and Dyson, 2001). 
 
1.5.2.2 The role of Rb protein 
 
Rb is known to regulate the progression from G1 to S phase of the cell cycle 
(Weinberg, 1995) and has been implicated in the differentiation of muscle cells (Gu 
et al., 1993) and adipocytes (Chen et al., 1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The regulation of the G1 phase of the cell cycle requires the binding of Rb to a 
number of cellular proteins, many of which are transcription factors. The best-studied 
transcription factor is the E2F family. Rb binds to E2F through its large pocket 
domain and negatively regulates its activity (Weinberg, 1995). Progression of a cell 
through the G1 and S phase requires inactivation of Rb by phosphorylation. 
Phosphorylation of Rb by cyclin D-dependent kinases (CDKs) and their cyclin 
partners (such as cyclin D, Cdk4 or Cdk6 and cyclin E) results in the release of Rb 
from E2F, leading to progression through the cell cycle (Lundberg and Weinberg, 
1998). It has been shown that the phosphorylation of Rb leads to its loss of function 
as cells progress through the G1 and S phase (Harbour et al., 1999). Loss of Rb 
function creates a selective pressure for the tumor to inactivate p53, which serves to 
eliminate cells with mutations in the Rb pathway (Harbour and Dean, 2000). 
Therefore, many tumors have mutations that inactivate both Rb and p53. 
 
1.5.2.3 Function of Rb in apoptosis 
 
Rb is inactivated either by a mutation in the gene or by the phosphorylation of the 
protein in almost all tumors. Loss of Rb function triggers the p53 apoptotic pathway 
(Morgenbesser et al., 1994). This link between Rb and p53 pathways can be 
explained by the fact that loss of Rb function leads to the release of E2F, which in 
turn triggers apoptosis by activating the tumour suppressor protein ARF (alternative 
reading frame) expression, which is encoded by the INK4A locus (Pomerantz et al., 
1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loss of Rb function can also induce p53-independent apoptosis and this may not be 
triggered by E2F.  
 
1.5.2.4 Rb-binding proteins 
 
Currently, there are at least 110 Rb-binding proteins reported. They are divided into 
three groups based on certain characteristics (Morris and Dyson, 2001). The first 
group consists of 15 kinases, phosphatases and kinase-regulators (Table 1.6). Most of 
these proteins have been shown to modify Rb posttranslationally in order to affect the 
function of Rb.  
 
Rb-binding protein Region of Rb binding 
Cyclin A Not mapped 
Cyclin A1 Large pocket 
Cyclin D1 Small pocket 
Cyclin D2 Small pocket 
Cyclin D3 Small pocket 
Cyclin E Not mapped 
p25 NCK5a Large pocket 
Cdc2 Not mapped 
Cdk2 C-domain 
Cdk4 Not mapped  
JNK 1 C-domain 
Raf Small pocket 
pRb kinase N-domain 
PP1α C-domain 
PP1δ Not mapped 
Table 1.6 The first group of Rb-binding proteins (i.e. kinases, phosphatases and 
their regulators). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The second group contains 72 transcriptional regulators, which in turn are grouped 
into three functional categories (Table 1.7): (1) factors repressing transcription, (2) 
factors activating transcription, and (3) factors affecting transcription in unknown 
ways.  
Rb-binding protein Region of Rb binding 
E2F-1 Large pocket 
E2F-2 Large pocket 
E2F-3a Large pocket 
E2F-3b Not mapped 
E2F-4 Large pocket 
DP-1 Not mapped 
DP-2 Not mapped 
RBP60 Large pocket 
RbAp46 Small pocket 
RbAp48 Small pocket 
HDAC1 Small pocket 
HDAC2 Small pocket 
HDAC3 Small pocket 
c-Ski B-domain 
Sno Not mapped 
Sin3a Not mapped 
RBP1 Small pocket 
RBP2 A-domain and spacer 
Bdp C-domain 
Elf-1 Large pocket 
CtIP Small pocket 
TFIIIB Large pocket 
TBP Not mapped 
BRF/TFIIB Not mapped 
UBF C-domain 
HBP1 Small pocket 
DNMT1 Small pocket 
NFκB p50 Not mapped 
RBak Not mapped 
P120E4F B and C-domain 
Table 1.7.1 A group of Rb–binding proteins that function by repressing 
transcription. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rb-binding protein Region of Rb binding 
MyoD B and C-domain (605-792) 
Myogenin B and C-domain (605-792) 
Myf-5 B and C-domain (605-792) 
MRF4 B and C-domain (605-792) 
NF-IL6 Small pocket 
C/EBP B and C-domain (612-767) 
c-Jun Small pocket 
JunB Not mapped 
JunD Not mapped 
Sp1 Not mapped 
Table 1.7.2 A group of Rb–binding proteins that function by activating 
transcription. 
 
Rb-binding protein Region of Rb binding 
BRG1 Small pocket 
HBrm1 Small pocket 
ATF-1 unmapped 
ATF-2 unmapped 
c-myc Small pocket 
N-myc Small pocket 
PU.1 Large pocket 
AP-2 Large pocket 
Id-2 Small pocket 
Purα Not mapped 
Cream-1/Rbap2 Not mapped 
Che-1 Not mapped 
TAFII250 All regions 
TAFII150 Large pocket 
TAFII80 Large pocket 
RIZ Not mapped 
Rim Not mapped 
Estrogen receptor Not mapped 
PML Small pocket 
Mdm2 C-domain 
p202 N (1-254) and large pocket 
Mi Not mapped 
pRb N (1-300) to C-domain 
Table 1.7.3 A group of Rb–binding proteins that affect transcription in unknown 
ways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The third group of Rb-binding proteins consists of 23 proteins that have a variety of 
functions, including regulating DNA replication, cell cycle and various nuclear 
processes (Table 1.7.3). 
 
Rb-binding protein Function Region of Rb binding 
c-Abl Tyrosine kinase C-domain 
Rak Tyrosine kinase Small pocket 
Bog Oncogene Not mapped 
Prohibitin Tumor suppressor gene Not mapped 
BRAC1 Tumor suppressor gene Large pocket 
p21CIPI/WAFI Cdk inhibitor Small pocket 
p57KIP2 Cdk inhibitor Not mapped 
H-nuc Metaphase spindle control Small pocket 
Mitosin Centromeres regulation Not mapped 
Nuclear lamin A Nuclear matrix B and C-domain 
Nuclear lamin C Nuclear matrix B and C-domain 
NRP/B Nuclear matrix Not mapped 
*P2P-R RNA processing Small pocket 
P84N5 RNA processing/ apoptosis N-domain (1-300) 
*RBQ-1/PACT Pre-RNA splicing unmapped 
RBQ-3 unknown B and C-domain 
Topo-Iiα Relax DNA supercoiling Small pocket 
DNA polα Replicative DNA polymerase Not mapped 
REC2 Recombinase Large pocket 
MCM7 Pre-replication complex N-domain (1-400) 
hsHec1p Chromosomal segregation Large pocket 
hsc73 Heat-shock protein N-domain 
hsp75 Heat –shock protein Small pocket 
*Theses are truncated homologues of the RBBP6 protein. 
Table 1.8 Rb binding proteins involved in regulating DNA replication, cell cycle and 
various nuclear processes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6 The ubiquitin-proteosome pathway 
1.6.1 Ubiquitin 
 
Ubiquitin is a highly conserved 76 residue protein found in all eukaryotes either free 
or covalently attached to cellular proteins (reviewed by Liakopoulus et al., 1998). 
The process by which ubiquitin is covalently linked to other proteins, is called 
ubiquitination. It involves the formation of an isopeptide bond between the C-
terminal glycine residue of ubiquitin and the amino group of a lysine residue of the 
target protein. Ubiquitination can target proteins for degradation by the 26S 
proteosome, a major protease of the cytosol and the nucleus of eukaryotes, which 
degrades proteins to small peptides, whereas ubiquitin is recycled. Ubiquitination can 
also target certain cell surface proteins to lysosomal degradation via the endocytic 
route (Jentsch and Pyrowolakis, 2000). Conjugated ubiquitin can act as a substrate for 
further ubiquitination reactions to form polyubiquitin. 
 
1.6.2 The ubiquitin pathway 
 
The ubiquitin pathway occurs via two steps: (1) the covalent attachment of multiple 
ubiquitin molecules to the target protein and (2) the degradation of the tagged protein 
by the 26S proteosome (Fig 1.16). Conjugation of ubiquitin to the target protein 
occurs via three steps involving ubiquitin activating enzyme (E1), ubiquitin-
conjugating enzyme (E2) and ubiquitin-protein ligases (E3) (Scheffner et al., 1995). 
E1 activates ubiquitin in an ATP-dependent manner, forming a thiol ester linkage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Haas, 1997). E2 then transfers the activated ubiquitin from E1 to a target protein that 
is specifically bound to E3 via a thiol ester linkage. There are different classes of E3 
enzymes. For the HECT (homologous to the E6-AP COOH terminus) domain E3s, 
the activated ubiquitin is transferred to E3, generating a third thiol ester intermediate, 
before being transferred to an E3-bound substrate. RING finger-containing E3s 
catalyse the direct transfer of the activated ubiquitin to the E3-bound substrate. E3 is 
then responsible for the covalent attachment of ubiquitin to the substrate. The 
ubiquitin molecule is generally transferred an amino group of an internal lysine 
residue in the substrate to generate an isopeptide bond. This resultant monoubiquitin 
substrate is usually not targeted for degradation by the 26S proteosome. However, in 
other cases, ubiquitin is conjugated to the N-terminal residue of the substrate 
(Breitschopf et al., 1998). In successive reactions, the polyubiquitin chain is 
synthesised by the transfer of additional ubiquitin to the Lys 48 of the previously 
conjugated molecule. The polyubiquitin chain serves as a recognition marker for the 
26S proteasome complex. The proteasome degrades the ubiquitin-tagged substrate 
into short peptides, which are released, as well as ubiquitin, which is recycled (Fig 
1.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 1.16 The ubiquitin pathway (taken from Glickman and Ciechanover, 2002). 
 
1.6.3 The ubiquitin-conjugating machinery 
1.6.3.1 Ubiquitin-Activating enzyme (E1) 
 
E1 exists as two isoforms of 110 and 117 kD, which are derived from a single gene 
and are found in both the nucleus and cytosol (Haas and Siepmann, 1997). This 
enzyme generates a high –energy thiolester intermediate with ubiquitin. In mammals 
there is only one E1 (Herschko and Ciechanover, 1998; Pickart, 2001). 
 
1.6.3.2 Ubiquitin-conjugating enzymes (E2) 
 
E2s are a superfamily of related proteins with a molecular weight of 14 to 35 kD. 
There are 11 E2 genes in yeast (Pickart, 2001) and 20 to 30 E2 genes in mammals 
(Scheffner et al., 1998). E2 genes are structurally similar, but have different 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
biological functions. Only 3 E2 genes in yeast are involved in the formation of the 
polyubiquitin degradation signal. The other yeast E2 genes are involved in the 
formation of mono-, di-, and tri-ubiquitin conjugates that are not targeted for 
degradation. 
 
1.6.3.3 Ubiquitin-protein ligases (E3) 
 
Ubiquitin-protein ligases play an important role in the ubiquitin pathway. They are 
responsible for the selective recognition of target proteins. E3 can bind both E2 and 
the target protein. They are classified into two major groups: HECT domain- and 
RING finger-containing E3s. 
The HECT (Homologous to E6-AP C-terminus) domain contains 350 amino acids. It 
mediates E2 binding and ubiquitination of the target protein via a thiolester linkage 
formation with ubiquitin. E6-AP (E6-Associated Protein) forms a complex with the 
papilloma virus E6 oncoprotein to ubiquitinate the p53 protein. 
 
The RING (Really Interesting New Gene) finger structure is defined by 8 cysteine 
and histidine residues that coordinate two zinc ions (Freemont, 2000). The RING 
finger E3s are either monomeric proteins or multiple subunit complexes (Pickart, 
2001). Some of the members of the monomeric RING finger E3 family are Mdm2, 
Ubr1 and Parkin, and they contain both the RING finger domain and the substrate-
recognition site. Members of the multiple subunit complex include the APC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Anaphase Promoting Complex), which is involved in the degradation of cell cycle 
regulators. 
 
1.7 The DWNN gene family 
1.7.1 Identification of DWNN domain 
 
DWNN (Domain With No Name) gene was first identified in a study to identify new 
genes involved in the CTL killing pathway (George, 1995) by RACE and inverse 
PCR methods. It was given this name because its sequence matched only one entry in 
the non-redundant NCBI database, a human EST 587 (from 21C4 clone, accession 
number T25012), which in turn did not match any known sequence in the database. 
Sequence analysis of the 21C4 clone showed that the mRNA is 1.1 kb long and 
contains 118 amino acids, encoding a 13 kD protein and hence this protein was 
named DWNN-13 in this study. Further sequence analysis showed that the sequence 
encodes a highly conserved region of 80 amino acids and a hydrophobic tail (Fig 
1.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1/1                                     31/11  
ATG TCC TGT GTg CAT TAT AAA tTT TCC tCT AAA CTC AAC TAt GAT ACC GTC ACC TTT Gat  
M   S   C   V   H   Y   K   F   S   S   K   L   N   Y   D   T   V   T   F   D    
 
61/21                                   91/31                                    
GGG CTC CAC ATC TCC CTC tGC GAC TTA aAG AAG CAG ATT ATG GgG AGA GAG AAG CTG aAA  
G   L   H   I   S   L   C   D   L   K   K   Q   I   M   G   R   E   K   L   K    
 
121/41                                  151/51                                   
GCT GCC GAC TGC GAC CTG CAG ATC ACC AAT GCG CAG ACg Aaa gAA gAa TAT ACT GAT GAT 
A   A   D   C   D   L   Q   I   T   N   A   Q   T   K   E   E   Y   T   D   D 
 
181/61                                  211/71                                   
AAT GCT CTG ATT CcT AAG AAT TCT TCt GTA ATT GTT agA aga ATt cCT ATT GGA GGT GTT  
N   A   L   I   P   K   N   S   S   V   I   V   R   R   I   P   I   G   G   V    
 
241/81                                  271/91                                   
AAA TCT ACA AGC AAG ACa TAT GTT aTA AGT CGA ACT GAA CCa GCg ATG Gca ACT Aca AAA  
K   S   T   S   K   T   Y   V   I   S   R   T   E   P   A   M   A   T   T   K    
 
301/101                                 331/111                                  
Gca gTA TGT AAA AAC ACa ATC Tca caC TTT TTC TAc ACA TTG CTT TTA CCT TTA 
A   V   C   K   N   T   I   S   H   F   F   Y   T   L   L   L   P   L 
 
Fig 1.17 Protein translation of the DWNN-13 gene showing the highly conserved 80 
aa region (red) and the hydrophobic C-terminal tail (blue). 
 
The 80 amino acid region (named the DWNN domain) was shown to be highly 
conserved throughout species, including humans, worms, flies, plants, algae and yeast 
(Fig 1.18) and has not been characterised previously.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Fig 1.18 Sequence alignment of the DWNN gene, showing the conserved amino 
acids within the DWNN domain in various species. 
 
The secondary structure of the conserved 80 amino acid DWNN domain has been 
recently solved and shown to consist of α-helices and β-sheets (Faro, 2004). The 3D 
structure of the DWNN domain has been found to be similar to that of ubiquitin (Fig 
1.19). There is no evidence that has been presented to date on the functional 
similarities between these two proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Fig 1.19 3D structures of (A) Ubiquitin and (B) DWNN domain (Faro, 2004). 
 
The human DWNN gene has been mapped on chromosome 16p11.1. Previous EST 
data showed that the human DWNN and RBBP 6 genes (previously identified gene 
which binds Rb and p53) lie separate, but adjacent on chromosome 16 (Rees, 
unpublished data). RT-PCR data, however, showed that DWNN and RBBP6 gene are 
part of the same transcript (Dlamini, unpublished data). Further analysis of this 
transcript revealed that its mRNA is 6.1 kb long that encodes a 200 kD protein (and 
hence this protein was named DWNN-200 in this study). Sequence analysis 
illustrated that this gene contains 18 exons and consists of several domains (Fig 1.20). 
These domains include the conserved DWNN domain (situated in exons 1 to 3), a 
CCHC zinc finger domain (situated in exon 5 and exon 6) and a C3HC4 type of 
RING finger domain, located in exons 7 to 10 (Fig 1.20). CCHC zinc finger domains 
are known to interact with single stranded RNA or DNA, while the C3HC4 RING 
finger domain has been shown to have ubiqutin-ligase activity. They are often found 
in E3 ubiquitin ligases (see section 1.6.3.3). Also, on the C terminal end of the gene, 
an alternatively spliced region has been identified in certain human cell lines (Chapter 
5) and has been mapped to exon 16. There is also an SR domain and an Rb-binding 
A B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
domain in exon 17 of this transcript. The DWNN-200 gene also contains a p53-
binding domain in exon 18 and a proline-rich region spanning exons 10 to 15. 
 
1.7.2 DWNN/RBBP6 homologues 
 
With the completion of the human genome sequence, the DWNN-200 gene has been 
officially named RBBP6 (accession number NP 008841). The NCBI BLAST 
database has (since 1995) revealed a wide range of species containing the RBBP6 
gene. Figure 1.21 shows the domain arrangement of the RBBP6 gene in various 
species. In humans, worms and flies the RBBP6 gene contains the DWNN domain, 
CCHC zinc motif, C4HC Ring finger domain, as well as the Rb- and p53- binding 
domains. In fungi, plants, protists and microsporidia, the RBBP6 domain structure is 
similar. The RBBP6 gene in these species contains the DWNN domain, CCHC zinc 
motif and C4HC Ring finger domain only. 
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Fig 1.21 Schematic representation of the domain structure of the DWNN-200 protein 
from different species. 
 
1.7.2.1 Homo sapiens RBBP6 (NP 008841) 
 
The human sequence of this gene has been sequenced to completion recently. The 
human RBBP6 encodes a protein that binds the underphosphorylated Rb protein 
(Sakai et al., 1995). The sequence analysis of this gene according to AceView 
revealed that it contains 13 alternatively spliced transcript variants that encode 13 
different isoforms. The gene is expressed highly in the placenta and various tissues, 
as well as in human cancer tissues. This data is consistent with the previous data 
showing the high levels of DWNN domain expression in human esophageal cancer 
tissues (Dlamini, unpublished). Sakai and colleagues first described the human 
RBBP6 gene in 1995. However, the full length sequence of this gene was not known 
then and they described the partial sequence of the gene, which they named RBQ-1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RBQ-1 (RBBP6) protein 
 
RBQ-1 (also known as RBBP6) was cloned from a human small cell lung carcinoma 
library as a novel protein of 140 kD in size and has been shown to bind to the Rb 
gene product (Sakai et al, 1995). Two other proteins; RBQ-2 and RBQ-3, which bind 
the Rb gene were also cloned in that study (Sakai, et al., 1995)). All three proteins 
bind to the underphosphorylated pRb. RBQ-1 and RBQ-3 showed no significant 
homology to each other (Saijo et al., 1995). 
 
The RBQ-1 sequence showed that this protein is homologous but shorter to that of the 
mouse PACT protein, (948 amino acids compared to 1583 amino acids of mouse 
PACT) but continues 182 bp upstream of the PACT protein. The overall amino acid 
homology between mouse PACT and human RBQ1 is 94 %, suggesting that the two 
proteins are highly conserved (Simons et al., 1997). 
 
The nucleotide sequence of RBQ-1 cDNA was shown to be 3011 bp in length and 
contains an open reading frame (ORF) that encodes 948 amino acids, with multiple 
repetitive motifs, one (the SRS) of which was previously described in the DNA-
binding protein Son3 (Berdichevskii et al., 1988). A putative alternatively spliced 34 
amino acid region was also found in the middle of this protein. RBQ-1 is a 140-kD 
protein that consists of 12 exons. Sakai et al., 1995, detected a ubiquitous 8.5 kb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
transcript in adult and fetal tissues by Northern blot analysis. They mapped the gene 
to chromosome 16p12.2. 
 
1.7.2.2 Mus musculus Rbbp6 (NM 011247) 
 
Recent data from Ensembl Gene however, reveals that the mouse contains two 
transcripts of the Rbbp6 gene. The first transcript (Stable ID: 
ENSMUST00000033043) contains 12 exons and encodes 1556 residue protein. The 
second transcript (Stable ID: ENSMUST00000052135) also contains 12 exons but 
encodes a 1590 residue protein. BLAST analysis has mapped the gene on 
chromosome 7. According to Mouse Genome Database (MGD), February 2004, the 
nucleic acid sequence of the mouse Rbbp6 shows 82.6 % identity to that of humans. 
 
Two research groups have previously identified the partial cDNAs of the mouse 
RBBP6 and have named them PACT (Simons et al., 1997) and P2P-R (Witte and 
Scott, 1997).  
 
p53 associated cellular protein-testes derived (PACT) 
 
PACT was isolated from the mouse testes expression library using p53 as a probe, in 
a study to identify cellular proteins interacting with p53 (Simons et al., 1997). The 
sequence analysis of PACT showed that the cDNA is 5177 bp long coding for 1583 
amino acids and contains 437 bp 3' non-coding region with a polyA signal and tail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The amino acid sequence of the 250 kD PACT showed interesting regions within the 
protein, including the 34 amino acid alternatively spliced region, a serine/arginine 
(SR) region and a 54 amino acid Lysine-rich region at the C-terminus. The SR 
domain has been shown to be a site in which serines are phosphorylated by a specific 
kinase (reviewed by Gui et al., 1994) and the lysine-rich domain has been suggested 
to play a role in in vivo modification. The protein is highly charged, containing 22.5 
% basic residues and 14.3 % acidic residues.  
 
PACT has been shown to localize to the nuclear speckles by three different anti-
PACT antibodies (Simons et al., 1997), which is where several pre-mRNA splicing 
components are found (Spector, 1993). This observation suggests that PACT might 
be connected to cellular pre-mRNA splicing mechanism. 
 
Proliferation potential protein related (P2P-R) protein 
 
P2P-R is a nuclear protein that binds both p53 and Rb proteins. It was cloned from a 
mouse cDNA library (Witte and Scott, 1997). It is expressed in a variety of murine 
tissues and cells. P2P-R cDNA is 5173 bp in length, containing a 4214 bp ORF 
encoding a highly basic 156.9 kD protein. It is an alternatively spliced product of the 
mouse PACT gene because it lacks one exon containing 102 nucleotides encoding 34 
amino acids (Scott et al., 2003). Analysis of the P2P-R cDNA revealed that the 
cDNA contains multiple domains including an N-terminal RING type zinc finger, a 
heterogenous nuclear ribonucleoprotein (hnRNP)-associated domain, an Rb1- and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p53-binding domain, a proline rich domain, an SR region, a single stranded 
nucleotide binding domain and a C- terminal lysine rich domain. A cell division 
sequence motif near the amino terminus and a potential nuclear localisation signal 
were identified within the P2P-R cDNA (Witte and Scott, 1997). The 5' region of 
P2P-R cDNA shows significant homology to RBQ1 cDNA (Sakai et al., 1995).  
 
P2P-R has been shown to play a role in the control of RNA metabolism (Simons, et 
al., 1997), apoptosis and p53-dependent transcription. It localizes in the nucleolus 
during interphase of murine and human cells and therefore is compatible with its role 
in RNA metabolism (Gao et al., 2002). Its ability to bind p53 correlates with the fact 
that p53 also localizes to the nucleoli in the interphase cells. P2P-R has been reported 
to localize in the periphery of chromosomes in the mitotic cells (Gao et al., 2002). 
P2P-R binds to proline-rich and C-terminal regulatory domains of p53 (Gao et al., 
2002). The proline-rich domain of p53 regulates the expression of both pro-apoptotic 
and anti-apoptotic genes. Western blot experiments have shown that P2P-R protein is 
expressed at higher levels in mitotic cells compared to other cells cycle states (Gao et 
al., 2002). Studies showing overexpression of near full length P2P-R resulted in slow 
cell cycle progression at metaphase and promotion of mitotic apoptosis. This is 
contrary to the overexpression of a smaller P2P-R domain that showed no significant 
detectable effect on cell cycle progression or apoptosis (Gao et al., 2002).  
 
Studies have shown that P2P-R is phosphorylated by cdc2 and SRPK1a protein 
kinases. It also interacts with scaffold attachment factor-B, a MARs (matrix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
attachment regions) binding factor, and may interact with nucleolin as well (Gao and 
Scott, 2002). P2P-R can also bind single stranded RNA. It is suggested that P2P-R 
may form complexes with Rb1 and /or p53 tumor suppressors and MARs-related 
factors, in a cell cycle and cell differentiation-dependent manner, to influence gene 
transcription/ expression and nuclear organization (Gao and Scott, 2002). Recent 
studies have shown that expression of the near full-length P2P-R promotes 
camptothecin-induced apoptosis in MCF 7 cells (Gao and Scott, 2003). The region 
responsible for this effect was identified and it has been shown that it overlaps with 
the p53-binding and the single-stranded nucleotide binding regions (Witte and Scott, 
1997). 
 
1.7.2.3 Saccharomyces cerevisiae RBBP6 (NP 012864) 
Mpe-1 protein 
 
Mpe1 is a Saccharomyces cerevisiae novel gene, identified by Vo and colleagues and 
is highly homologous to the human RBBP6 protein. It has been shown to interact 
with the PCF11 protein, encoding a protein of 441 amino acids, with a molecular 
weight of 49.5 kD (Vo et al., 2001). Mpe-1 is essential for cell viability and contains 
a zinc knuckle motif, which is implicated in protein-nucleic acid interactions (Breg 
and Shi, 1996; Laity et al., 2001). The zinc knuckle motif found in Mpe-1 is 
homologous t to the zinc knuckle found in the human RBBP6 protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mpe-1 is required for the specific cleavage and polyadenylation of pre-mRNA. Mpe1 
has been shown to be a component of the cleavage and polyadenylation factor 
complex (CPF) but it is not essential for the stability of the CPF (Vo et al., 2001). It 
is a conserved protein, with homologies found in S. pombe, A. thaliana, D. 
melanogaster and humans. The protein sequence of Mpe1 contains the conserved 
zinc and RING finger motifs, as well as the DWNN domain.  
Figure 1.22 shows the schematic representation of the some of the RBBP6 
homologues, discussed above. 
 
1.7.2.4 Other RBBP6 homologues 
 
The UniGene and GeneCard databases show evidence for the presence of other 
RBBP6 homologues, including Arabidopsis thaliana (accession number NM124114), 
Drosophila melanogaster (accession number CG3231), Danio rerio (BG 737479), 
Xenopus laevis (BJ614254) and Rattus norvegicus (XP219296). Table 1.8 shows the 
comparison of the RBBP6 protein sequences from different species homologues to 
the human RBBP6 sequence. No work has been undertaken in these organisms, as 
compared to the human, mouse and yeast RBBP6 genes. 
 
Organism % identity to 
humans 
Database 
Rattus norvegicus (rat) 85.1 HomoloGene 
Xenopus laevis (African clawed 
frog) 
82.14 HomoloGene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drosophila melanogaster (fruit 
fly) 
73.42 HomoloGene 
Mus musculus (mouse) 82.66 Mouse Genome Database 
(MGD) 
Danio rerio (zebrafish) 77.14 HomoloGene 
Ciona intestinalis (sea squirt) 73.93 HomoloGene 
Arabidopsis thaliana (thale 
cress) 
73.3 HomoloGene 
Table 1.9 Protein similarities of the RBBP6 homologues to humans. 
 
1.8 Retrovirus promoter-trap insertional mutagenesis 
 
Retrovirus insertional mutagenesis has been used to isolate genes responsible for 
recessive phenotypes (Goff, 1987). However, this approach is inefficient due to the 
large number (5x106-1x108) of integration events it requires to disrupt a single copy 
cellular gene (Varmus et al., 1981). Promoter-trap retroviral vectors have therefore 
been designed in order to increase the efficiency of insertional mutagenesis (von 
Melchner and Ruley, 1989). One such vector involved the positioning of a promoter-
less selectable marker gene downstream of the splice acceptor site so that when the 
retrovirus inserts into an intron of an expressed gene, the selectable marker gene is 
expressed (Brenner et al., 1989). 
 
Another type of promoter-trap retrovirus vector involved the insertion of a promoter-
less selectable marker gene into the U3 region of the 3’long terminal repeat (LTR) of 
an enhancer-less MoMLV (von Melchner and Ruley, 1989). Upon duplication of the 
LTR prior integration, the selectable marker is situated in the 5’ LTR such that it is 
located 30 nucleotides from the host genomic DNA. The selectable marker is only 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
expressed when the retroviral vector integrates within a few hundred base pair of an 
active cellular promoter.  
 
The latter vector has been used to isolate cellular promoters by using the retrovirus as 
a promoter trap (von Melchner et al., 1990). This vector has also been used to isolate 
genes involved in the processing and presentation of antigens to cytotoxic T cells 
(CTL) (George, 1995) and in a study to identify genes involved in ceramide-induced 
apoptosis (Meyer, 2003). 
 
Cell lines described in this thesis have been generated using the promoter-trap 
mutagenesis approach (George, 1995). The vector used in this case was the 
tkneoU3hygro, which contained the hygromycin phosphotransferase gene, which 
confers resistance to hygromycin B. Chinese hamster ovary (CHO) cells were used as 
targets due to their functionally haploid nature (Siminovitch, 1985), implying that an 
integration event may lead to a loss of gene function. The CHO cells were initially 
modified by transfection of L-HA and MHC class I Kk, conferring sensitivity to lysis 
by HA-specific Kk restricted CTL, the selection agent. Hence, more than 100 CTL 
resistant cell lines were generated this way (George, 1995). 
 
1.9 Objectives  
 
The aim of this study was to characterise previously generated promoter-trapped 
CHO cell lines from a study to identify genes involved in the CTL killing pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(George, 1995). It is expected that the identified genes would play a role in the 
expression, processing or presentation of antigens by MHC class I molecules or in the 
recognition, adhesion or lytic mechanism of CTL. It is predicted that not only novel 
genes will be identified from this study, but also previously identified genes. 
 
The identified gene(s) would have to be characterized in order to identify their 
function. Identification of more genes involved in the processing, presentation and 
killing of antigens by CTLs would lead to a broader understanding of this process and 
hence, opening more targets for candidate drug discovery. 
 
 
 
 
 
 
 
 
 
CHAPTER 2: MATERIALS AND METHODS. 
 
2.1 Materials and suppliers 
 
40 % 37.5:1 acrylamide: bisacrylamide mix   Promega 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Agarose       Whitehead Scientific 
Alexa Fluor 488 goat anti-rabbit IgG antibody  Molecular Probes 
Alexa Fluor 594 goat anti-rabbit IgG antibody  Molecular Probes 
Alexa Fluor 488 chicken anti-mouse IgG antibody  Molecular Probes 
Ampicillin       Roche Diagnostics 
AMPS (Ammonium persulphate)    Merck 
APOPercentage Assay kit     Biocolor Ltd 
BSA (Bovine serum albumin)    Roche Diagnostics 
Boric acid       Merck 
Cell culture media and reagents    Gibco Life Technologies 
Cesium chloride      Roche Diagnostics 
Chloroform       Merck 
Chloramphenicol      Sigma 
Coomassie Brilliant Blue R-250    Sigma 
DAPI (4,6-Diaminidine-2-phenylindoledihydrochloride) Roche Diagnostics 
DEPC (Diethyl Pyrocarbonate)    Sigma 
DMSO (Dimethyl sulphoxide)    Roche Diagnostics 
Ethidium bromide      Sigma 
EDTA (Ethylenediamineetetraaceticacid)   Merck 
Hydrochloric acid      Merck 
Kanamycin monophosphate     Roche Diagnostics 
LightCycler FastStart DNA Master PLUS SYBR Green I Roche Applied Science 
Lipofectamine 2000 transfection reagent   Invitrogen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MOPS        Roche Diagnostics 
Mouse-anti-mouse MHC I 2q KK antibody   Serotec 
Phenol        Invitrogen 
PMSF (Phenylmethylsulphonyl fluoride)   Roche Diagnostics 
Proteinase K       Roche Diagnostics 
PVDF (Polyvinylidene difluoride) membrane  Amersham   
        Biotechnologies 
Restriction enzymes      Roche Diagnostics 
SDS (Sodium dodecyl sulphate)    Merck 
Staurosporine       Roche Diagnostics 
T4 DNA ligase      Promega 
TEMED       Promega 
Tris (hydroxymethyl) aminomethane    Merck 
Triton X-100       Merck 
TRIzol reagent      Gibco Life Technologies 
Tween-20     Merck 
Vectorshield Hard Set mounting medium   Vectorshield 
Yeast extract       Merck 
Zeocin        Invitrogen 
 
2.2 Solutions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2x TY broth 1.6 % Tryptone, 1 % yeast extract, 5 g/l 
NaCl 
3:5M KOAc 3 M KOAc, 5 M glacial acetic acid pH 
5.0 
10x Ligase Buffer 660 mM Tris.Cl, 50 mM MgCl2, 10 mM 
DTT, 10 mM ATP and 10 % 
polyethylene glycol, pH 7.5 
10x MOPS  200 mM MOPS, 50 mM sodium acetate, 
10 mM EDTA, pH 8.0 
10x PCR Buffer  100 mM Tris.Cl, 500 mM KCl and 
0.1 % gelatin, pH 8.3 
10x TBE 0.9 M Tris, 0.89 M boric acid, 25 mM 
EDTA, pH 8.3 
AMPS      10 % ammonium persulphate 
Coomassie Blue destaining solution 40 % methanol, 10 % acetic acid and 
10 % (w/v) glycerol 
Coomassie Blue staining solution 40 % methanol, 10 % acetic acid and 
0.1 % Coomassie Brilliant Blue R-250 
stain 
Digestion buffer 100 mM NaCl, 10 mM Tris.Cl, 25 mM 
EDTA, 0.5 % SDS and 0.1 mg/ml 
proteinase K, pH 8.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DNA loading buffer 30 % (w/v) glycerol, 15 mM EDTA 
pH 8.0, 0.5 %(w/v) bromophenol blue 
FACS buffer 1 % foetal calf serum in PBS 
GTE 10 mM EDTA, 1 % glucose 50 mM 
Tris.Cl, pH 7.4 
L-agar 1 % tryptone, 0.5 % yeast extract, 10 g/l 
NaCl, 1.2 % agar, antibiotic as required 
NaOH/SDS 200 mM NaOH, 1 % SDS 
Permeabilising buffer 0.1 % Triton X-100 in PBS 
Phenol/Chloroform 1:1 (v/v) phenol: chloroform saturated 
with 20 mM Tris.Cl, pH 8.0 
Protein lysis buffer 150 mM NaCl, 10 mM Tris.Cl, 1 mM 
MgCl2, 0.1 mM ZnCl2, 1 % (w/v) Triton 
X-100, 10 mM DTT, 0.5 mM PMSF, 
pH 7.4 
SDS-PAGE running buffer 25 mM Tris, 192 mM Glycine, 0.1 % 
SDS, pH 7.5 
Separating gel 10 % acrylamide mix, 0.375 M Tris.Cl 
0.1 % SDS, 0.1 % AMPS and 0.1 % 
TEMED, pH 8.8 
Stacking gel 4 % acrylamide mix, 0.25 M Tris.Cl, 
0.1  % SDS, 0.1 % AMPS and 0.1 % 
TEMED, pH 6.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TE      10 mM Tris.Cl, 1 mM EDTA, pH 7.4 
Transformation buffer 1 (Tfb 1) 30 mM KOAc, 50 mM MnCl2, 100 mM 
KCl, 10 mM CaCl2, 15 % (w/v) glycerol 
Transformation buffer 2 (Tfb 2) 10 mM Na-MOPS 10 mM KCl, 75 mM 
CaCl2, 15 % (w/v) glycerol, pH 7.0 
Transfer Buffer 25 mM Tris, 192 mM Glycine, 10 % 
Methanol 
TYM broth 2 % tryptone, 0.5 % yeast extract, 0.1 M 
NaCl, 10 mM MgCl2 
All solutions were made up in deionised water unless stated otherwise. 
 
 
 
 
2.3 Bacterial culture 
2.3.1 Strains 
 
Name Genotype 
E. coli MC1061 F-, araD139, (ara leu)7697, ΔlacX74, galU-, galK-, hsr-, hsm+, 
strA (Casadabhan and Cohen, 1980) 
E. coli NM554 RecA13, araD139 Δ(araleu)7696 Δ(lac)17A galU galK hsdR 
rpsL (Str+) mcrA mcrB (Casadabhan and Cohen, 1980) 
E. coli XL1-
Blue 
RecA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, 
lac[F’proAB, lacIqΔZM15, Tn10(tetr)] (Stratagene) 
Table 2.1 Bacterial strains used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 Selection 
 
All bacteria were grown in 2xTY broth, and on nutrient agar plates with or without 
antibiotics. Ampicillin was added to the 2XTY broth at a final concentration of 100 
μg/ml, while kanamycin monophosphate was added at a final concentration of 30 
μg/ml. 
 
2.3.3 Storage of bacterial strains 
 
Overnight cultures were diluted by addition of an equal volume of sterile glycerol and 
then frozen at –70°C. 
 
2.4 Cloning vectors 
2.4.1 pGEM-T Easy vector (Promega) 
 
pGEM-T Easy vector is used for cloning of PCR products. The vector, which is 3.0 
kb in size, is prepared by digestion with the restriction enzyme Eco RV, followed by 
the addition of a 3' terminal thymidine to both ends. The single 3' -T overhangs at the 
insertion site improves the efficiency of ligation of a PCR product (which has extra 
dA residues added to the PCR product by Taq Polymerase) into the plasmid by 
preventing recircularisation of the vector. The high copy number pGEM-T Easy 
vector contains T7 and SP6 RNA Polymerase promoters flanking the multiple 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cloning site within the α-peptide coding region of the enzyme β-galactosidase. 
Insertional inactivation of the peptide allows recombinant clones to be directly 
identified by colour screening on indicator plates. pGEM-T Easy vector also contains 
the origin of replication of the filamentous phage f1 for the preparation of single-
stranded DNA phage.  
 
Fig 2.1  Circular map of pGEM-T Easy vector and the multiple cloning 
site (MCS). 
2.4.2 pBluescript II (Stratagene)  
 
pBluescript is a 3.0 kb high copy number ColE1-based phagemid, which has a 
versatile polylinker in four possible variants of the vector: (SK +/-; KS +/-). It 
contains the origin of replication from the f1 filamentous phage to allow rescue the 
single stranded DNA. The (+) and (-) orientations of the f1 intergenic region allow 
the rescue of either the sense or antisense DNA strand. Single stranded DNA can then 
be used for sequencing and site-directed mutagenesis. It contains T3 and T7 
promoters for in vitro transcription of RNA. It contains a gene conferring resistance 
to ampicillin. The MCS is within the Lac Z α peptide gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 2.2  pBluescript II SK (+) circular map with its MCS. 
 
2.4.3 pEGFP-C1 (Clontech)  
 
The green fluorescent protein (GFP) isolated from the jellyfish Aequorea victoriai as 
a reporter molecule that can be used to monitor gene expression and protein 
localisation (Chalfie et al., 1994). GFP fluoresces bright green when exposed to UV 
light, making it easily detectable by microscopy or flow cytometry. pEGFP-C1 is an 
optimised GFP variant. It encodes a red-shifted variant of the wild type Green 
Fluorescent, which has been optimised for brighter fluorescence and higher 
expression in mammalian cells It is a 4.7 kb vector and the MCS is situated between 
the EGFP coding sequences and the SV40 polyadenylation signal. Genes cloned in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the MCS will be expressed as fusions to the C terminus of GFP if they are in the same 
reading frame as EGFP and there are no intervening stop codons (Clontech, 1999). 
 
Fig 2.3 The map and MCS of pEGFP-C1 vector. 
 
2.4.4 pDsRed1-C1 (Clontech)  
 
Red Fluorescent Protein (RFP) is the only commercially available red fluorescing 
protein used for expression studies. pDsRed1-C1, a 4.7 kb vector, encodes a red 
fluorescent protein, DsRed1. Red fluorescent protein was originally isolated from 
Discosoma sp (Matz et al., 1999). It has a vivid red fluorescence, making it ideal for 
multiple labelling with other GFP variants, e.g. EGFP. The MCS in pDsRed1-C1 is 
positioned between the DsRed1 coding sequence and the SV40 polyadenylation 
signal. Genes cloned in the MCS will be expressed as fusions to the C-terminus of 
DsRed1 if they are in the same reading frame as DsRed1 and there are no intervening 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
stop codons. The SV40 poly A signal downstream of the MCS directs proper 
processing of the 3' end of mRNA transcripts. The vector also contains an SV40 
origin for replication in mammalian cells expressing the SV40 T-antigen. A 
neomycin resistance cassette (Neor) allows stably transfected eukaryotic cells to be 
selected using G418. A bacterial promoter upstream of this cassette expresses 
kanamycin resistance in E. coli. The pDsRed1-C1 backbone also provides a Col E1 
origin of replication for propagation in E. coli and f1 origin for single-stranded DNA 
production (Living Colors, 1996). 
 
 
Fig 2.4  Circular map of pDsRed1 vector map and its MCS. 
 
2.4.5 pcDNA3.1/Zeo(+) (Invitrogen)  
 
pcDNA3.1/Zeo (+) is a 5.0 kb vector designed for high-level stable and transient 
mammalian expression. It is available with the MCS in the forward (+) and reverse    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(-) orientations to facilitate cloning. The CMV promoter provides high-level 
expression in a wide range of mammalian cells. The Zeocin resistance gene allows 
selection in both E. coli and mammalian cells in the presence of the antibiotic Zeocin. 
The vector also contains the T7 promoter for in vitro transcription in the sense 
orientation, an ampicillin resistant gene and f1 origin for the rescue of single-stranded 
DNA. 
Fig 2.5  Circular map of pcDNA3.1/Zeo vector. 
 
2.5 Preparation of competent E. coli cells for transformation 
 
A single colony of the desired bacterial strain was inoculated into 20 ml TYM broth 
and grown with vigorous shaking at 37°C to A600 = 0.2. The culture was added to 100 
ml TYM and grown to A600 = 0.2. The culture was transferred to 400 ml TYM broth 
and grown under the same conditions to A600 = 0.6. The cells were rapidly cooled in 
iced water and were centrifuged at 3000 g for 10 min at 4°C. The bacterial pellet was 
resuspended on ice in 250 ml of ice cold Tfb1 and incubated for 60 min on ice. The 
cells were recovered by centrifugation at 3000 g for 10 min at 4°C. The pellet was 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gently resuspended in 50 ml of Tfb2, divided into 500µl aliquots and frozen in liquid 
nitrogen. The aliquots were stored at –70°C. 
 
 
 
 
2.6 Transformation of E. coli cells 
 
Competent cells were thawed on ice and 100 µl was added to 10 ng of plasmid DNA. 
The mixture incubated left on ice for 30 min, followed by heat shocking at 37°C for 5 
min. 900 µl of 2xTY broth was added to the transformation and the cells incubated 
for a further 60 min at 37°C, to allow expression of the antibiotic resistance markers. 
The transformed cells were plated on appropriate antibiotic-containing plates and 
incubated at 37°C for 16 hrs. 
 
2.7 Preparation of plasmid DNA 
2.7.1 Large-scale preparation 
 
10 ml of a saturated culture of plasmid-containing E. coli was diluted into 1000 ml 
2xTY broth containing the appropriate antibiotic and grown for 16 hrs with shaking 
at 37°C. The bacteria were pelleted by centrifugation at 4 500 g for 10 min at 4°C. 
The pellet was resuspended in 4 ml GTE and incubated on ice for 10 min. The cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
were lysed by the addition of 8 ml NaOH/SDS with gentle swirling and incubated on 
ice for 10 min. 6 ml of 3:5 M KOAc was added and mixed gently to neutralise the 
alkali, and the mixture incubated on ice for 10 min. The precipitate of cell debris, 
chromosomal DNA and SDS was removed by centrifugation at 4 500 g for 15 min at 
4°C. The supernatant was filtered through glass wool to remove particulate material 
and the nucleic acids precipitated by the addition of 0.8 volumes propan-2-ol, 
followed by incubation at –20°C for 20 min. The precipitate was pelleted by 
centrifugation at 10 000 g for 10 min at 4°C. Plasmid DNA was separated from RNA 
by double CsCl/ethidium bromide fractionation. 
 
2.7.2 Double CsCl/ethidium bromide fractionation 
 
This method was used to prepare high quality plasmid DNA for transfection of 
eukaryotic cell lines.  
 
The propan-2-ol pellet (section 2.7.1) was resuspended in 4.5 ml of TE. The solution 
was mixed with 4 mg ethidium bromide and 5.75 g CsCl to give a final density of 
1.61 g/ml. This mixture was centrifuged at 10 000 g for 10 min at 20°C. The pellet 
was mainly RNA. The supernatant was transferred to Quickseal tubes and centrifuged 
at 55 000 g for 18 hrs at 20°C in NVi 65 rotor. The plasmid DNA was visualised with 
a 360 nm UV illumination and recovered using a syringe and made up to 5 ml with 
TE/CsCl and ethidium bromide to give a final density of 1.61 g/ml. This mixture was 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
transferred to a clean Quickseal tube and centrifuged at 55 000 g for 18 hrs at 20°C in 
NVi 65 rotor. The plasmid DNA was again recovered and an equal volume of NaCl- 
saturated isopropan-2-ol was added to remove the ethidium bromide. This extraction 
was repeated four times. Two volumes of water and one volume of isopropan-2-ol 
were added to precipitate the DNA. This mixture was mixed well and incubated on 
ice for 10 min. The DNA was recovered by centrifugation at 10 000 g for 15 min. 
The pellet was resuspended in TE at 1 mg/ml and stored at 4°C (short term) or –20°C 
(long term).  
 
2.7.3 Small-scale preparation (minipreps) 
 
In order to analyse large numbers of transformants, plasmid DNA was isolated from 
overnight cultures of E. coli picked from single colonies. This method yielded DNA 
of sufficient quantity and purity to perform restriction analyses and DNA sequencing. 
4 ml cultures of plasmid-containing E. coli were grown in 2xTY broth containing the 
appropriate antibiotic for 16 hrs. The bacteria were pelleted at 6 000 g for 10 min, and 
resuspended in 200 µl GTE. The mixture was incubated at 22°C for 5 min. 400 µl 
NaOH/SDS was added and mixed gently to lyse the cells and incubated at 22°C for 
another 5 min. The mixture was neutralised by the addition of 300 µl 3:5 M KOAc, 
mixed gently and centrifuged at 13 200 g for 15 min. 800 µl of the supernatant was 
added to 600 µl propan-2-ol in a fresh tube and incubated at –20°C for 30 min. The 
precipitate of nucleic acid was pelleted and washed with 70 % ethanol. The pellet was 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dissolved in 500 µl TE. 100 µg/ml RNAse was added to the DNA and incubated at 
37°C for 1 hr. The RNAse treated DNA was extracted with phenol/chloroform and 
the upper aqueous phase was recovered. The DNA from the recovered phase was 
precipitated with 0.3 M sodium acetate and 2.5 volumes of ethanol and incubated at –
20°C for 30 min. The precipitate was centrifuged at 10 000 g for 10 min, washed with 
70 % ethanol and redissolved in 100 µl TE.  
2.8 Manipulation of plasmid DNA 
2.8.1 Ethanol precipitation 
 
DNA in solution was precipitated by the addition of NaOAc to 0.3 M, followed by 2 
volumes ethanol. The solution was mixed well and incubated at –20°C for 30 min. 
DNA was recovered as a pellet by centrifugation at 10 000 g for 10 min. 
 
2.8.2 Ammonium acetate precipitation 
 
DNA in solution was separated from dNTPs and short oligonucleotides (18 bases) by 
precipitating the DNA as above, except that a final concentration of 2 M NH4OAc 
was used in place of 0.3 M sodium acetate. 
 
2.8.3 Phenol/chloroform extraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This is a general method for removing proteins such as restriction enzymes from a 
solution of DNA. Generally, 100 μl of the DNA solution was vortexed with an equal 
volume of phenol/chloroform and centrifuged at 10 000 g for 2 min. The supernatant 
was recovered and re-extracted with phenol: chloroform. This supernatant was 
precipitated with ethanol (section 2.8.1) to recover the DNA and remove trace 
amounts of organic solvents. 
 
2.8.4 Restriction enzyme digests 
 
Restriction enzymes were used according to the manufacturers’ instructions. In 
general, plasmid DNA was digested with 1U of enzyme per 1 μg DNA for 2 hrs at 
37°C. After restriction digests, enzymes were inactivated if necessary by incubation 
at 65°C for 15 min, or by extraction with phenol/chloroform followed by 
precipitation with ethanol. Where multiple digests were performed, the buffer 
conditions were selected to be compatible with both enzymes. When this was not 
possible the first enzyme was removed by phenol/chloroform extraction and ethanol 
precipitation, the buffer conditions adjusted accordingly and the second digest 
performed. 
 
2.8.5 Ligation of DNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ligations were carried out in a 10 µl total reaction, consisting of 1 μl 10x Ligase 
buffer, 1 ng of the vector, 10 ng DNA, 1 U T4 DNA ligase at 22°C for at least 3 hrs 
or at 4°C for 16 hrs.  
 
2.9 Agarose gel electrophoresis of DNA 
 
A variety of DNA fragments used in this project ranged between 0.3 and 6 kb and 
were resolved on a 0.6 or 2 % agarose gel. Gels were prepared by boiling the 
appropriate amount of agarose in 1xTBE, cooling to 50°C, adding EtBr to 1 µg/ml 
and allowing it to set in a gel tray. The DNA sample to be electrophoresed was mixed 
with 0.5 volumes of DNA loading buffer before loading into the gel. DNA molecular 
weight markers (section 2.9.1) were also loaded in order to estimate the size of DNA 
fragments. Gels were electrophoresed in 1xTBE at 10 V/cm and the DNA was 
visualised by illuminating the gel under UV light on a transilluminator. When DNA 
was to be recovered from the gel, a long wavelength 360 nm lamp was used to avoid 
damage to the DNA. 
 
2.9.1 DNA molecular weight markers 
 
Two DNA molecular weight markers were used: pTZ and pKG 2. pTZ was used to 
estimated DNA sizes of 1.2 kb and less, while pKG 2 was used to estimate DNA 
sizes of between 6 kb and 1.6 kb. pTZ marker was made by digesting pTZ 18R vector 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
with Hinf I and pKG 2 was made by digesting pKG-IX with Bam HI and Hind III at 
37°C for 1 hr to produce the indicated sizes. 
 
 
 
 
 
 
 
 
    
       
 
 
Fig 2.6  Agarose gel showing the sizes of the DNA molecular weight markers. 
 
2.9.2 Purification of DNA fragments from agarose gels 
 
After electrophoresis, the DNA of interest was recovered from the gel using the 
Geneclean kit II (Southern Cross Biotechnology). This kit was used according to the 
manufacturer's instructions. 
 
5.9 kb
1.6 kb
1.2 kb 
517 bp 
396 bp 
356 bp 
201 bp 
79 bp 
pKG 2 pTZ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.10 Polymerase Chain Reaction (PCR) amplification 
2.10.1 Standard PCR 
 
The PCR was used to amplify regions of the DNA from plasmids. The reaction 
consisted of template DNA, 1X PCR buffer, 50 μM dNTPs, 0.2 pmol of each of the 
two PCR primers, 1 U Taq DNA polymerase and 2 mM MgCl2. The final volume 
was made up to 25 µl with sterile water. The reaction was performed using following 
cycles:  
 
95°C for 2 minute (Initial denaturation) 
94°C for 30 seconds (Denaturation) 
(Tm-5°C) for 30 seconds (Annealing) 
72°C for 2 minutes (Extension) 
72°C for 10 minutes (Final extension) 
The cycles were followed by incubation at 4°C. 
 
2.10.2 Inverse PCR (Figure 2.7) 
 
This protocol was used to isolate DNA adjacent to known sequence in genomic DNA. 
Primers were designed to one end of the known sequence (Hygromycin sequence) 
that prime in opposite directions and have a six base-cutter enzyme site between 
them. 1 µg of genomic DNA was digested with a frequent cutting enzyme (e.g. Nla 
35 cycles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III) and that does not cut between the ends of the two primers. The enzyme was 
removed from the DNA by heat inactivating at 65˚C for 15 minutes or by 
phenol/chloroform extraction (section 2.8.3). The genomic DNA fragments generated 
were recircularised by adding 10μl of digested DNA, 1 x ligase buffer and 3U T4 
DNA ligase to a final volume of 100 μl. The reaction was incubated at 22˚C for 3 hrs. 
The T4 DNA ligase was inactivated by heating at 70°C for 20 min. The recircularised 
DNA was digested with Aat II or Eag I in a total volume of 60µl for 2 hrs and the 
enzyme was heat inactivated at 70˚C for 15 min. 2μl of the resultant reaction mix was 
used in a subsequent 25μl PCR reaction (section 2.10). 
2.11 Sequencing of double stranded DNA 
 
DNA sequencing using the ABI 310 DNA Sequencer was employed. The BigDye 
Terminator Ready Reaction Kit version 3.0 (ABI) was used and this kit includes 
AmpliTaq DNA Polymerase, FS, the BigDye terminators and all the required 
components for the sequencing reaction. Sequencing reaction consisted of the 
following: 
REAGENT QUANTITY 
Terminator Ready Reaction Mix 2 μl 
Double-stranded DNA 200-500 ng 
Primer 3.2 pmol 
Deionised water To a final volume of 10 μl 
Table 2.2 The sequencing reaction protocol. 
 
GeneAmp PCR System 9700 was used and the following conditions were used: 
STEP ACTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Repeat the following for 25 cycles: 
96°C for 10 sec. 
60°C for 4 min. 
2 Hold at 4°C 
Table 2.3 PCR cycles for sequencing. 
 
Precipitation of extension products: 
The contents of each extension reaction were transferred into a 1.5 ml tube. 8 μl 
deionised water and 32 μl of 95 % ethanol were added. The tubes were vortexed 
briefly and incubated at room temperature for 30 min. Tubes were centrifuged for 20 
min at 15 000 g. Supernatants were carefully aspirated. 250 μl of 70 % ethanol was 
added to the tubes and vortexed briefly. Tubes were centrifuged at 15 000 g for 20 
min. This step was repeated twice and the pellets were dried and either stored at –
20°C or loaded immediately onto the ABI 310 Genetic Analyser. 12.5 μl of Template 
Suppressor Reagent (TSR) was added and tubes were vortexed briefly. The samples 
were denatured at 95°C for 2 min and tubes were placed on ice immediately. The 
samples were loaded onto the ABI 310 PRISMTM Genetic Analyser (Applied 
Biosystem) and the data was collected using the ABI 310 PRISMTM Collection 
Software and analysed using the Sequencing Analysis 3.4.1 Software. 
 
2.12 Preparation of Genomic DNA from mammalian cell lines 
 
Cells cultured in 25cm2 tissue culture flasks were washed with 10 ml ice-cold PBS. 
1 ml of digestion buffer was added to the cells, which were then scraped off from the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
flasks. The sample was incubated for 12-18 hrs with gentle shaking at 37°C in tightly 
capped tubes. The samples were thoroughly extracted with an equal volume of 
phenol/chloroform/isoamyl alcohol and centrifuged at 15 000 g for 10 min. The 
aqueous (top) layer was transferred to a new tube and 0.5 volumes of 7.5 M 
ammonium acetate and 2 volumes 100 % ethanol was added. The DNA was 
recovered by centrifugation at 15 000 g for 2 min and rinsed with 70 % ethanol. The 
pellet was resuspended in TE buffer. 
 
2.13 Cell culture 
2.13.1 Cell lines 
 
CELL LINES SPECIES CELL TYPE MEDIA 
CHO-Y10 Chinese Hamster Ovary, epithelial Complete Hams F12 
CHO-Mut8 (3x8)3.5 Chinese Hamster Ovary, epithelial Complete Hams F12 
CHO-Mut10 (3x8)3.5 Chinese Hamster Ovary, epithelial Complete Hams F12 
CHO-Mut16 (3x8)3.5 Chinese Hamster Ovary, epithelial Complete Hams F12 
CHO-J363 Chinese Hamster Ovary, epithelial Complete Hams F12 
NHF  Human Normal Fibroblast  Complete DMEM 
HeLa  Human Cervix, carcinoma, 
epitheloid 
Complete DMEM 
MG-63 Human Bone, osteosarcoma Complete DMEM 
MEL-2 Human Melanoma Complete DMEM 
Hep G2 Human Liver carcinoma Complete DMEM 
Table 2.4 Cell lines used for tissue culture. 
 
2.13.2 Tissue culture media 
 
MEDIA COMPONENTS 
Complete Hams F12 Hams F12 + 5 % FCS + 1 μg/ml Penicillin Streptomycin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete DMEM DMEM + 10 % FCS + 1 μg/ml Penicillin Streptomycin 
CTL assay medium RMPI-1640 + 10 % FCS + Glutamine + 10 mM HEPES+1 μg/ml 
Penicillin Streptomycin 
Table 2.5 Tissue culture media used. 
 
2.13.3 Propagation and storage of cell lines 
 
Cells were maintained in an incubator at 37°C in 5 % CO2. Cells were passaged when 
confluent by trypsinisation of the cell monolayer (0.125 % trypsin in PBS), and 
seeded into cell culture flasks or onto glass coverslips at a density of 1:10. Cells were 
frozen in 90 % FCS and 10 % DMSO and stored at -150°C. 
 
2.13.4 Transfection of cell lines  
2.13.4.1  Transient transfection of cell lines 
 
DNA prepared by double caesium chloride/ethidium bromide fractionation was used 
for all transfection procedures (section 2.7.2). Cells were transfected using 
Lipofectamine 2000 transfection reagent (Invitrogen) in 6 well plates (1 μg DNA per 
well) according to the manufacturer's instructions. After 24-48 hours, cells were fixed 
with 4 % paraformaldehyde, stained with DAPI and mounted on slides for evaluation 
by fluorescent microscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.13.4.2  Stable transfection of cell lines 
 
Stable transfections were performed using the lipofectamine method used for 
transient transfections (section 2.13.3.1). After 24 hours, the cells were passaged at a 
1:10 dilution into a fresh growth medium. Cells were grown in the selective medium, 
containing 300 μg/ml Zeocin, for 3 to 8 weeks until colonies of resistant cells grew. 
The individual colonies were cloned using cloning rings and propagated for 
subsequent assays. 
 
2.14 Immunofluorescent microscopy 
2.14.1 Fixation and permeabilisation of cells 
 
Cells were grown on coverslips until confluent. Cells were washed twice with warm 
PBS and incubated with 4 % paraformaldehyde in PBS at 22°C for 15 min and were 
rinsed three times with PBS. This was followed by permeabilisation in 
permeabilisation buffer for 5 min. The cells were washed twice in PBS and incubated 
for 30 min PBS/0.5 % BSA.  
 
2.14.2 Immunostaining of cells 
 
Fixed and permeabilised cells on cover slips were incubated at 22°C for 1 hr in 
primary antibody diluted in PBS/0.05 % BSA. The cells were washed in PBS/0.5 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BSA and then incubated in a diluted dye-conjugated secondary antibody for 1 hr and 
washed again. The cells were then counterstained with DAPI, which stains the DNA, 
for 5 min, washed with PBS/0.5 % BSA and mounted onto a microscope slide using 
the Vectorshield hard set mounting medium. Staining was visualised with a Zeiss 
Axiophot immunofluorescence microscope/camera system. 
 
 
 
 
2.15 FACS Analysis 
 
Approximately 3x106 cells were harvested from confluent flasks and resuspended in 
100 μl of a 1:100 dilution of the primary antibody (mouse monoclonal anti-mouse 
MHC-I 2qKK) in FACS buffer. Cells were incubated on ice with occasional shaking 
for I hour, washed twice with FACS buffer and resuspended in 100 μl of a 1:100 
dilution of FITC conjugated chicken anti-mouse IgG monoclonal antibody. Cells 
were incubated on ice for 1 hour with occasional shaking, washed twice with FACS 
buffer and resuspended in 400 μl FACS buffer. Cells were analysed using the Cell 
Quest Pro Software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.16 CTL killing assay 
2.16.1 Stimulation of CTL 
 
Spleens from 3-month old female CBA/Ca mice were provided by Dr Keith Gould 
(Imperial College London, UK). Each spleen was placed into 10 ml RPMI-1640 
medium and crushed in a tissue culture plate using forceps. The cells were further 
disaggregated by drawing the suspension up five times through a 19 gauge needle and 
syringe. The spleenocytes were harvested by centrifugation at 2600 rpm and washed 
twice with RPMI-1640 medium. The final pellet was resuspended in 3 ml of filter 
sterilised RPMI-1640 containing 10 % FCS and 5 μM synthetic peptide epitope 
(IEGGWTGMI for HA8 CTL clone) and incubated at 37°C in an atmosphere of 5 % 
CO2 for 90 min. The feeder cells were then irradiated with 2500 rads for 5 min using 
Gammacell 40 irradiation apparatus to prevent cell division and incubated for 1 hr at 
37°C in an atmosphere of 5 % CO2. The feeder cells were then washed three times 
with RPMI-1640 medium to prevent carry over of the peptide. 107 feeder cells were 
then resuspended in RPMI medium and added to 2x106 CTL in 25 cm2 flasks. 
 
2.16.2 Harvesting of CTL 
 
The effector CTL cells were harvested by centrifugation and were resuspended in 
CTL assay medium at a concentration of 2x106 cells/ml. Successive two fold dilution 
of the effector CTL were made representing 10, 5, 2.5 and 1.25 effector: 1 target 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ratio. The CTL were plated in round-bottomed 96 well microtitre plates in triplicates 
in a final volume of 100 μl. The experimental wells contained 100 μl of CTL and 50 
μl of the target cells. The control wells were prepared in quadruplicates containing 50 
μl target cells and 100 μl CTL assay medium for spontaneous release or 100 μl 5 % 
Triton X 100 for maximum release. The plates were incubated for 6 hrs at 37°C in an 
atmosphere of 5 % CO2. After the incubation of the plates for 6 hrs, the plates were 
centrifuged at 1000 rpm for 5 min and removed 40 ml of the supernatant into a Luma 
plate and the plate was left to dry in a 37°C oven for 16 hrs for counting on a 
microplate scintillation counter. The amount of target cells killed was calculated by 
measuring the amount of 51Cr released. The following formula was used for the 
calculation of the amount of target cells killed: 
 
 
 
 
2.16.3 Harvesting of target cells 
 
The target cells were cultured in 75 cm2 flask and were harvested when confluent in 
PBS containing 0.5 mM EDTA. The cells were then resuspended in CTL assay 
medium at a concentration of 107 cells/ml. 2x106 cells were labelled with 40 μCi of 
51Cr in a total volume of 0.3 ml and were incubated at 37°C in an atmosphere of 5 % 
CO2 for 90 min. 
% specific 51Cr release= 
release from target by CTL- spontaneous release 
maximum release- spontaneous release 
X 100
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The cells were then washed twice with CTL assay medium and were adjusted to be 
2x105 cells/ml with the CTL assay medium. The cells were then incubated at 37°C in 
an atmosphere of 5 % CO2 whilst harvesting the CTL (section 2.16.2). 
 
2.17 APOPercentageTM Apoptosis Assay 
 
The APOPercentage assay is a detection and measurement system to monitor the 
occurrence of apoptosis in mammalian cells. Cells were grown in six well plates until 
confluent. Cells were then induced with at a concentration of 1 μM for 1-3 hrs. The 
cells were then washed twice with PBS and 1 ml of the APOPercentage dye was 
added to each well and incubated at 37°C for 1 hr. The Dye was removed and the 
cells were washed twice with PBS. Photographs were taken using the Nikon inverted 
light microscopy. The PBS was removed from the cells and 0.5 ml of trypsin was 
added to each well and cells were allowed to round up (and not detach) before the 
trypsin was removed. The cells were then gently resuspended in 2 ml of complete 
Hams F12 median and were analysed by FACS (section 2.15). 
 
2.18 Proteins 
2.18.1 Isolation of protein from cell monolayers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells were grown to ~80 % confluency in 75 cm2 tissues culture flasks and were 
washed twice with PBS to remove traces of serum and then 150 μl of protein lysis 
buffer was added per flask. The cells were scraped from the flasks using cell scrapers. 
The samples were vortexed for 1 min, sonicated for 1 min and boiled for 5 min and 
stored at –20°C until required. Approximately 30 μl of protein was subjected to SDS-
PAGE and analysed by Western blotting. 
 
2.18.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) of proteins 
 
Proteins were separated by denaturing SDS-PAGE under reducing conditions 
according to the method of Laemmli, 1970. Gels were made from a 40 % stock of 
premixed 37.5:1 acrylamide:bisacrylamide and consisted of a separating gel and a 
stacking gel, which was added to the top of the separating gel. Gels were run at 
10V/cm for 1 hr, using the Mighty Small apparatus (Hoeffer). 
 
2.18.3 Staining and destaining of PAGE gels 
 
Gels were fixed in SDS-PAGE staining solution for 30 min. De-staining was 
achieved by multiple washes with SDS-PAGE destaining solution.  
 
218.4 Western Blotting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Bio-Rad MiniProtean Trans Blot system was used to transfer proteins separated by 
SDS-PAGE onto PVDF membranes. Gels, sponges, Whatman paper were 
equilibrated in pre-chilled transfer buffer for 30 min. PVDF membrane was immersed 
in 100 % methanol, rinsed in distilled water before equilibration in transfer buffer and 
blotting. The gel was then positioned on top of a piece of Whatman 3MM paper. 
PVDF membrane was placed on top of the gel, taking care to remove bubbles. 3MM 
paper was placed over the PVDF membrane and then placed inside a blotting 
cassette. Protein was electroblotted onto the PVDF membrane at 200 mA for 2-3 hrs 
at 4˚C. 
 
After blotting, the PVDF membrane was blocked for 1 hr at 22˚C in PBS, 5 % non-fat 
dried milk, 0.1 % (v/v) Tween-20. The filter was rinsed three times for 10 minutes in 
wash buffer. The membrane was incubated in 1:5000 dilution of the primary antibody 
for 1 hr at 22°C in a shaker. The membrane was rinsed three times for 10 min in wash 
buffer. The membrane was incubated in 1:20000 dilution of the secondary antibody 
for 1 hr at 22˚C in a shaker. Finally the membrane was rinsed three times for 10 
minutes with fresh changes of wash buffer at 22˚C. The membrane was placed on 
Saran Wrap. Chemilluminescent detection was carried out according to the 
manufacturer’s instructions (ECL, Amersham) and the blots were exposed to ECL 
film (Amersham). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.19 RNA Extraction 
 
Approximately 108 cultured cells in 25cm2 tissue culture flasks were washed with 
PBS. The cells were homogenised in 3 ml TRIzol reagent (Gibco life technologies) 
and incubated with shaking at 22˚C for 2 hrs. 1.5 ml of chloroform was added to the 
homogenate and this solution was mixed vigorously and incubated at 22°C for 10 
min. After centrifugation at 15 000 g for 1 hr at 4°C, the upper aqueous layer was 
transferred to a new tube. RNA was precipitated by the addition of 1.5 ml propan-2-ol 
and incubated at 22˚C for 15 min and then incubated at 4°C for 16 hrs. The RNA was 
pelleted by centrifugation at 3000 g for 30 min at 4°C. The pellet was washed with 70 
% ethanol and resuspended in 100 µl of DEPC treated water. The RNA was stored at 
–70°C in 20 µl aliquots. 
 
2.20 Agarose gel electrophoresis of RNA 
 
1 % (w/v) of agarose melted in 10 ml 10 x MOPS buffer and 85 ml distilled water 
and was allowed to cool about 50°C, 5.4 ml of 37 % (v/v) formaldehyde was added 
and the solution was allowed to set in a gel tray. RNA to be electrophoresed was 
mixed with 10 µl of formaldehyde gel loading buffer. The sample was heated at 65°C 
for 5 min and loaded on the gel. The gel was run in 1x MOPS running buffer at 
50 V/cm for 1 hr. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.21 cDNA synthesis 
 
First strand cDNA synthesis (AMV) kit for RT (Roche Applied Science) was used. 
The reaction for the first strand cDNA synthesis consisted of the following reagents: 
 
REAGENT VOLUME/ 1 SAMPLE FINAL 
CONCENTRATION 
10x reaction buffer 2 μl 1x 
25 mM MgCl2 4 μl 5 mM 
10 mM dNTPs 2 μl 1 mM 
Primer Variable 0.75-1.0 μM 
RNAse inhibitor 1 μl 50 units 
AMV reverse transcriptase 0.8 μl 20 units 
Sterile water To final volume of 20 μl  
RNA 1 μg  
Table 2.6  Reactions used for the first strand cDNA synthesis. 
 
The mixture was vortexed and centrifuged briefly. The reaction was incubated at 
25°C for 10 minutes and then at 42°C for 60 minutes. Following the 42°C incubation, 
the AMV reverse transcriptase was denatured by incubating at 99°C for 5 minutes 
and then cooled to 4°C for 5 minutes and the resultant first strand cDNA preparation 
was stored at –20°C. The cDNA synthesised was used for amplification using the 
standard PCR protocol (section 2.10.1). 
 
2.22 Real –Time quantitative RT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A PCR reaction mix containing 4 μl of LightCycler FastStart DNA MasterPLUS SYBR 
Green Reaction Mix (Roche Applied Science), 140 ng cDNA, 0,5 μM of each primer 
and water added to a final volume of 20 μl was prepared. A negative control 
contained the above mix, except that the DNA was replaced with water. The PCR 
mix was then transferred into capillary tubes in pre-cooled centrifuge adapters and 
these were centrifuged at 700 x g for 5 sec. The capillaries were placed into the 
LightCycler Carousel and into the LightCycler instrument. The reaction were 
performed using the following cycles:  
 
 
 
 
 
Program Step Temp Time Temperature 
Transition Rate 
Fluorescence 
acquisition 
Pre-incubation  95°C 10 min 20°C/sec None 
Amplification Denaturation 95°C 10 sec 20°C/sec None 
Amplification Annealing Primer-
dependent 
10 sec 20°C/sec None 
Amplification Extension 72°C 5 sec 20°C/sec Single 
Melting curve Denaturation 95°C 0 20°C/sec None 
Melting curve Annealing 65°C 15 sec 20°C/sec None 
Melting curve Melting 95°C 0 0.1°C/sec Continuous 
Cooling  40°C 30 sec 20°C/sec None 
Table 2.7 PCR conditions used for the Real-Time quantitative PCR. 
 
 
45 cycles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: IDENTIFICATION OF THE DWNN GENE IN PROMOTER 
TRAPPED CELL LINES. 
 
3.1 Introduction 
 
Over 100 CTL resistant cell lines were generated in a previous study using promoter 
trap mutagenesis experiments (George, 1995). The system of retrovirus promoter trap 
mutagenesis involves the insertion of a promoter-less selectable marker gene, 
hygromycin, into the U3 region of the Long Terminal Repeat (LTR) of the Moloney 
murine leukaemia virus (MoMLV). Prior integration, the LTR duplicates and the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hygromycin gene is positioned in the 5' LTR such that it is located 30 nucleotides 
from the host genomic DNA (von Melchner and Ruley, 1989). Hamster ovary (CHO) 
cells were used because of their ‘functional haploidy’ characteristic and therefore 
integration can lead to the loss of gene function (Hubbard et al., 1994).  
 
In order to identify the DNA sequence adjacent to the site of retroviral integration, 
inverse PCR has been exploited. Inverse PCR is a specific application of the general 
PCR technique (Ochman et al, 1988). It amplifies cellular DNA adjacent to an 
integrated provirus given the sequence information for the provirus (Silver and 
Keerikatte, 1989). This technique is useful for studies of insertional mutagenesis and 
other situations in which one wishes to isolate DNA adjacent to a region of known 
sequence. The protocol consists of five steps (Fig 3.1): isolation of genomic DNA, 
restriction digestion of the genomic DNA, circularisation of the digested DNA, 
reopening of the circular DNA and amplification of the inverse DNA fragment 
(section 2.10.2). The inverse PCR primers are designed such that they are directed 
away from each other, as opposed to the conventional PCR primers, which are facing 
towards each other. This allows for the amplification of the unknown sequence either 
on the 5' or 3' end of the integrated provirus. Analysis of the 5' end of the integrated 
provirus is referred to as 5' inverse PCR, while the analysis of the 3' end of the 
integrated provirus is called 3' inverse PCR. 
 
This chapter describes the analysis of both the 5' and 3' end of the retrovirus from 
four promoter-trapped cell lines using the inverse PCR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.2 Analysis of the retroviral promoter-trapped cell lines by Inverse PCR 
3.2.1 Isolation and restriction digestion of genomic DNA 
 
Genomic DNA was isolated from four promoter trapped cell lines, CHO-Mut8 
(3x8)3.5, CHO-Mut10 (3x8)3.5, CHO-Mut16 (3x8)3.5 and CHO-J363 (section 2.12). 
Fig 3.2 shows an agarose gel electrophoresis of the undigested and digested genomic 
DNA samples from three of the promoter-trapped cell lines. The undigested genomic 
DNA samples show a high molecular weight fragment, which represents the genomic 
DNA, as well as the low molecular weight fragments, which represent RNA. Upon 
digestion of the genomic DNA with Eco RI, the low molecular weight RNA 
fragments disappear due to degradation and the genomic DNA is digested to a low 
molecular weight smear (Fig 3.2).  
 
The digested DNA was circularised with T4 DNA ligase (Promega) at a dilute DNA 
concentration that favours the formation of monomeric circles (Collins and 
Weissman, 1984). In order to increase the efficiency of PCR amplification, the 
circular DNA molecules were first cleaved with a restriction enzyme that cuts 
between the inverse PCR primers only, within the hygromycin gene (Fig 3.4). In this 
case, the restriction enzyme Eag I was used for the 3' IPCR (Fig 3.1) and Aat II was 
used for amplification of the 5' end (Fig 3.11). The inverse PCR primers were 
designed within the hygromycin gene (Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2 Amplification of the hygromycin resistant gene 
 
In order to confirm that the cell lines that were analysed contained the promoter trap 
retrovirus, amplification of the hygromycin resistant gene (which is expressed upon 
integration of the retrovirus) was performed. Primers flanking the hygromycin 
sequence were designed. These primers would amplify both 5' and 3' of the Long 
Terminal Repeat (LTR) hygromycin gene and produce the same size fragment (Fig 
3.3a). The PCR was performed on the genomic DNA of the four cell lines and 
yielded a 249 bp fragment in all the cell lines (Fig 3.3c). This means that all four of 
these cell lines contain the retrovirus and would be suitable for inverse PCR analysis.  
3.2.3 Amplification of the 3' end of unknown genomic sequence  
 
Two rounds of amplification were performed in order to obtain the inverse PCR 
products. The first round was performed using primers 1051 and 1052, while the 
second round of amplification was carried out using internal primers 1050 and 1053 
(Figure 3.4). This kind of amplification is supposed to produce two products: the 5' 
end hygromycin fragment derived from the 5' LTR end of the provirus and the 3' end 
of the provirus containing the adjacent genomic sequence (Fig 3.1).  
 
Figure 3.5 shows the inverse PCR products of an Eco RI digested DNA. CHO-Mut8 
(3x8)3.5 cell line produced two fragments of approximately 1.2 kb to 1.3 kb. These 
fragments should correspond to the 5' hygromycin “control” fragment and part of the 
hygromycin gene plus the genomic DNA in which the retrovirus has integrated into. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHO-Mut10 (3x8)3.5 cell showed no amplification at all. This could be due to the 
low concentration of the genomic DNA (Fig 3.2). CHO-Mut16 (3x8)3.5 cell lines 
gave a single fragment of >1.2 kb, while CHO-J363 also produced a single fragment 
of about 1.0 kb. 
 
3.2.4 Sequencing of the 3' end inverse PCR products 
 
All the inverse PCR fragments were purified from the agarose gel and sequenced 
directly (section 2.11). The fragments were sequenced with primer 1053. The 
sequences of the entire inverse PCR products obtained are shown in figure 3.6. The 
DNA sequence of the tkneoU3hygro hygromycin gene is indicated in red, while that 
of the hamster genomic DNA is indicated in blue (Fig 3.6).  
 
The sequences obtained were analyzed using the BLAST (Basic Local Alignment 
Search Tool) (Altschul et al., 1990). BLAST was performed using the non-redundant 
database, which included all GenBank, RefSeq, Nucleotide, EMB, DDB and PDB 
sequences.  
 
The 1.3 kb fragment (top fragment) from CHO-Mut8 (3x8)3.5 produced significant 
matches against three regions. One was from a mouse DNA sequence from clone 
RP23-35D7, on chromosome 11 (Fig 3.7). The other two regions matched the human 
chromosome 17 (CTD-2301B9) and clone RP11-253F9 respectively. Further analysis 
on these three regions showed no gene sequences have been assigned in these regions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
yet. Therefore, no further analysis was undertaken on these fragments. The 1.2 kb 
fragment (bottom fragment) matched the Moloney murine leukemia virus sequence as 
expected (Fig 3.8).  
The sequence obtained from the inverse PCR product of CHO-J363 cell line matched 
the hygromycin sequence (Fig 3.9). 
 
The BLAST search analysis of sequence of the inverse PCR product obtained from 
CHO-Mut16 (3x8)3.5 produced a significant match against a mouse gene, which was 
named DWNN (Domain With No Name) (Fig 3.10). It was named DWNN since its 
function was not yet known and not much data was known about it. The sequence 
data revealed that it is highly conserved in eukaryotes.  
 
CELL LINE  NCBI SEQUENCE MATCHES 
CHO-Mut8 (3x8)3.5 (top 
fragment) 
Mouse DNA sequence from clone RP23-35D7, 
chromosome 11 
Homo sapiens chromosome 17 clone CTD-2301B9 
Homo sapiens 12 BAC RP11-253F9 
CHO-Mut8 (3x8)3.5 (bottom 
fragment) 
Retrovirus sequence 
CHO-Mut16 (3x8)3.5 Mouse DWNN 
CHO-J363 Retrovirus sequence 
CHO-Mut10 (3x8)3.5 No PCR product 
Table 3.1 Summary of the BLAST search results for the 3' inverse PCR 
products. 
 
3.2.5 Amplification of the 5' end of the unknown genomic sequence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5' inverse PCR was performed in order to analyze the 5' end of the genomic sequence 
and also to compare the 5' and 3' genomic sequences. This PCR was performed the 
same way as the 3' inverse PCR, except that the ligated genomic DNA was linearised 
with Aat II (Fig 3.11.). The first round of amplification was performed using primers 
884 and C, while the second round of amplification was performed with primers 1034 
and G (Fig 3.12). 
 
Figure 3.13 shows an agarose gel of the 5' inverse PCR results. Lane 1 represents the 
negative control (no DNA added) and lanes 2, 3 and 4 represent the inverse PCR 
results from CHO-Mut8 (3x8)3.5, CHO-Mut16 (3x8)3.5 and CHO-Mut10 (3x8)3.5 
cell lines respectively. The hygromycin ‘control’ fragment of 428 bp was detected in 
all the cell lines. Other fragments were cut out of the gel and purified for sequencing.  
 
3.2.6 Sequencing of the 5' end inverse PCR products 
 
Only one fragment from each cell line was sequenced using primer G. All the 
sequences analyzed showed the presence of the retrovirus (red text) and the genomic 
sequence (blue). Figure 3.14 shows the DNA sequences CHO-Mut8 (3x8)3.5, CHO-
Mut16 (3x8)3.5 and CHO-Mut10 (3x8)3.5. 
 
 The genomic DNA sequence was analyzed using the BLAST. The BLAST search 
results of the genomic sequences from CHO-Mut8 (3x8)3.5 and CHO-Mut16 
(3x8)3.5 produced the same match, which is the mouse DWNN (Fig 3.15 and Fig 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.16). This gene was also identified from CHO-Mut16 (3x8)3.5 from the 3' inverse 
PCR (section 3.2.4).  
 
The genomic sequence from CHO-Mut10 (3x8)3.5 was too short (9 bases long) to 
match anything significant in the database using the BLAST (Fig 3.17). The sequence 
from CHO-J363 cells did not show any match with the retrovirus sequence (Fig 
3.17a). This was of concern because it meant that this fragment was not an inverse 
PCR product, although the hygromycin resistant gene was amplified from this 
fragment (section 3.2.2). It was therefore, concluded that this fragment was a 
contamination picked up during PCR. However, the BLAST search analysis was 
performed on the whole sequence and the sequence matched a mouse DNA sequence 
on chromosome 11. Figure 3.17b shows the first 11 hits obtained using BLAST. 
Table 3.2 summarizes the BLAST search results from the 5' inverse PCR. 
 
CELL LINE  DATABASE SEQUENCE MATCHES 
CHO-Mut8 (3x8)3.5 Mouse DWNN gene 
CHO-Mut16 (3x8)3.5 Mouse DWNN gene 
CHO-Mut10 (3x8)3.5 No significant match 
CHO-J363 Mouse DNA sequence from clone RP23-170A23, chromosome 
11 
Table 3.2 Summary of the BLAST search results for the 5' inverse PCR 
products. 
 
3.3 Screening for other DWNN knock-out cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primers have been designed within the DWNN and the hygromycin sequence in order 
to screen for other cell lines in which the DWNN gene has been knocked-out. A 
forward primer, designated 7.3, was designed within the 5' region of the DWNN gene 
(Fig 3.18) and was used in conjunction with the reverse primer from the hygromycin 
gene of the retrovirus (primer 883) (Fig 3.3). This PCR would produce a fragment of 
>301 bp in those cell lines that contain the promoter-trapped DWNN gene, and no 
fragment would be produced in cell lines where the DWNN gene has not been 
mutagenised by the retrovirus. The presence of the promoter-trapped DWNN in 
CHO-Mut 8 (3x8)3.5, CHO-Mut 16(3x8)3.5 and CHO-J363 has been confirmed in 
this way (Fig 3.19b) and the other cell lines analyzed have shown negative results 
(data not shown). 
 
Another primer (7.3R) was designed on 3' end of the DWNN sequence and this 
primer was used in conjunction with primer 1041 on the hygromycin gene in a PCR 
reaction. This PCR reaction would amplify a fragment of 223 bp in length (Fig 
3.20a). This PCR was performed as to double check that the PCR fragment being 
amplifies are genuine. The PCR was performed on the four promoter-trapped CH cell 
lines used in this study, as well as other promoter-trapped cell lines. The results 
showed that only CHO-Mut8 (3x8)3.5 and CHO-Mut8 (3x8)3.5 produced a fragment 
of 223 bp and no other cell lines analyzed produced a fragment (Fig 1.20b). These 
results complement the inverse PCR data and the PCR performed with 7.3 and 883 
primers for CHO-Mut8 (3x8)3.5 and CHO-Mut8 (3x8)3.5. However, since the 
inverse PCR and this PCR failed to identify DWNN in CHO-J363, it was safe to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
conclude that the data obtained in the 7.3 and 883 PCR for CHO-J363 was not 
genuine, it could have been a PCR contamination. 
 
 
 
3.4 DWNN sequence analysis 
 
The sequences of the cell lines in which DWNN was identified (i.e. CHO-Mut 8 
(3x8)3.5, CHO-Mut 16(3x8)3.5 and CHO-Mut 7 (3x8)3.5 from RACE PCR, George, 
1995) were analyzed in order to determine the site of retroviral integration. The 
‘trivial’ sequence from CHO-J363 was also included in this analysis (data not 
shown). The sequence analysis showed that in all these cell lines the site of retroviral 
integration is the same (Fig 3.21a-c, f). The site of integration on these cell lines was 
also identical to that of CHO-Mut 7(3x8)3.5 (Fig 3.21e), where DWNN was first 
isolated using RACE PCR (George, 1995). This could mean that either this particular 
integration site is the ‘hot spot’ for retroviral integration or that these cell lines 
originate from the same clone. The former speculation confirms previous reports of 
the presence of retroviral ‘hot spots’ within the host genome (Shih et al., 1988). 
 
3.5 Discussion 
 
Four promoter-trapped retroviral mutagenesis CHO cell lines have been analyzed in 
this study. A positive control experiment was performed in order to confirm the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
presence of the retrovirus in these cell lines. All four cell lines produced the 
hygromycin fragment, indicating that the promoter-trap mutagenesis experiment was 
performed successfully and that these cell lines contained the promoter-trapped 
retrovirus.  
In order to identify genes that have been mutagenised within these cell lines, both 5' 
and 3' inverse PCR has been employed. This method yields two products, one from 
the 3' end for the 5' inverse PCR (or from the 5' end in case of the 3' inverse PCR) 
which is of constant size in all the cell lines and a variable 5' end fragment for the 5' 
inverse PCR (or a variable 3' end fragment for the 3' inverse PCR), containing the 
insertion site into the unknown genomic sequence. However, in some cell lines, only 
one fragment was amplified (Fig 3.5), which either represented the genomic sequence 
or the control hygromycin sequence. This could be due to the inability of the Taq 
Polymerase to amplify the big-sized fragments produced from these cell lines. It is 
expected that PCR products produced by Eco RI digests would result in big-sized 
fragments. However, the 5' IPCR was able to produce the control hygromycin 
fragment as well as the genomic fragment. 
 
Sequence analysis of the 5' and 3' inverse PCR products identified an interesting 
gene, named DWNN, from CHO-Mut 8 (3x8)3.5 and CHO-Mut 16 (3x8)3.5). In 
other cell lines, the genomic sequences were either too short to show any significant 
matches from the database or only the retrovirus could be identified. The DWNN 
gene identified from CHO-Mut 8 (3x8)3.5 and CHO-Mut 16 (3x8)3.5 corresponds to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the previously research done (George, 1995), where the same gene was isolated on 
CHO-Mut 7 (3x8)3.5 using RACE PCR.  
 
Primers were designed within the DWNN and the hygromycin sequences in order to 
screen other cell lines for the presence of DWNN. This was used to screen for other 
cell lines in which has been knocked out. The presence of the knocked-out DWNN in 
CHO-Mut 8 (3x8)3.5, CHO-Mut 16 (3x8)3.5 and CHO-J363 has been confirmed in 
this way. It was later determined that product amplified from the CHO-J363 cell line 
was not authentic and that it was a possible PCR contaminant. 
 
Further analysis of the DWNN sequence in these cell lines showed that they all had 
the same site of retroviral integration, meaning that the retrovirus inserted in the same 
position of the DWNN gene. This either meant that this particular site was a hot spot 
for retroviral integration or that these cell lines all originated from the same clone. 
The latter might be a possibility since CHO-Mut 8 (3x8)3.5, CHO-Mut 16 (3x8)3.5 
and CHO-Mut 17 (3x8)3.5 cell lines were cloned from the same plate (George, 1995). 
These results also confirmed the suggestion that the DWNN sequence amplified from 
CHO-J363 was not authentic. There was no possibility that CHO-J363 cell line might 
have originated from the same clone as CHO-Mut 8 (3x8)3.5, CHO-Mut 16 (3x8)3.5 
and CHO-Mut 17 (3x8)3.5 cell lines since CHO-J363 cell line was generated by a 
different person in a different study (Newton, 1995)from the CHO-Mut 8 (3x8)3.5, 
CHO-Mut 16 (3x8)3.5 and CHO-Mut 17 (3x8)3.5 cell lines. Therefore, the possibility 
that CHO-J363 could be a DWNN-knocked cell line was ruled out. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 It is unclear why the 3' and 5' IPCR from CHO-Mut 8 (3x8)3.5 cell line amplified two 
different sequences. However, the DWNN-Hygro PCR (section 3.3) confirmed the 
presence of the DWNN gene in this cell line. 
 
The research undertaken in this project was designed to evaluate the role of DWNN 
and to elucidate its involvement in CTL killing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4: GENERATION OF THE HUMAN DWNN-13 CONSTRUCT. 
 
4.1 Introduction 
 
The DWNN gene was first isolated from a promoter-trapped CHO cell line, CHO-
Mut7 (3x8)3.5 (George, 1995). The sequence of the DWNN gene from CHO-Mut7 
(3x8)3.5 matched a human EST 587, from the 21C4 cDNA clone (accession number 
T25012). The 21c4 cDNA clone was ordered from ATCC (Rockville, USA). The 
cDNA was then sequenced and the complete consensus sequence showed that it is 1.1 
kb in length and codes for a 118-residue protein (Pretorius, 2000). A conserved 80-
residue domain was identified within the 118–residue DWNN protein and a 
hydrophobic C-terminal tail. The 118-residue protein encodes a 13 kD protein and 
hence was named DWNN-13 (Fig 4.1). This chapter describes the isolation of the 
118-residue protein, named DWNN-13 and the cloning of DWNN-13 cDNA into 
pEGFP-C1 and pcDNA 3.1/Zeo vectors. . 
 
4.2 Amplification of DWNN-13 cDNA 
4.2.1 Primer design 
 
Primers amplifying the 118 amino acid DWNN coding sequence were designed such 
that the forward primer (DWNN F) incorporated a Bam HI restriction site at the 5' 
end of the coding region (for cloning purposes) and the reverse primer (DWNN R) 
incorporated an Xho I site at the 3' end of the amplified DWNN gene (for cloning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
purposes) and also provided a TAA termination codon for the amplified DWNN 
gene. Six bases before the Bam HI and Xho I sites were incorporated to allow 
efficient restriction digest of the PCR product (see Table 4.1). 
 
4.2.2 Amplification and sequencing of DWNN-13 clone 
 
The DWNN-13 gene was amplified from the 21C4 cDNA clone (Fig 4.2a) using the 
designed DWNNF and DWNNR primers in a PCR reaction (section 2.10.1). A 383 
bp PCR product was observed on a 1 % agarose gel electrophoresis (Fig 4.2b).  
 
The PCR products were eluted and sequenced directly with DWNN F and DWNN R 
primers on the ABI 310 Sequencer (Chapter 2.11). The sequences obtained from both 
primers showed the presence of the DWNN sequence, the Bam HI and Xho I sites, as 
well as the TAA stop codon (Fig 4.3). This indicated that the amplified DWNN gene 
was in the correct reading frame and had all the cloning sites and stop codon. The 
sequences were analysed using BLAST. The sequences with both DWNNF and 
DWNNR primers matched the DWNN protein against the non-redundant sequences 
in the database (Fig 4.4). When comparing the analysed sequences with the 21c4 
cDNA (accession number T25012), a 100 % identity was observed (Fig 4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 Subcloning of the DWNN-13 cDNA 
4.3.1 Construction of the pEGFC1-DWNN-13 fusion protein 
 
The pEGFPC1-DWNN-13 fusion protein was constructed by cloning the PCR 
product (section 4.2.2) into pEGFPC1 vector (section 2.4.3). The resultant PCR 
product (Fig 4.2) was first digested with Bam HI and Xho I to release a 363 bp 
fragment. The 363 bp resultant fragment was purified from the agarose gel using the 
Geneclean Kit II (section 2.9.2). This fragment was then used for cloning into 
pEGFPC1 vector between the Bgl II and Sal I sites for subsequent experiments (Fig 
4.6a). Cloning between Bam HI and Xho I sites of the pEGFPC1 vector was 
abandoned because this would have allowed cloning of the PCR product in the 
reverse orientation (Fig 4.6b). Therefore, Bgl II and Sal I sites were instead used for 
the cloning of the PCR product. The Bam HI/ Bgl II and Xho I/ Sal I sites have the 
same overhang and therefore cloning was possible but all sites were destroyed during 
cloning. E.coli MC1061 cells were transformed (section 2.6) and the plasmid DNA 
was isolated and purified using the double cesium chloride gradient centrifugation 
(section 2.7.2). The plasmid DNA was then digested with Pst I (a site present on the 
DWNN-13 cDNA) and Bam HI (a site present on the multiple cloning site of 
pEGFPC1 vector, Fig 4.6b), in order to identify the recombinants that contained the 
DWNN insert and clone 8 was identified as a positive clone (Fig 4.6c). As a control, 
pEGFP-C1 vector was also digested with Bam HI and Pst I. Only a 4.7 kb fragment 
was observed in the control, compared to the 215 bp fragment obtained from the 
restriction digestion of clone 8 (Fig 4.6c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.3.2 Subcloning of DWNN-13 cDNA into pcDNA3.1/Zeo vector 
 
The 21C4 clone (obtained from ATCC, Rockville, USA) containing the 118 amino 
acid DWNN, was cloned between Not I and Xho I sites of pTd7 vector. This clone 
was digested with Bam HI and Xho I, in order to release the 929 bp DWNN insert 
(Fig 4.7a). This insert was purified from an agarose gel using the Geneclean kit 
(section 2.9.2) and was cloned between Bam HI and Xho I digested pcDNA3.1/Zeo 
vector. Restriction digest of one of the positive clones, clone 3, was performed using 
Bam HI and Xho I, in order to confirm the presence of the insert. As a control, 
pcDNA3.1/Zeo vector was digested with Bam HI and Xho I (Fig 4.7c). Using the 
double cesium chloride gradient protocol (section 2.7.2), plasmid DNA from the 
positive clone 3 was prepared for stable transfections (chapter 7).  
 
4.4 Discussion 
 
The DWNN-13 gene was successfully amplified from 21C4 clone (accession number 
T25012) using the PCR technique. Sequence analysis showed a 100 % identity of the 
amplified product with the 21c4 cDNA (accession number T25012). Subcloning of 
the DWNN-13 gene into pEGFP-C1 and pcDNA3.1/Zeo vectors was performed 
successfully. The pEGFC1-DWNN-13 fusion protein was used for expression in 
mammalian cells for protein localisation studies and the pcDNA3.1/Zeo-DWNN-13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
construct was stably transfected into mammalian cells for CTL killing experiments, 
as will be discussed in subsequent chapters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5: CONSTRUCTION OF THE HUMAN DWNN-200 cDNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1 Introduction 
 
The human DWNN gene is located on chromosome 16. Human DWNN gene encodes 
two transcripts of 1.1 kb and 6.1 kb encoding 13 kD and 200 kD proteins 
respectively. The two proteins were named DWNN-13 and DWNN-200. The 
consensus human DWNN-200 sequence was assembled from various EST data 
sequences and partial cDNA clones and sequence analysis of the gene showed that it 
consists of two promoters and 19 exons (Rees, unpublished). 
 
This chapter describes the isolation, sequencing and assembly of DWNN-200 cDNA 
from non-cancer (normal human fibroblast, NHF) and cancer human cell lines (HeLa 
and MG-63) for functional studies. 
 
5.2 Generation of DWNN-200 cDNA by RT-PCR 
5.2.1 Designing of primers 
 
The coding sequence of DWNN-200 is 5.3 kb long and it has proven to be difficult to 
amplify the whole fragment using PCR techniques. Therefore, four sets of primers 
were designed from the assembled DWNN-200 cDNA, so that they were overlapping 
and had restriction sites in the overlapping regions, in order to facilitate the cloning of 
the different fragments obtained from PCR (Table 5.1 and Fig 5.1a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2 Amplification of DWNN-200 cDNA 
 
Messenger RNA was isolated from normal and cancer human cell lines, purified with 
oligo dT and cDNA was synthesised with AMV Reverse transcriptase (Chapter 2.15). 
The cDNA was then amplified using the four sets of primers (Table 5.1) in separate 
PCR reactions. Fragments of expected sizes were obtained (Fig 5.1a and 5.1b) from 
both the NHF and the human cancer cell lines. Table 5.2 lists the cell lines from 
which the four fragments were amplified and the amount which was sequenced from 
each fragment.  
 
Each PCR fragment was then cloned separately into the pGEM T Easy vector (Fig 
5.1b) and restriction digests were performed in order to screen for the positive clones. 
Fragment 1 was digested with Bam HI and Pvu II to release a 1.5 kb fragment (Fig 
5.2a); fragment 2 was digested with Pvu II and Hind III, releasing a 1.3 kb fragment 
(Fig 5.2b); fragment 3 with Hind III and Pvu II and fragment 4 digested with Pvu II 
and Eco RI producing fragment sizes of 1.3 kb and 1.7 kb respectively (Fig 5.3a, b). 
All the clones from the four fragments contained the expected sized- fragments upon 
restriction digestion, suggesting that the clones were correct. 
 
FRAGMENT CELL LINE SEQUENCE 
1 HeLa 
NHF 
100 % 
100 % 
2 MEL-2 
NHF 
100 % 
100 % 
3 HeLa 100 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hep G 
NHF 
60 % 
100 % 
4 HeLa 
MG-63 
NHF 
100 % 
50 % 
100 % 
Table 5.2 Cell lines used for the amplification and sequencing of DWNN-200 
cDNA. 
 
5.3 Sequencing of DWNN-200 cDNA 
5.3.1 Sequencing of DWNN-200 clones from cancer cell lines  
 
The different clones isolated from the human cancer cell lines were sequenced in both 
strands, using M13 forward and reverse primers as well as with PCR primers (Table 
5.1) and internal sequencing primers, designed along the entire region of the 
assembled DWNN-200 cDNA (Table 5.3). However, clones derived from Hep G and 
MG-63 cell lines were not sequenced fully, only 50-60 % was sequenced (see table 
5.3). All the sequences obtained showed a 100 % identity with the assembled 
DWNN-200 cDNA, except for the sequences from fragment 1 (from HeLa) and 
fragment 3 (from HeLa and Hep G). Also, the sequence from fragment 2 showed that 
exon 16, which corresponds to 102 bp, of this cell line was missing. 
 
Sequences from fragment 1 showed two base changes at residues 1275 and 1496, 
which are situated within the RING finger domain of the DWNN-200 gene. At 
residue 1275, there was a change from base A to T (Fig 5.4a, b). This base change 
resulted in the change in the amino acid sequence at position 289 from Leucine to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glutamine (Fig 5.4c). Residue 1496 showed a base change from base C to T and this 
resulted in a change in amino acid at position 363 from Serine to Proline (Fig 5.5a, b, 
c). All the three clones isolated from this fragment were sequenced and they all 
showed the same changes. Analysis of all the sequences in the Genebank and NCBI 
SNP databases showed no variations within these regions. It can therefore be 
concluded that these two base changes may be functionally significant and are due to 
mutations and are not variations. The Leucine to Glutamine mutation was designated 
L289Q and the Serine to Proline mutation was designated S363P. 
 
The sequences from fragment 3 (from both HeLa and Hep G) showed a base deletion, 
base A, at base 4034 in exon 17 (Fig 5.6a, b). All seven clones isolated from this 
fragment showed the same base deletion. This base deletion caused a frameshift of 
the sequences downstream and this resulted in the introduction of several stop codons 
(Fig 5.6c). Fragments 1 and 3 were amplified with primers RBBP6 1F and RBBP6 
2R and RBBP6 4F and RBBP6 3R respectively (Fig 5.1) and were isolated from 
HeLa and Hep G cells. 
 
 
5.3.2 Sequencing of DWNN-200 clones from NHF cell line 
 
The NHF cell line were also sequenced with the same primers used for sequencing 
the clones isolated from cancer cell lines. All the clones were sequenced in both 
directions to ensure that the sequences obtained were correct. The sequence analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of all the clones showed 100 % identity with the assembled DWNN-200 sequence. 
Figures 5.7 and 5.8 show the sequences from the RING finger region of fragment 1, 
which were shown to be mutated in HeLa cells. The sequences from this cell line 
showed a 100 % identity with the assembled DWNN-200 sequence. Figure 5.9 shows 
the presence of A in fragment 3, which was missing in HeLa and Hep G cells.  
 
Furthermore, RT-PCR and sequence analysis of HeLa and NHF cells have revealed 
that these cell lines are missing the 244 bp fragment in exon 16. Amplification using 
primers situated outside exon 16 was performed. The forward primer (RBBP 1F) is 
situated in exon 11, while the reverse primer (16R) is found in exon 17 (Fig 5.10). 
Amplification using these primers produced a 856 bp fragment, if exon 16 is missing 
and if exon 16 is present fragments of 958 bp and 856 bp will be produced, meaning 
that exon 16 is alternatively spliced (Fig 5.10). It was concluded therefore that in 
HeLa and NHF cells, exon 16 was spliced out, while in MG-63 cell line it was 
alternatively spliced. 
 
 
5.4 Assembly of the full-length DWNN-200 cDNA 
 
In order to generate the full length DWNN-200 cDNA, the digested fragments (Fig 
5.2 and Fig 5.3) would have to be cloned together into pBC KS cloning vector. 
However, it was impossible to clone all four fragments in a single reaction. It was 
therefore decided to first clone two fragments in a single reaction, that is clone Bam 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HI/ Pvu II digested fragment 1 and Pvu II/ Hind III digested fragment 2 into Bam HI/ 
Hind III digested pBC SK vector in a single reaction to generated fragment A (Fig 
5.11a) and clone Hind III/ Pvu II digested fragment 3 and Pvu II/ Eco RI digested 
fragment 4 into Hind III/ Eco RI digested pBC SK vector in a separated reaction, 
generating fragment B (Fig 5.11b). Ultimately, Bam HI/ Hind III digested fragment A 
and Hind II/ Eco RI digested fragment B would then be cloned into Bam HI/Eco RI 
digested pBS SK to generated the full length DWNN-200 cDNA (Fig 5.11c). 
 
However, attempts to clone the Bam HI/ Pvu II digested fragment 1 and 
Pvu II/Hind III digested fragment 2 into pBC SK+ digested with Bam HI and Hind III 
were unsuccessful. Meanwhile, the Hind III/Pvu II digested fragment 3 and Pvu 
II/Eco RI digested fragment 4 were cloned successfully between the Hind III and Eco 
RI sites of pBC SK+ and restriction digests of the positive clones with Hind III and 
Eco RI gave an expected 3.2 kb sized fragment B (Fig 5.12b). This fragment was then 
excised and eluted using the Geneclean kit (section 2.9.2). Fragments 1 and 2, as well 
as the 3.2 kb fragment 5 (Fig 5.12b) were cloned between Bam HI and Eco RI sites of 
pBS KS+ sites (Fig 5.13a). The positive clones were digested with Bam HI and Xho I 
to release fragments of 2.0 kb, 3.0 kb and 3.8 kb (Fig 5.13b). In order to release the 
5.8 kb full length DWNN cDNA from pBS vector, the positive clones were first 
digested with Xho I to completion, and then partially digested with Bam HI (Fig 
5.13b). A partial Bam HI digest was performed due to the second internal Bam HI 
site within the DWNN cDNA (Fig 5.13a). The 5.8 kb full-length DWNN cDNA was 
then cloned into other vector systems for subsequent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Ultimately two forms of DWNN-200 cDNA were cloned: the wild type DWNN-200 
cDNA and the L289Q and S363P mutated DWNN-200 cDNA, designated 
L289Q:S363P DWNN-200 cDNA. The wild type DWNN-200 cDNA was 
constructed from the NHF cell line, while the L289Q:S363P DWNN-200 cDNA was 
constructed from the various human cancer cell lines, as well as the NHF cell line. 
Both these cDNAs were cloned into in pDsRed1-C1 vector for localisation studies 
(Chapter 6). No further analysis was performed on the truncated DWNN-200, which 
was designated ΔA4034 DWNN-200 cDNA. Table 5.4 summarizes the cell lines and 
the four DWNN fragments used in the construction of the wild type, L289Q:S363P 
and ΔA4034 DWNN-200 cDNA 
 
 
 
 
DWNN-200 cDNA FRAGMENT CELL LINE 
Wld type 1 
2 
3 
4 
NHF 
NHF 
NHF 
NHF 
L289Q:S363P 1 
2 
3 
4 
HeLa 
MEL-2 
HeLa 
NHF 
ΔA4034 1 
2 
3 
4 
NHF 
MEL-2 
NHF 
Hep G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.4 Summary of the cell lines used in the construction of the DWNN-200 
cDNA. 
 
5.5 Discussion 
 
This chapter describes the cloning and sequencing of the full length 5.8 kb human 
DWNN-200 cDNA, which encodes a 200 kD protein. Three forms of DWNN-200 
cDNA were isolated in this study: the wild type, the L289Q and S363P mutated and 
the C-terminal truncated DWNN-200. However, only the wild type and the 
L289Q:S363P DWNN-200 cDNA were cloned for further characterisation. No 
further analysis was performed on the ΔA4034 DWNN-200 cDNA. The DWNN-200 
cDNA isolated from a various non-cancerous human cell lines was sequenced and 
showed a 100 % identity with the assembled DWNN-200 sequence, except in three 
positions. The sequence of DWNN-200 cDNA isolated from HeLa and Hep G cell 
lines showed two base changes within the RING finger domain and a base deletion at 
position 4034 in exon 17. The two base changes within the RING finger domain 
resulted in the amino acid changes, which might alter the protein structure and 
consequently the protein function. Studies have shown that the RING finger domain 
may function in direct protein binding of several proteins (Houvras et al., 2000) and 
functions as ubiquitin-protein ligase (E3) (Hashizume et al., 2001). Mutations within 
this domain might therefore alter this function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The base deletion at residue 4034 resulted in a frameshift on the downstream 
sequences, which therefore introduced stop codons downstream, leading to a 
truncation of the predicted protein. However, the RING finger mutations and deletion 
were not present in oher human cancer lines tested, such as MG-63 and CaSki. The 
rest of the DWNN-200 sequence was shown to have 100 % sequence identity with 
the assembled DWNN-200 sequence.  
 
It has been described previously that a region of 34 amino acid of the PACT protein 
is alternatively spliced (Simons et al, 1997). It was also discovered in this study that 
the 34 amino acid alternatively spliced region is present in MG-63 cell line and not in 
HeLa and NHF cells. This region has been mapped to exon 16 of the DWNN gene. 
The DWNN-200 cDNA cloned in this study is missing the alternatively spliced 
region. It therefore still remains under investigation as to whether the presence or 
absence of this region plays a vital role in the functioning of the DWNN gene. 
 
The ‘wild type’ DWNN-200 cDNA was cloned into pcDNA 3.1/ Zeo vector for 
transfection into mammalian cells, for functional studies (described in chapter 7), 
while both forms of the DWNN-200 cDNA were cloned into pEGFP C1 for 
localisation studies (Chapter 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6: LOCALISATION OF DWNN PROTEIN. 
 
6.1 Introduction 
 
Clontech has developed several optimised GFP variants, such as enhanced green 
fluorescent protein (EGFP) (section 2.4.3), red fluorescent protein (DsRed) (section 
2.4.4) and enhanced yellow fluorescent protein (EYFP), with which they have 
constructed mammalian expression vectors. This chapter describes the use of EGFP 
and DsRed for monitoring DWNN localisation in CHO cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.2 Subcloning of DWNN-13 cDNA into pEGFP-C1 vector 
 
The pEGFP-C1-DWNN-13 fusion protein was assembled as described in section 
4.3.1. The double cesium chloride gradient protocol (section 2.7.2) was used for the 
preparation of plasmid DNA for transfection into mammalian cells (Fig 6.1).  
 
6.3 Subcloning of DWNN-200 cDNA into pDsRed1-C1 vector 
 
DWNN-200 cDNA cloned into pBS KS+ was digested with Xho I to completion and 
then partially digested with Bam HI to release a 5.8 kb full length DWNN-200 clone 
(Fig 6.2b). This fragment was excised from a 0.8 % agarose gel and purified using the 
Geneclean kit (section 2.9.2) and was cloned between Bgl II and Sal I sites of 
pDsRed1-C1 (Fig 6.3a). Bam HI and Bgl II have the same overhang, as well as Xho I 
and Sal, therefore it was possible to clone the Bam HI/ Xho I digested DWNN cDNA 
between the Bgl II and Sal sites of pDsRed1-C1. However, all the four sites were 
destroyed during cloning and therefore they will not cut when digested with the 
respective restriction enzymes. The positive clones were then screened by restriction 
digestion of the plasmid DNA with Bam HI and Xho I to yield two fragments of 7.8 
kb and 2.0 kb (Fig 6.4b).  
 
The same procedure was employed to clone the L289Q and S363P mutated DWNN-
200 cDNA (Fig 6.4a) Positive clones were also identified by restriction digestion of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the plasmid DNA with Bam HI and Xho I and fragments of correct sizes were 
visualized on a 0.8 % agarose gel electrophoresis (Fig 6.4b).  
 
In comparison, the pDsRed1-C1 vector digested with Bam HI and Xho I produced a 
4.1 kb fragment (Fig 6.4c). 
 
Both the wild type and the L289Q and S363P mutated DWNN-200 constructs express 
pDsRed1-C1-DWNN-200 fusion proteins. The double cesium chloride gradient 
protocol (2.7.2) was used to prepare plasmid DNA for both constructs for transfection 
into mammalian cells. 
 
 
6.4 Transient expression of fusion proteins in cultured cells 
6.4.1 Transient expression of pEGFPC1-DWNN-13 construct 
 
CHO-Y10, CHO-Mut16 (3x8)3.5 and CHO-Mut8 (3x8)3.5 cells were used for the 
transient transfections and were grown to 70 % confluency on coverslips in six well 
plates (Chapter 2.17.3.1). All the plasmid DNA used for transfections were purified 
using double caesium chloride gradient protocol (section 2.7.2) to ensure that the 
DNA was highly pure and good quality for transfections. Cells were transfected with 
1 μg of plasmid DNA using the Lipofectamine 2000 Reagent (Invitrogen) according 
to the manufacturers instructions (section 2.13.3.1). Cells were transfected with DNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
constructs encoding EGFP alone, DsRed1-C1 alone, EGFP- tagged DWNN-13 
(section 6.2) and DsRed1-C1-tagged wild type DWNN-200 and DsRed1-C1- tagged 
L289Q and S363P mutated DWNN-200 (section 6.3). After 24-48 hours, cells were 
fixed in 4 % paraformaldehyde and stained with DAPI to localise the DNA. The 
coverslips were mounted onto slides using the Vectorshield Hard Set Mounting 
medium (Vectorshield) and were analysed using fluorescent microscopy (section 
2.14.2).  
 
Analysis of the control slides (i.e. cells transfected with EGFP and DsRed1-C1 alone) 
showed that the transfection efficiency varied from 30-60 % in different experiments. 
Figure 6.5 showed that cells transfected with EGFPC1 and DsRed1-C1 only 
demonstrated no specific localisation, with a distribution of the GFP and the red 
fluorescent protein (DsRed1-C1) in the cytoplasm and the nucleus. However, all cells 
transiently transfected with EGFP-tagged with DWNN-13 showed cytoplasmic and 
an intense nuclear localisation (Fig 6.6). 
 
6.4.2 Transient expression of pDsRed1-C1-DWNN-200 fusion proteins 
 
CHO-Y10, CHO-Mut 8 (3x8)3.5 and CHO-Mut 16 (3x8)3.5 cells were transiently 
transfected with both the wild type and L289Q and S363P mutated pDsRed1-C1- and 
pEGFP-C1-DWNN-200 constructs (section 2.13.3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells transfected with pDsRed1-C1 alone and pDsRed1-C1 tagged with DWNN-200 
cDNAs were transfected for up to 72 hours. The transfection efficiency was very low 
and no photographs were taken. 
 
Due to the low transfection efficiency of the pDsRed1-C1-DWNN-200 constructs, 
the same constructs were rebuilt in pEGFP-C1 vector (data not shown). The same 
procedure was followed for transient transfections of cultured cells (see section 
2.13.3.1). 
 
Both the wild type and the L289Q and S363P mutated DWNN-200-pEGFP-C1 
constructs showed cytoplasmic and an intense nuclear localisation in all the cell lines 
examined (Fig 6.7 and 6.8). It was also observed that some cells were expressing the 
GFP-DWNN protein more intensely than the others. 
 
6.5 Discussion 
 
In an attempt to determine the localisation of DWNN protein in CHO cells, GFP was 
employed as a reporter for DWNN localisation in vivo. Both EGFP-C1-DWNN-13 
and pDsRed1-C1-DWNN-200 constructs were generated. These constructs were 
transiently transfected in CHO-Y10, CHO-Mut8 (3x8)3.5, CHO-Mut16 (3x8)3.5 and 
HeLa cells. pDsRed1-C1-DWNN-200 constructs, however RFP constructs showed 
very low transfection efficiency in all the cell lines. The DWNN-200 cDNA of both 
forms were then cloned into EGFP-C1 vector. The results showed that both forms of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the protein (DWNN-13 and DWNN-200), when fused to GFP, are expressed in both 
the nucleus and cytoplasm of the cells.  
 
 
 
 
 
 
 
 
CHAPTER 7: GENERATION OF STABLE DWNN-COMPLEMENTED 
MUTANT CELL LINES. 
 
7.1 Introduction 
 
In order to evaluate the outcome of complementing the DWNN-mutant cell lines with 
DWNN expression, pZeo-DWNN constructs encoding the full-length wild type 
DWNN-200 and DWNN-13 were developed. These were stably transfected into 
DWNN-mutant CHO-Mut 8(3x8)3.5 and CHO-Mut 16(3x8)3.5. 
 
This chapter describes the development of DWNN-13 and DWNN-200 constructs in 
a mammalian pcDNA3.1/Zeo vector, which are stably transfected into mammalian 
CHO cell lines. pcDNA3.1/Zeo vector has been used for this study because it is 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
suitable for transfecting into mammalian cells and confers resistance to Zeocin, which 
is a unique antibiotic for these cell lines, meaning that the cell lines should be 
susceptible to the antibiotic unless they are expressing the pcDNA3.1/Zeo-DWNN 
constructs. 
 
7.2 Subcloning of DWNN-13 cDNA into pcDNA3.1/Zeo vector 
 
The cloning of the DWNN-13 cDNA into pcDNA3.1/Zeo vector was described in 
section 4.3.2 of this thesis. Using the double cesium chloride gradient protocol 
(section 2.7.2), plasmid DNA was prepared for the stable transfections.  
 
7.3 Subcloning of DWNN-200 cDNA into pcDNA3.1/Zeo vector 
 
The wild type DWNN-200 cDNA constructed as described in section 5.4 was 
digested with Xho I to completion and partially digested with Bam HI in order to 
release the 5.8 kb fragment (Fig 7.1a). This fragment was cloned between Bam HI 
and Xho I sites of pcDNA3.1/Zeo (Fig 7.1a). On digestion with Bam HI and Xho I 
restriction enzymes, pcDNA3.1/Zeo vector produced a 5.0 kb fragment (Fig 7.1b). 
Correct constructs were identified by digesting the plasmid DNA with Bam HI and 
Hind III. Clones containing the DWNN-200 insert produced four fragments of sizes 
1.01 kb, 2 kb, 3.8 kb and 5 kb (Fig 7.2a). Figure 7.2b shows the restriction digest of 
the positive clones, digested with Bam HI and Hind III. Using the double cesium 
chloride gradient protocol, plasmid DNA was prepared for transfections into 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mammalian cells. 
 
7.4 Determination of the optimal concentration of Zeocin for selection of 
CHO-Y10 cells 
 
In order to establish the minimum concentration of Zeocin required for the selection 
of stable transfected clones, CHO-Y10 cells were seeded into 6 wells and grown until 
confluent. They were then exposed to various Zeocin concentrations, replacing the 
selective media every 3-4 days. CHO-Y10 cells were exposed to concentrations of 50 
μg/ml, 100 μg/ml, 200 μg/ml, 300 μg/ml, 500 μg/ml, 800 μg/ml and 1000 μg/ml. The 
effects of Zeocin on CHO-Y10 were monitored over 7 days of exposure. In cells 
treated with 50 μg/ml and 100 μg/ml of Zeocin there was an increase in size of the 
cells compared to the untreated cells (Fig 7.3a-d). While cells exposed to Zeocin 
concentrations between 200 μg/ml and 400 μg/ml started to enlarge and showed an 
abnormal cell shape (Fig 7.3e-f). At concentrations above 400 μg/ml the morphology 
of the cells was abnormal and were enlarged. There was a clear breakdown of the 
plasma and nuclear membranes (Fig 7.3g-h). After 14 days of exposure cells treated 
with Zeocin at concentrations between 50 μg/ml and 100 μg/ml cells were still 
enlarged and abnormal in shape; while those cells treated with concentrations 
between 200 μg/ml and 1000 μg/ml were completely broken down and only cell 
debris remained. It was therefore concluded that at concentrations between 200 μg/ml 
and 400 μg/ml, Zeocin kills all the cells within two weeks and these concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
corresponded to the manufacturer’s protocol and the documented literature (Graham 
et al., 1977 and Mulsant et al., 1988). Therefore 300 μg/ml Zeocin was chosen to be 
the optimal concentration for the selection of stable transfected cells. 
 
7.5 Stable transfection of pcDNA3.1/Zeo-DWNN-13 and pcDNA3.1/Zeo-
DWNN-200 constructs into mammalian cells 
 
The stable transfection of CHO-Mut8 (3x8)3.5 and CHO-Mut16 (3x8)3.5 was 
performed using the lipofectamine method (section 2.13.3.2) with DNA constructs 
containing pcDNA3.1/Zeo-DWNN-13, pcDNA3.1/Zeo-DWNN-200 and CIT BAC 
clone, accession number AC010321 (obtained from Los Alamos National Laboratory 
for the US Dept of Energy in New Mexico) in six well culture plates. CIT BAC clone 
is a 20 kb genomic DNA containing the full length DWNN cDNA, which is situated 
in the middle the clone. Table 7.1 summarizes the DNA constructs used for the 
transfections of the mammalian cells. 
 
CELL LINE DNA TRANSFECTED 
CHO-Mut 8 (3x8)3.5 pcDNA3.1/Zeo-DWNN-200 
CHO-Mut 8 (3x8)3.5 pcDNA3.1/Zeo-DWNN-13 and pcDNA3.1/Zeo-DWNN-200 
CHO-Mut 16 (3x8)3.5 pcDNA3.1/Zeo-DWNN-13 
CHO-Mut 16 (3x8)3.5 BAC clone and pcDNA3.1/Zeo-DWNN-200 
CHO-Mut 16 (3x8)3.5 BAC clone and pcDNA3.1/Zeo vector 
Table 7.1 Summary of DNA constructs used for transfecting CHO-Mut 8 
(3x8)3.5 and CHO-Mut 16 (3x8)3.5 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thereafter, the stable clones were selected and continuously cultured in 300 μg/ml 
Zeocin. This concentration has been determined to kill CHO-Y10 optimally (section 
7.4). After 3 to 4 weeks single isolated colonies, the number of colonies obtained 
varied from 5 to 15 colonies from each plate, and these were cloned using cloning 
rings (section 2.13.3.2) and were continuously propagated in media containing 
300 μg/ml Zeocin. Figure 7.4 shows a representation of the colonies obtained from 
each transfected plate. 
 
7.6 Discussion 
 
Plasmids containing DWNN DNA cloned into pcDNA3.1/Zeo vector encoding both 
the DWNN-13 and DWNN-200 protein were developed. These were stably 
transfected into CHO-Mut 8(3x8)3.5 and CHO-Mut 16(3x8)3.5 successfully. The 
cells were either transfected with constructs encoding DWNN-13, DWNN-200 or 
both. The DWNN BAC clone was also used for the transfection of the cells. The 
concentration of 300 μg/ml of Zeocin was determined to be the optimal concentration 
for the selection of the stably transfected clones. Stable Zeocin resistant clones were 
observed after 3 weeks of selection and 5- 15 clones were isolated from the various 
plates. Fig 6.4 shows an example of clones that were selected after 4 weeks. These 
clones were analysed further and compared to the DWNN-mutant cell lines (Chapter 
8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 8: ANALYSIS OF THE DWNN-MUTANT AND DWNN-
COMPLEMENTED MUTANT CELL LINES. 
 
8.1 Introduction 
 
In order to characterise a novel gene, it is important to determine its function. There 
are various ways of determining the role of a gene. This chapter employs a number of 
techniques in order to elucidate the function of the DWNN gene. These techniques 
are carried out in both the DWNN-mutant cell lines (chapter 3) and in DWNN-
complemented mutant cell lines (chapter 7).  
 
Generation of anti-DWNN antibodies (Lutya, 2002) has assisted in determining the 
subcellular localisation of the endogenous DWNN in vivo, by making use of 
immunostaining and Western blot analysis, and hence providing more insight into the 
functioning of the DWNN gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This chapter also investigates the effect of exposure to CTLs and staurosporine-
induced apoptosis on the cell lines in order to explore the role of DWNN in CTL 
resistance, and to relate CTL resistance to chemically induced cell death. 
 
 
 
8.2 Analysis of the DWNN expression 
8.2.1 Immunofluorescent microscopy 
 
In order to determine the subcellular localisation of the endogenous DWNN protein 
in cultured mammalian cells, polyclonal antibodies specific for the DWNN-13 
protein have been generated in rabbits (Lutya, 2002). Antibody staining experiments 
were performed in DWNN-mutant and DWNN-complemented mutant cell lines, as 
well as in CHO-Y10, HeLa and MG-63 cells. Table 8.1 lists all the cell lines used in 
for antibody staining, a detailed description of these cell lines is presented in table 
2.6.  
 
CELL LINE DESCRIPTION 
CHO-Y10 Chinese Hamster, parental cell line 
CHO-Mut8 (3x8)3.5 Chinese Hamster, DWNN-mutant cell line 
CHO-Mut16 (3x8)3.5 Chinese Hamster, DWNN-mutant cell line 
CHO-Mut8 (3x8)3.5/ DWNN-200 & 
DWNN-13 
Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut8 (3x8)3.5/ DWNN-200 Chinese Hamster, DWNN-complemented 
mutant cell line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHO-Mut16 (3x8)3.5/ DWNN-13 Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut16 (3x8)3.5/ BAC clone & 
DWNN-13 
Chinese Hamster, DWNN-complemented 
mutant cell line 
HeLa Human, cervical cancer cell line 
MG-63 Human, bone cancer cell line 
Table 8.1 Description of the cell lines used for Immunostaining. 
 
The cell lines were grown on coverslips until confluent. Cells were fixed as described 
in section 2.14.1. The anti-DWNN antibody was used at a 1:100 000 dilution, while 
the Alexa Fluor 594 (red dye) or Alexa 499 (green dye) anti-rabbit antibody was used 
at a dilution of 1:500. DAPI was used to stain the DNA and was used at a final 
concentration of 15 μg/ml. Staining was visualised using fluorescent microscopy 
(section 2.14.2). 
 
All cells stained with DAPI showed nuclear staining as expected because DAPI stains 
the DNA. Controls included cells stained with preimmune serum and cells stained 
with the Alexa Fluor 594 anti-rabbit IgG antibody only. Cells stained with the Alexa 
Fluor 594 anti-rabbit IgG antibody were negative (Fig 8.1a). This proved that the 
results obtained from cells stained with the polyclonal anti-DWNN antibody were 
due to the effect of this antibody and not the Alexa Fluor 594 anti-rabbit IgG 
antibody. Cells stained with the preimmune serum were also labelled with the 
secondary Alexa Fluor 594 goat anti-rabbit IgG antibody and no staining was seen 
(Fig 8.1b). In HeLa, MG-63 and CHO-Y10 cell lines, the endogenous DWNN 
localised predominantly in the nucleus, but small amounts were also present in the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cytoplasm (Fig 8.1c, d, e). DWNN-complemented mutant cell lines stained with the 
anti-DWNN antibodies also showed a significantly nuclear staining (Fig 8.1h, i, j, k).  
 
However, in CHO-Mut 8 (3x8)3.5 cells, DWNN preferentially localised in the 
cytoplasm and it was completely excluded from the nucleus in all cells (Fig 8.1f). 
Localisation of DWNN in CHO-Mut 16 (3x8)3.5 cells showed two types of 
distribution. There were some cells in which DWNN was distributed in both the 
cytoplasm and the nucleus, while other cells DWNN localised in the cytoplasm only 
(Fig 8.1g). This suggests that CHO-Mut 16 (3x8)3.5 cell line might be polyclonal. 
 
8.2.2 Western blot analysis 
 
In order to determine the DWNN protein levels and the size of the expressed protein 
in CHO-Mut8 (3x8)3.5 and CHO-Mut16(3x8)3.5 cells, as well as in the DWNN-
complemented mutant cell lines, Western blots analysis was employed, using the 
polyclonal anti-DWNN antibody as a probe (section 2.18). Table 8.2 lists the cell 
lines used for Western blot analysis. Total protein extracts were isolated from the 
DWNN-mutant and DWNN-complemented mutant cell lines (section 2.18.1) and 
were resolved on a 10 % SDS-PAGE (section 2.18.2). The results showed three 
fragments of approximately 160 kD, 105 kD and 13 kD, which were present in all the 
CHO cell lines (Fig 8.2). The 13 kD fragment might represent the DWNN-13 protein. 
It is unclear what the other two fragments might be, but they might represent the 
DWNN-200 protein, although their sizes are smaller than the predicted 200 kD of the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DWNN-200 protein. This might suggests that the DWNN-200 protein is modified in 
vivo or that the DWNN-200 gene is expressing the truncated protein form or there is 
antibody cross reactivity. Several attempts of the Western blotting experiments, 
probing with anti-PACT (M56) mouse monoclonal IgG1 antibodies (Santa Cruz 
Biotechnology) failed to produce results. 
 
CELL LINE DESCRIPTION 
CHO-Y10 Chinese Hamster, parental cell line 
CHO-Mut8 (3x8)3.5 Chinese Hamster, DWNN-mutant cell 
line 
CHO-Mut16 (3x8)3.5 Chinese Hamster, DWNN-mutant cell 
line 
CHO-Mut8 (3x8)3.5/ DWNN-200 & DWNN-13 Chinese Hamster, DWNN-
complemented mutant cell line 
CHO-Mut8 (3x8)3.5/ DWNN-200 Chinese Hamster, DWNN-
complemented mutant cell line 
CHO-Mut16 (3x8)3.5/ DWNN-13 Chinese Hamster, DWNN-
complemented mutant cell line 
CHO-Mut16 (3x8)3.5/ BAC clone & DWNN-13 Chinese Hamster, DWNN-
complemented mutant cell line 
Table 8.2 Cell lines used for Western blot analysis. 
 
8.3 CTL killing analysis 
8.3.1 Target cell lines used 
 
The following cell lines were used for the CTL killing studies: CHO 22, CHO-Y10, 
CHO-Mut8 (3x8)3.5, CHO-Mut16 (3x8)3.5, CHO-J363 and the DWNN-
complemented mutant cell lines (Table 8.3). The target cells were grown in 75 cm2 
flasks until confluency and were harvested for labelling with 51Cr as described in 
section 2.16.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
CELL LINE DESCRIPTION 
CHO-Y10 Chinese Hamster, parental cell line 
CHO-Mut8 (3x8)3.5 Chinese Hamster, DWNN-mutant cell line 
CHO-Mut16 (3x8)3.5 Chinese Hamster, DWNN-mutant cell line 
CHO-J363 Chinese Hamster cell line, promoter-trapped 
CHO 22 Chinese Hamster cell line, non promoter-
trapped 
CHO-Mut8 (3x8)3.5/ DWNN-200 & DWNN-
13 
Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut8 (3x8)3.5/ DWNN-200 Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut16 (3x8)3.5/ DWNN-13 Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut16 (3x8)3.5/ BAC clone & DWNN-
13 
Chinese Hamster, DWNN-complemented 
mutant cell line 
Table 8.3 Cell lines used for the CTL killing assay. 
 
8.3.2 CTL killing assay 
 
The HA8 CTL clone was used for the killing assays and was harvested as described 
in section 2.16.1 and 2.20.2. Target cells were exposed to different dilutions of CTL 
for 6 hrs. Lysis of the target cells was quantitated by measuring the amount of 51Cr 
released from the target cells. Table 8.3 lists the target cell lines used for the CTL 
killing assay. CHO-Y10 and CHO-J363 were shown to be sensitive to lysis by HA8-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specific CTL, (Fig 8.3a). However, CHO-Mut8 (3x8)3.5, CHO-Mut16 (3x8)3.5 and 
the DWNN-complemented mutant cells lines were found to be completely resistant to 
lysis on exposure to HA8–specific CTL (Fig 8.3a, b, c).  
 
8.4 Analysis of the expression of the transfected MHC class I H-2KK and 
Haemagglutinin transgenes 
 
In the earlier study, all the promoter-trapped cell lines, including the parental cell 
line, CHO-Y10, were transfected with A/PR8/34 Haemagglutinin (HA) and MHC 
class I H-2KK in order to be recognized by HA specific KK restricted CTL clones, 
HA8 and HA11 (George, 1994). Loss of expression of either of the two transgenes in 
the target cell lines would result in the HA specific KK restricted CTL clones not 
recognizing the target cell lines. It was therefore crucial to ensure that the failure of 
the HA8 specific CTL clone to recognize the DWNN-mutant and DWNN-
complemented mutant cell lines (section 8.3.2) was not due to the loss of expression 
of the transfected transgenes in these cell lines. Therefore, analysis of the expression 
of both the transgenes was undertaken.  
 
8.4.1 FACS analysis for the expression of the MHC class I H-2KK 
 
The cell surface expression of MHC class I KK was investigated by antibody staining 
and FACS analysis as described in section 2.15. This experiment was carried out in 
CHO-Y10, CHO-Mut 8 (3x8)3.5 and CHO-Mut 16 (3x8)3.5 and the DWNN-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
complemented mutant cell lines (see Table 8.4). CHO 22 cells were also used as a 
negative control because they were not transfected with MHC class I KK.  
 
CELL LINE DESCRIPTION 
CHO-Y10 Chinese Hamster, parental cell line 
CHO-Mut8 (3x8)3.5 Chinese Hamster, DWNN-mutant cell line 
CHO-Mut16 (3x8)3.5 Chinese Hamster, DWNN-mutant cell line 
CHO 22 Chinese Hamster cell line, non promoter-
trapped 
CHO-Mut8 (3x8)3.5/ DWNN-200 & 
DWNN-13 
Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut8 (3x8)3.5/ DWNN-200 Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut16 (3x8)3.5/ DWNN-13 Chinese Hamster, DWNN-complemented 
mutant cell line 
Table 8.4 Cell lines used for the analysis of MHC class I H-2KK expression. 
 
The results showed that all the cell lines analysed were expressing MHC class I H-
2KK glycoprotein at the same levels as the parental CHO-Y10 cell line, except for the 
CHO 22 cells, which the stained negative for MHC class I KK. This was as expected 
because the CHO 22 cells were not transfected with MHC class I H-2KK (Fig 8.4). 
CHO 22 cells were also stained with the secondary FITC conjugated anti-mouse IgG 
monoclonal antibody (Molecular Probes) to test for any background staining. These 
cells stained negative (green peak, Fig 8.4), indicating that the secondary antibody 
does not give any background staining. 
 
Immunofluorescence microscopy also confirmed these results. The cells were stained 
with a mouse monoclonal anti-H-2KK antibody (Molecular Probes) as described in 
section 2.14.1. Table 8.5 shows the list of cell lines used for this experiment. Figure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.5 shows the expression of MHC class I H-2KK on the cell surface of CHO-Y10, 
CHO-Mut 8 (3x8)3.5, CHO-Mut 16 (3x8)3.5 and CHO-Mut 8 (3x8)3/DWNN-200. 
 
CELL LINE DESCRIPTION 
CHO-Y10 Chinese Hamster, parental cell line 
CHO-Mut8 (3x8)3.5 Chinese Hamster, DWNN-mutant cell 
line 
CHO-Mut16 (3x8)3.5 Chinese Hamster, DWNN-mutant cell 
line 
CHO-Mut8 (3x8)3.5/ DWNN-200 Chinese Hamster, DWNN-complemented 
mutant cell line 
Table 8.5 Cell lines used in the staining of the endogenous MHC class I H-2KK. 
 
FACS analysis and immunofluorescence staining showed that MHC class I H-2KK 
was expressed at satisfactory levels in all the cell lines. This shows that there was no 
loss of MHC class I H-2KK expression of through the cloning process and subsequent 
expansion of these clones. 
 
8.4.2 Analysis of the influenza haemagglutinin (HA) expression 
 
As stated in section 8.4.1, the promoter-trapped target cell lines were double 
transfected with the L-HA, L-HA-puro and MHC class I H-2KK transgenes in order to 
be recognised by HA specific KK restricted CTL clones, HA8 and HA11.  
 
Subsequently the levels of the HA protein in these cells were determined. The cells 
lines were originally transfected with two forms of HA transcripts, the full length HA 
transcript, encoding a 1.7 kb fragment and a truncated 1.2 kb HA linked to a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
puromycin (HA-Puro) transcript (George, 1995). The full length HA nucleotide 
sequence is represented in figure 8.6 and the sequence of the HA8 and HA11 epitopes 
is underlined. However, antibodies against the HA protein were not available in the 
laboratory, for performing FACS of western blots. However, in the early study 
(George, 1994) the HA protein could not be detected on western blots. It was 
therefore chosen to analyse the sequence and the levels of HA mRNA in these cell 
lines in order to show that the sequence is correct and that the mRNA is expressed. 
This was achieved by firstly amplifying suitably size fragments from both the full 
length HA and HA-Puro transcripts and analysing the sequence of these fragments, 
and secondly by making use of Real-Time Quantitative PCR to compare the levels of 
expression of the HA mRNA amongst the DWNN-mutant lines and the DWNN-
complemented mutant cell lines. Table 8.6 lists all the primer sequences used for the 
amplification of the HA fragment. 
 
PRIMER 
NAME 
PRIMER SEQUENCE POSITION 
4298 5' CTTGCTAAAACCCGGAGACA 3' 726-756 
4299 5' AACTCAAAACATCCATTTCCG 3' 1459-1480 
4300 5' CTTGCAGCTCGGTGACC 3' 388-404 
3819 5' TCCAGAAGTAGTGAGGAGGC 3' 296-324 
HAF 5' TTCGCACTGAGTAGAGG 3' 802-818 
HAR 5' GTAATCCCGTTAATGGCATT 3' 1148-1167 
Table 8.6 Sequence of the primers used for the amplification of HA. 
 
8.4.3 PCR amplification and sequencing of HA mRNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total RNA was isolated from CHO-Y10, DWNN-mutant and DWNN-complemented 
mutant cell lines as described in section 2.19 and was shown to contain intact 18S and 
28S rRNA (Fig 8.7). cDNA was reverse transcribed from RNA preparations using 
primers 4299 and 4300 (Fig 8.8a, c), complementary to the 3' end of the full length 
HA or to the 3' end of the HA-Puro cDNA respectively. PCR amplification was 
performed using primer 4299 or primer 4300 and a forward primer 4298 (Fig 8.8a, c). 
The resulting PCR products contained sequences encoding the antigenic epitopes for 
HA11 and HA8 (Fig 8.8b). 
 
All cell lines analysed for primer 4298 and 4299 gave PCR products of expected sizes 
(Fig 8.8b), indicating that they are expressing the HA transcript. The PCR products 
were sequenced directly with primers 4298 and 4299. Sequencing analysis showed 
that both the HA11 and HA8 epitopes were still intact (data not shown). In order to 
determine whether the epitopes are in frame, the 5' end of the HA transcript had to be 
sequenced as well. Primer 3819, which is complementary to the SV40 early promoter 
of pKG16AG vector, which expresses HA, was used together with primer HAR to 
amplify a fragment of 1.281 kb (Fig 8.9a). The expected fragment was amplified in 
all three cell lines (Fig 8.9b) and was sequenced directly using primers 3819 and 
HAR and the sequencing results showed that the epitopes are in the correct reading 
frame. 
 
However, it was impossible to amplify the HA-Puro fragment from the cell lines 
(data not shown), this could have been due to the primer 4300 not amplifying well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However the cell lines were cultured in the presence of puromycin and were resistant 
to the antibiotic, indicating that these cells were expressing the puromycin resistance 
gene. 
 
Therefore, both HA constructs (L-HA and L-HA-puro) are expressed in the cells and 
should be available to be processed and presented to MHC class I H-2KK. 
 
8.4.5 Real-Time Quantitative PCR analysis of the HA mRNA amplification 
 
In order to analyse the levels of HA mRNA in the CHO cell lines, Real-Time 
quantitative PCR was utilised (section 2.22). Table 8.7 lists the cell lines used in the 
Real-Time Quantitative PCR. The HA mRNA levels were determined relative to the 
housekeeping gene, hypoxanthine phosphoribosyltransferase (HPRT), which was 
used as a standard. Primers were designed using the Real-Time Quantitative PCR 
probe design software (Roche Diagnostics). The primers used for the amplification of 
the HA/HA-puro fragments were HAF and HAR (Table 8.6), which amplify a 
fragment of 365 bp as shown in figure 8.10a. The HA fragment was amplified in all 
the cell lines analysed non-quantitatively (Fig 8.10b). 
 
CELL LINE DESCRIPTION 
CHO-Y10 Chinese Hamster, parental cell line 
CHO-Mut8 (3x8)3.5 Chinese Hamster, DWNN-mutant cell 
line 
CHO-Mut16 (3x8)3.5 Chinese Hamster, DWNN-mutant cell 
line 
Table 8.7 Cell lines used for the analysis of HA expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Reactions for determining the relative HRPT and HA gene expression in samples was 
set up as described in section 2.21. The relative standard curve was prepared with 10 
fold serial dilutions (undiluted, 1:10 and 1:100) of cDNA from CHO-Y10, CHO-Mut8 
(3x8)3.5 and CHO-Mut16 (3x8)3.5 cell  lines. The template concentrations were given 
arbitrary values of 1 (for undiluted), 0.1 (for 1:10 dilution) and 0.01 (for 1:100 
dilution). 
 
The default (fit point/arithmetic) method of Real-Time Quantitative Software version 
3 was used to determine the relative starting copy numbers of target in each reaction. 
The Real-Time Quantitative Software generates a standard curve by plotting the 
logarithm of fluorescence versus the cycle number for each serial dilution of the 
standard template and then identifies the crossing point (cycle number) where the 
fluorescent signal emerges from background and enters the log-linear phase. Each 
crossing point is then plotted against the user-defined concentration of that standard 
to produce a standard curve. The relative gene expression is expressed as a ratio of 
the target gene (HA) concentration to the housekeeping gene (HPRT) concentration. 
 
Figures 8.11 and 8.12 show the representative Real-Time Quantitative PCR 
amplification curves and the respective standard curves for both HPRT and HA 
respectively, using the 10 fold serial dilutions of cDNA from all three cell lines 
(Table 8.7). The linear regression analysis of the standard curves (CP plotted against 
log cDNA input) showed high linearity, with regression coefficients (r) greater than 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.90. The Real-Time Quantitative PCR efficiencies (E) were calculated from the 
resulting slopes provided by the Real-Time Quantitative PCR software and was 
calculated according to the equation:  
 
E= 10[-1/slope] (Rasmussen, 2001) 
 
The Real-Time Quantitative PCR efficiencies were calculated in all three cell lines 
for both the HPRT and HA genes and were shown to be almost equal (ranging from 
1.9 to 2.2) (Fig 8.11 and 8.12). Figure 8.13 shows the standard curve of the combined 
cell lines for both HPRT and HA genes. 
 
For each cell line, the expression of HA was normalized with the HPRT expression 
from the respective cell line. The results were then expressed as the ratio of the 
normalized HA expression of the sample (CHO-Mut8 (3x8)3.5 or CHO-Mut16 (3x8)3.5) 
versus the control (CHO-Y10). In order to determine this ration, the following equation 
was used: 
        (Etarget)ΔCPtarget
(control-sample) 
  R= 
        (Eref) ΔCPref(control-reference) (Pfaffl, 2001) 
 
where the Etarget and Eref are the efficiencies of the target (CHO-Mut8 (3x8)3.5 or 
CHO-Mut16 (3x8)3.5) and reference genes (HPRT) respectively; ΔCPtarget is the crossing 
point (CP) deviation of control-sample of the target gene transcript and ΔCpref is the 
CP deviation of control-sample of reference gene transcript. Table 8.8 lists the ΔCP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
values between control and investigated samples, as well as the calculated ratios of 
the target gene (HA) and in comparison to the reference gene (HPRT).  
 
The ratio of the normalized HA expression of CHO-Mut8 (3x8)3.5 and CHO-Mut16 
(3x8)3.5 versus CHO-Y10 was calculated for each of the serial dilutions. It was determined 
that CHO-Y10 and CHO-Mut16 (3x8)3.5 are expressing comparable levels of the HA gene, 
as the ration of HA expression in CHO-Mut16 (3x8)3.5 ranges from 0.3 to 1.6 between the 
serial diluted sample. However, CHO-Mut8 (3x8)3.5 seems to have substantially reduced HA 
levels. The calculated ratios show that there is between 100 to 500-fold reduction in HA 
levels in CHO-Mut8 (3x8)3.5, as compared to CHO-Y10.  
 
It can therefore be concluded that CHO-Mut8 (3x8)3.5 (and consequently DWNN-
complemented CHO-Mut8 (3x8)3.5 cells) are resistant to HA8-specific CTL killing due to 
the reduced HA levels, and hence could not be recognised by the CTLs. It is however, 
unclear why CHO-Mut16 (3x8)3.5 are resistant to HA8-specific CTL killing because they are 
expressing similar levels of HA as CHO-Y10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLES HPRT CP 
VALUES 
HA CP 
VALUES 
ΔCP 
HA 
ΔCP 
HPRT 
RATIO OF HA 
EXPRESSION 
Y10 undiluted 28.78 21.13    
Y10 1:10 33.54 25.16    
Y10 1:100 34.59 28.45    
CHO-Mut8 (3x8)3.5 
undiluted 
25.68 22.78 -1.65 3.09 0.04 
CHO-Mut8 (3x8)3.5 
1:10 
28.63 26.99 -1.83 4.91 0.01 
CHO-Mut8 (3x8)3.5 
1:100 
31.97 30.01 -1.56 2.62 0.05 
CHO-Mut16 (3x8)3.5 
undiluted 
27.56 18.98 2.15 1.22 1.46 
CHO-Mut16 (3x8)3.5 
1:10 
30.76 23.77 1.39 2.78 0.27 
CHO-Mut16 (3x8)3.5 
1:100 
33.85 26.76 1.69 0.74 1.58 
Table 8.8 CP values, ΔCP and the calculated ratios of the relative HA expression 
of CHO-Mut8 (3x8)3.5 or CHO-Mut16 (3x8)3.5 versus CHO-Y10. 
 
8.5 Apoptosis killing assay 
 
Since the DWNN-mutant and DWNN-complemented mutant cell lines did not show 
any specific lysis with HA8 specific CTL, as compared to CHO-Y10 and CHO-J363 
cell lines (section 8.5.2), it was therefore decided to evaluate the induction of 
apoptosis in these cell lines with the classic apoptosis inducer, staurosporine. 
Staurosporine was used as a method of inducing apoptosis in these cell lines. 
Staurosporine (Streptomyces staurospores) is a relatively non-selective protein kinase 
inhibitor, which blocks many kinases to different degrees. Staurosporine is often used 
as a general method for inducing apoptosis (Kabir et al., 2002) and has been shown to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
induce apoptosis in a wide variety of cell types (Bertrand et al, 1994) Table 8.9 lists 
the cell lines used in the staurosporine-induced apoptosis assay. 
 
CELL LINE DESCRIPTION 
CHO-Y10 Chinese Hamster, parental cell line 
CHO-Mut8 (3x8)3.5 Chinese Hamster, DWNN-mutant cell 
line 
CHO-Mut16 (3x8)3.5 Chinese Hamster, DWNN-mutant cell 
line 
CHO-Mut8 (3x8)3.5/ DWNN-200 & DWNN-
13 
Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut8 (3x8)3.5/ DWNN-200 Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut16 (3x8)3.5/ DWNN-13 Chinese Hamster, DWNN-complemented 
mutant cell line 
CHO-Mut16 (3x8)3.5/ BAC clone & DWNN-
13 
Chinese Hamster, DWNN-complemented 
mutant cell line 
Table 8.9 Cell used in the APOPercentageTM apoptosis assay. 
 
Cells were propagated in six well plates and were treated with 1 μM staurosporine for 
3 hours. In order to measure the occurrence apoptosis the APOPercentageTM 
apoptosis assay was used (section 2.17). This assay works by the accumulation of the 
APOPercentageTM dye within all cells that are at the mid-phase stage of apoptosis. 
This stage corresponds with the translocation of phosphatidylserine to the outer 
surface of the cell membrane (Fadok et al., 1992). In other words, all cells 
undergoing ‘mid-phase apoptosis’ will be stained fluorescent pink with the 
APOPercentageTM dye and the actual percentage of apoptotic cells is measured by 
FACS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow cytometric analysis showed that 44 % of CHO-Y10 and 45 % of CHO-Mut16 
(3x8)3.5 treated with 1 μM Staurosporine, compared to the 8 and 16 % of cells that 
underwent spontaneous apoptosis in the untreated samples (Fig 8.15). However, in 
DWNN-complemented mutant CHO cell lines there seemed to be more cells resistant 
to staurosporine induction, compared to CHO-Y1O and CHO-Mut16 (3x8)3.5 cells. 
For instance, in CHO-Mut16 (3x8)3/DWNN-13 and CHO-Mut16 (3x8)3.5 /BAC & 
DWNN-13 cells only 26 % and 28 % of the cells were apoptotic respectively and in 
CHO-Mut8 (3x8)3.5/DWNN-13 & DWNN-200 and CHO-Mut8 (3x8)3.5/ DWNN-
200 cells the percentage of apoptotic cells was 22 and 24 respectively. 
 
8.6 Discussion 
 
In an attempt to understand the role played by DWNN in mammalian cells, an 
investigation has been carried out in DWNN-mutant CHO cells complemented with 
the DWNN cDNA versus the DWNN-mutant cell lines. Antibody staining of human 
cancer cell lines, CHO-Y10, CHO-J363 and DWNN-complemented mutant cell lines 
using anti-DWNN antibody showed that the endogenous DWNN is localised 
predominantly in the nucleus and also to a much lower level in the cytoplasm. 
However, CHO-Mut 8(3x8)3.5 and CHO-Mut 16(3x8)3.5 cells showed nuclear 
exclusion of the DWNN protein but there was cytoplasmic staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Western blot analysis detected a 13 kD protein (corresponding to DWNN-13), and 
two other proteins of about 160 kD and 105 kD in size in all the cell lines derived 
from CHO. These proteins might correspond to the degradation products of the 
DWNN-200 protein or might be truncated forms of the DWNN-200 protein, or they 
represent antibody cross reactivity.  
 
The cell lines were exposed to CTLs in order to elucidate the role played by DWNN 
in CTL killing. The results showed that the DWNN mutant and DWNN-
complemented mutant cell lines were completely resistant to CTL killing compared 
the CHO-Y10 and CHO-J363 cell lines.  
 
FACS analysis showed that the expression of the MHC class I KK glycoprotein on the 
cell surface of the DWNN mutant and DWNN-complemented mutant cell lines was 
comparable to the parental cell line, CHO-Y10.  
 
PCR and sequencing analysis, coupled with the resistance of the cell lines to 
puromycin, confirmed the reading frame and the expression of both copies the L-HA 
mRNA and L-HA-puro transgenes.  
 
However, Real-Time Quantitative PCR showed that the expression of HA is 
comparable in CHO-Y10 and CHO-Mut16 (3x8)3.5 cells and substantially reduced in 
CHO-Mut8 (3x8)3.5 cells. The results imply that there was insufficient HA levels in 
CHO-Mut8 (3x8)3.5 and consequently in DWNN-complemented CHO-Mut8 (3x8)3.5, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hence the cell lines were resistant to CTL killing. However, CHO-Mut16 (3x8)3.5 
have been shown to be expressing similar HA levels as CH-Y10, but yet are resistant 
to CTL killing. However, immunofluorescence data (Fig 8.1) suggested that CHO-
Mut16 (3x8)3.5 cell line is polyclonal. . It is therefore, postulated that some of the 
clones which are DWNN negative might contain reduced levels of HA and those 
clones staining positive for DWNN have similar HA levels as CHO-Y10. This 
however, still does not explain why CHO-Mut16 (3x8)3.5 cell line is totally resistant 
to CTL killing, similarly as CHO-Mut8 (3x8)3.5 (Fig 8.3). Re-cloning of the CHO-
Mut16 (3x8)3.5 cell line will lead to a better understanding of the presence of the 
levels of HA and DWNN expression, as well as the extent of CTL resistance of this 
cell line 
 
It is hypothesised that the knocking-out of DWNN by promoter-trap mutagenesis 
might have resulted in the disruption of polyadenylation signal of the plasmid vector 
containing the L-HA and L-HA-Puro constructs (George, 1995), resulting in the 
instability of the HA mRNA. This therefore, resulted in reduced levels of HA in 
CHO-Mut8 (3x8)3.5 cells and consequently, resistance to CTL killing. It is therefore 
proposed that DWNN plays a role in the 3' polyadenylation process and this proposal 
corresponds with the previous study of the DWNN yeast homologue, Mpe1, which 
was shown to be essential in the cleavage and polyadenylation of mRNA (Vo et al, 
2001). 
The effect of apoptosis induction in DWNN-mutant and DWNN-complemented 
mutant cell lines was also investigated. This was carried out by exposing the cells to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
staurosporine and the apoptosis was measured by APOPercentageTM assay. The 
results suggest that the cells complemented with DWNN are resistant to 
Staurosporine-induced apoptosis compared to CHO-Y10 and the DWNN mutant cell 
lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 9: GENERAL DISCUSSION. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.1 Identification of the DWNN gene in promoter-trapped cell lines (Chapter 
3) 
 
Four Chinese Hamster ovary cell lines which were generated from a previous study 
(George, 1994) to identify novel genes involved in the processing and presentation of 
antigens to CTL killing by promoter trap mutagenesis have been used in this study.  
 
Inverse PCR was utilised in order to identify the genes mutated in these cell lines. A 
gene, named DWNN, has been identified by this method in CHO-Mut8 (3x8)3.5, 
CHO-Mut 16 (3x8)3.5 cell lines, and also in an earlier study by RACE PCR in CHO-
Mut7 (3x8)3.5 (George, 1994). This gene was previously shown to have no 
significant matches to any entries in the database and was not yet characterised 
(George, 1994). Analysis of the DWNN sequence in all these cell lines showed the 
same site of retrovirus integration. This suggested that either this particular site was a 
hot spot for the retrovirus integration site or that all these cell lines originated from 
the same clone during the selection of these cell lines in the promoter-trap 
mutagenesis study (George, 1994).  
 
The human DWNN gene was shown to encode two proteins of 13 kD and 200 kD, 
named DWNN-13 and DWNN-200 respectively. 
9.2 Generation of the human DWNN-13 construct (Chapter 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This section reports the isolation of DWNN-13 cDNA using PCR. DWNN-13 cDNA 
was amplified from 21C4 clone (obtained from ATCC, Rockville, USA). Sequence 
analysis of DWNN-13 showed that the PCR product amplified was correct and had 
100 % identity with the DWNN sequence in the database (accession number 
T25012). DWNN-13 cDNA was successfully cloned into pEGFPC1 vector for 
localisation studies (chapter 6) and also cloned into pcDNA3.1/Zeo vector for stable 
expression into cells (chapter 7). 
 
9.3 Construction of the human DWNN-200 cDNA (Chapter 5) 
 
DWNN-200 cDNA was constructed from mRNA isolated human cell lines. After 
several unsuccessful attempts of amplifying the entire 5.8 kb region, it was decided to 
amplify smaller fragments of ~1 kb along the entire gene. The fragments were then 
assembled together to generate the full length construct.  
 
The 5.8 kb DWNN cDNA was sequenced in both strands. Three different constructs 
were generated: a wild type DWNN-200, a L289Q:S363P DWNN-200 and a ΔA4034 
DWNN-200. The wild type DWNN-200 cDNA was shown to have a 100 % sequence 
identity to the assembled DWNN-200 sequence. The L289Q:S363P DWNN-200 
cDNA contained two mutations within the RING finger of the DWNN gene. These 
mutations were identified from an epithelial cancer cell line, HeLa, and were not 
found in the other human cancer lines analysed, MG-63 and CaSki. The third 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
construct generated, the ΔA4034 DWNN-200, contained a deletion of an adenosine at 
residue 4034 and therefore resulted in the truncation of the DWNN protein at the C-
terminus. The base deletion was only observed in HeLa cell line and not in any other 
human cancer lines analysed. Further investigations are needed to explore the 
possibility of these mutations contributing to the phenotype of this cell line. 
 
It is however not surprising to find mutations in this gene isolated from a cancer cell 
line because in a previous study, two nucleotide deletions were also found in the 
RBQ1 gene, a truncated human DWNN homologue (Sakai et al., 1995). RBQ1 was 
isolated from a human small cell lung carcinoma cell line. The two nucleotide 
deletions present in RBQ1 are however, absent from the HeLa cells and the mutations 
that were found in this study were absent from all the DWNN sequences present in 
the database.  
 
The wild type DWNN-200 cDNA was successfully cloned into pEGFP C1 and 
pcDNA 3.1/Zeo vectors for localisation studies and stable transfections. The 
L289Q:S363P DWNN-200 cDNA was also cloned into pEGFP C1 vector to 
determine whether the mutations would have any effect on the expression of the 
DWNN protein in mammalian cells. No further analysis was performed on the 
truncated DWNN-200 cDNA. 
9.4 Localisation of DWNN protein (Chapter 6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both the DWNN-13 and DWNN-200 proteins were successfully cloned into pEGFP 
C1 vector, which serves as a fluorescent tag for monitoring the expression and 
localisation of the DWNN protein in CHO cells. In addition, the L289Q:S363P 
mutated DWNN-200 construct (generated in Chapter 5) was also used in these 
experiments. 
 
All three forms of the DWNN constructs (DWNN-13wild type DWNN-200 and 
L289Q:S363P DWNN-200) were efficiently transfected into CHO cells and they 
were shown to localise identically inside the cells. They showed an intense nuclear 
staining and slight staining in the cytoplasm, compared to the GFP alone, which 
stained the entire cell. It was therefore concluded that the localisation signal of this 
protein is within the DWNN-13 domain due to the same pattern of localisation of the 
protein within the cell. It was also shown that the mutations within the RING finger 
did not affect the localisation of the protein. 
 
9.5 Generation of stable DWNN-complemented mutant cell lines (Chapter 7) 
 
pcDNA 3.1/Zeo vector was used in the cloning of both DWNN-13 and DWNN-200 
cDNA. These constructs were then stably transfected into CHO-Mut8 (3x8)3.5 and 
CHO-Mut16 (3x8)3.5. 300 μg/ml Zeocin was found to be the optimal concentration 
for the selection of stably transfected cell clones. The Zeocin resistant clones were 
cloned singly using cloning rings and in total about 50 resistant clones were isolated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The various clones contained CHO-Mut8 (3x8)3.5 cells expressing either DWNN-
200 or both DWNN-13 and DWNN-200 and CHO-Mut16 (3x8)3.5 cells expressing 
DWNN-13, DWNN BAC clone (CIT-254DM10 accession number AC010321) or 
both DWNN BAC clone and DWNN-13. These clones were used for further analysis 
(in comparison with the DWNN-mutant cell lines) in order to elucidate the function 
of the DWNN gene (Chapter 8). 
 
9.6 Analysis of the DWNN-mutant and DWNN-complemented mutant cell 
lines  (Chapter 8) 
 
In order to determine the function of DWNN in mammalian cells, analysis of the 
DWNN-mutant and DWNN-complemented mutant cell lines was undertaken. Firstly, 
the analysis of the DWNN expression in these cell lines was evaluated. The 
subcellular localisation of the endogenous DWNN protein in these cells was 
investigated using immunostaining with polyclonal anti-DWNN antibodies. The 
results demonstrated that the parental CHO-Y10 cells, the DWNN-complemented 
mutant cell lines, CHO-J363, HeLa and MG-63 cell lines showed an intense DWNN 
staining in the nucleus. These findings are consistent with the previously reported 
nuclear staining of the mouse homologue partial cDNA, P2PR (Witte and Scott, 
1997). However, in CHO-Mut8 (3x8)3.5 and CHO-Mut 16(3x8)3.5 cells anti-DWNN 
antibodies did not stain the nucleus and only stained the cytoplasm. It can therefore 
be concluded that the endogenous DWNN protein is localised mainly within the 
nucleus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Western blots were carried out in order to determine the size of the DWNN protein 
expressed in DWNN-mutant and DWNN-complemented mutant cell lines. The 
results showed three bands of sizes, 13 kD 105 kD and 160 kD. The 13 kD protein 
corresponds to the DWNN-13 transcript. However, it still remains unclear what the 
other two large-sized proteins are but it is speculated that they may be degradation 
products of the DWNN-200 protein or cross reaction of antibodies or even the 
truncation of the DWNN protein on the other allele. 
 
The DWNN–mutant cell lines were generated from a previous study to identify genes 
involved in CTL killing (George, 1994). It was therefore interesting to investigate the 
effects of CTL killing on these cells lines as well as in the DWNN-complemented 
mutant cells. Analysis of these cell lines for susceptibility to lysis by HA8 CTL clone 
by 51Cr-release assay showed that these cell lines were totally resistant to killing with 
the HA8 CTL compared to CHO-Y10 and CHO-J363 cell lines. In order to ensure 
that the resistance of these cell lines to CTL killing was not due to the loss of 
expression of the previously transfected MHC class I H-2KK and HA genes, 
expression levels of both these genes was analysed in these cell lines. All the cell 
lines were expressing comparable levels of MHC class I H-2KK using the FACScan.  
Real-Time Quantitative PCR showed that the levels of the HA mRNA were reduced 
by 100-fold in CHO-Mut8 (3x8)3.5 compared to CHO-Y10. However, CHO-Mut16 
(3x8)3.5 expressed comparable HA levels with CHO-Y10. This data explains why 
the CHO-Mut8 (3x8)3.5 cells were resistant to CTL killing because they are not 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
expressing enough HA levels and therefore cannot be recognised by the HA8-specific 
CTL clone. On the contrary, CHO-Mut16 (3x8)3.5 are expressing similar levels of 
HA as CHO-Y10 but yet are resistant to CTL killing. It is unclear what is causing 
these cells to be resistant, but from immunofluorescence microscopy (section 8.2.1) it 
was discovered that CHO-Mut16 (3x8)3.5 cells are polyclonal. Re-cloning of this cell 
lines might provide additional information about the levels of CTL resistance in this 
cell line.  
 
It is therefore hypothesized that by knocking-out DWNN using promoter-trap 
mutagenesis, might have led to the disruption of polyadenylation processing of the 
transfected L-HA and L-HA-puro, resulting in insufficient HA mRNA. 
 
In an attempt to discover the role of the DWNN gene, the effects of apoptosis were 
also investigated in the cell lines. Cell lines were treated with staurosporine and 
apoptosis was measured using the APOPercentage TM assay. It was discovered that 
the DWNN-complemented mutant cell lines were less susceptible to staurosporine-
induced apoptosis measured by the APOPercentage assay, as compared to CHO-Y10 
and DWNN-mutant lines. This finding was analogous to the observations made in 
experiments where CHO cells transduced with DWNN-13 protein were less 
susceptible to apoptosis induced by serum-deprivation, compared to non-transduced 
CHO cells (Seameco, personal communication). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.7 Conclusion 
 
This study has shown that inverse PCR can be employed in order to identify 
promoter-trapped genes. A novel gene, DWNN, has been identified in promoter-
trapped cell lines using the inverse PCR. 
 
Sequence analysis showed that DWNN is a conserved protein, found in all 
eukaryotes. It is encodes two proteins of 13 kD and 200 kD. The 13 kD proteins 
contains the DWNN domain only, while the 200 kD protein is attached to several 
domain, including the CCHC domain, the C3HC4 domain, the Rb -and p53- binding 
domains. The Rb- and p53-binding domains have been previously shown to bind to 
tumour suppressor genes, Rb and p53 respectively. 
 
In an attempt to investigate the role played by the DWNN gene, several experiments 
have been undertaken and the following conclusions were drawn: 
(a) Immunostaining experiments, together with GFP transient expression 
studies, confirmed that DWNN is localised in the nucleus. 
(b) Strong evidence has been presented in this study on the involvement of 
this gene in human cancers. Identification of several mutations in the 
human cervical cancer cell line (HeLa) has led to the question of whether 
the mutations within the DWNN gene contribute to the phenotype in this 
cell line. Analysis of more cancer cell lines needs to be undertaken in 
order to understand the role played by DWNN in human cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) There seems to be some correlation between this gene and apoptosis. 
Further studies need to be undertaken in order to investigate the exact role 
played by this gene in apoptosis.  
(d) The presence of the Rb- and p53-binding domains on the human DWNN-
200 gene might suggest that this gene interacts with the Rb and p53 
tumour suppressors.  
(e) The ubiquitin-like structure of the DWNN domain, which has been 
recently solved (Faro, 2004), coupled with the coupled with the presence 
of the RING finger domain within the DWNN-200 gene, suggests the 
possibility that DWNN operates as an E3 ubiquitin ligase, tagging 
probably p53, Rb or even itself for degradation. 
(f) Finally, this study proposes the involvement of DWNN in the 3’ 
polyadenylation process. 
 
 
 
9.8 Future Work 
 
Several mutations have been identified within the RING finger domain of the 
DWNN-200 gene in this study. GFP fused to DWNN-200 containing these RING 
finger mutations did not seem to affect the localisation of DWNN in mammalian cells 
(chapter 6). The effect of these mutations on p53 and Rb interactions will have to be 
characterised through in vitro studies using protein expression and BIACore analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The characterisation of DWNN interactions with p53 and Rb with this system will 
provide a detailed understanding of the effects of mutations on these interactions. 
These experiments will strengthen our understanding of the involvement of DWNN 
in tumours and the role of DWNN mutations in disrupting the p53 and Rb systems of 
tumour suppression. 
 
It is unclear what role is played by the alternatively spliced region (in exon 16) of the 
DWNN-200 gene. All the constructs built in this study were missing exon 16, it 
would therefore be interesting to establish the effects of overexpressing DWNN-200 
containing exon 16 have on localisation, CTL killing and apoptosis. 
 
Full-length DWNN-200 cDNA clones containing the RING finger mutations need to 
be expressed in mammalian cells in order to evaluate their function in CTL killing 
and apoptosis induction assays. This study showed that mutant cell lines 
complemented with the wild type DWNN-200 cDNA showed slight resistance to 
staurosporine-induced apoptosis measured by the APOPercentageTM assay. 
Additional tests need be undertaken in DWNN-mutant and DWNN-complemented 
mutant CHO lines to investigate their resistance to apoptosis induced by several 
known apoptotic inducers such as staurosporine, camptothecin, ceramide, as well 
recombinant perforin and granzymes. Apoptosis will then be measured using various 
assays, such as determination of caspase 3 activity, PARP cleavage and Annexin V 
staining. This will determine whether the apoptotic pathway has been blocked or not 
in these cell lines, and if it has been blocked, where in the pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This study proposes the involvement DWNN in the polyadenylation process. This 
proposal will be confirmed by analysis of the 3' end of the HA mRNA of both CHO-
Mut8 (3x8)3.5 and re-selected CHO-Mut16 (3x8)3.5 cells. This study will determine 
if the 3' HA mRNA has been properly processed. 
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